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Dendritic cells are efficient antigen-presenting-cells that 
can be used in tumour-antigen specific vaccination for 
malignant disease.  Melanoma patients were recently treated 
with a dendritic cell vaccine expressing gp100 and Melan-A 
antigens after non-viral (CL22 peptide) transfection.  
Although clinical and immunological responses were noted, 
there was no correlation between responses and whole antigen 
expression levels in the vaccine cells that varied widely.  
Here, it is established that patient cells expressed 
detectable levels of Class I restricted epitopes from both 
antigens, although there was no correlation with whole antigen 
detection.   CL22 transfected dendritic cells could 
simultaneously present a viral antigen (EBNA1) to CD8 and CD4 
T-cells, which had not previously been demonstrated. Using RNA 
transfection, it was demonstrated that early after 
transfection cells are whole Melan-A positive yet negative for 
Class I epitopes and with time Melan-A antigen levels fall 
whilst Class I epitopes are generated.  Loss of whole antigen 
expression seemed related to lysosomal function and, unlike 
the viral antigen EBNA1, Class I presentation from Melan-A was 
lysosome-dependent.  For Class II presentation of EBNA1, 
cellular localisation seems to determine access to the Class 
II pathway although this depends on the time-scale over which 
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CHAPTER 1: INTRODUCTION 
 
1.1. Antigen processing pathways . 
 
T-lymphocytes recognise antigen differently to B-cells that 
recognise three-dimensional determinants of intact antigen. 
T-cells interact with pre-processed, digested forms of 
antigen (Gell and Benacerraf, 1959).  APCs degrade protein 
antigens into constituent peptides that are presented to T-
cells bound to Major Histocompatibility Complex (MHC) 
molecules at the cell surface (Groothuis and Neefjes, 2005 
and Jensen, 2007). 
 
Protein antigens are presented to T-cells expressing αβ T-
cell receptor chains, and glycolipid antigen is presented 
via CD1a molecules expressed on DCs to either gamma-delta or 
alpha-beta T-cells or NK/T cells (Cohen at al., 2009).  
 
1.2. The MHC Class I pathway. 
 
 
The MHC Class I pathway is universally active and evolved as 
a rapid defense again intracellular, particularly, viral 
infection (Figure 1.1).  It allows intracellular antigen, 






cytotoxic CD8 positive T-lymphocytes (Elliot and Neefjes, 
2006).   
 
Degradation of intracellular proteins for antigen 
presentation involves several cellular processes.  
Proteasomal processing is central (Baumeister et al., 1998).  
The proteasome is a large, multicatalytic, barrel-shaped 
complex found in nuclear and cytoplasmic compartments.  
Hydrolysis of polypeptide chains leads to the generation of 
peptides of 8-20 residues in length: longer than optimal for 
Class I binding.  Processing of proteasomal substrates is 
non-selective: the majority of substrates are in fact newly 
synthesised proteins that are defective, misfolded or 
prematurely truncated (Yewdell et al., 2001) although 
correctly folded mature and senescent proteins are also 
degraded.  Processing of newly-formed proteins couples viral 
infection with rapid and early presentation to cytotoxic T-
lymphocytes.  Aberrant protein manufacture is thought to 
primarily lead to DRiP (defective-ribosomal-product) 
formation, although specialised ‘immuno-ribosomes’ may 
produce faulty polypeptide chains for antigen presentation 




The importance of DRiPs was suggested by the linkage between 
Class I presentation and protein synthesis and ribosomal 
function (Khan et al., 2001 and Qian et al., 2006), and by 
the fact that most newly-formed proteins were rapidly 
degraded (Schubert et al., 2000).  Destabilisation of an 
influenza antigen by amino terminal modifications did not 
have any effect on generation of Class I peptides assessed 
by T-cell stimulation or presence of peptides in APC 
extracts (Goth, Nyugen and Shastri, 1996), suggesting that 
peptide supply did not directly relate to the stability of 
intact protein. 
 
Khan et al (2001) showed that Class I presentation from the 
LCMV nucleoprotein ceased immediately when protein synthesis 
was terminated using a tetracycline-dependent promoter.  
This antigen is highly stable, yet CD8 T-lymphocytes 
specific for Class I epitopes within it are readily 
detectable in infected mice and epitope presentation is 
proteasome dependent (Schwarz et al., 2000 and Schubert et 
al., 2000).   
 
Ubiquitination is tightly linked with proteasomal function.  
Ubiquitin is a highly conserved 76 amino acid polypeptide.  
Ubiquitin ligases covalently attach ubiquitin to the amino 
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terminus or to the amino group of an internal lysine residue 
of the protein marked for degradation.  Ubiquitin ‘tails’ 
permit a stable interaction with the 26S, enzymatically 
active, subunit of the proteasome (Glickman and Ciechanover, 
2002).   
 
Polypeptides leaving the proteasome are further degraded by 
cytosolic aminopeptidases including tripeptidyl peptidase II 
(TPPII)(Reits et al., 2004) and others (York et al., 2003).  
There is a process of ‘selection’ where there is a limited 
opportunity for peptides to bind to the MHC Class I 
molecules – indeed of all proteins entering the proteasome 
only 0.1 to 1% will lead to the generation of Class I 
binding peptides.  Due to the rapid action and efficiency of 
cytoplasmic peptidases, nascent peptides have only 
approximately 8 seconds to interact with the Class I 
machinery before becoming too small to do so.   
 
During these eight seconds, peptides of approximately 8-16 
residues must interact with either TAP or be sheltered from 
degradation by chaperone proteins.  This is because their 
‘target’, MHC Class I molecules, is found in a different 
compartment – the endoplasmic reticulum (ER) and peptides do 
not readily cross lipid bilayers. TAP is an ATP dependent 
6 
 
heterodimeric (TAP1 and 2) membrane pump spanning the ER 
membrane (Lankat-Buttgereit et al., 2002).  TAP is selective 
for 8-12 residues peptides and excludes those with chemical 
modifications at the amino terminus or those with proline at 
position 2 or 3 as these have low binding affinities to 
Class I molecules (Momburg et al., 1994).   
 
TAP is a component of a large multimeric complex in the ER 
membrane – the MHC Class I loading complex.  The additional 
proteins are Class I molecules, chaperones Erp57 and 
calnexin and the peptide-editing molecule tapasin (Cresswell 
et al., 1999).  Peptides transported into the ER interact 
with the heterodimers of beta-2-microglobulin and MHC Class 
I heavy chain and this releases them from the complex for 
subsequent transport to the cell surface.  TAP substrates 
are often longer than ideal for Class I binding and the 
enzyme ERAAP may trim peptides to the optimal size – 8-10 
residues (Saric et al., 2002).   
 
The chaperone protein disulfide isomerase aids selection of 




TAP functions in a reasonably sequence independent fashion 
in order to supply peptides for binding to HLA molecules 
that are extremely polymorphic (Groothuis and Neefjes, 
2005).   
 
This process is inefficient and most proteins and peptides 
are immunologically irrelevant – 2 x 106 proteins are 
degraded yet only 2 x 104 Class I molecules are loaded with 
peptide (Yewdell et al., 2003).  There is significant 
reserve within the system allowing responses to stress or 
viral infection.  Rapid degradation of polypeptides means 
that only peptides binding with very high affinity to MHC 
Class I heavy chains are ‘selected’ – maintaining high 
levels of peptide-MHC complexes for several days on the 
surface of APCs to allow expansion of T-cell populations 
(Elliot and Neefjes, 2006).   
 
1.3. MHC Class I pathway in dendritic cells. 
 
 
Upon antigenic stimulation, IFNγ is produced and this causes 
upregulation of all components of the MHC Class I loading 
complex.  It also has effects on the proteasome.  In 
professional antigen presenting cells and when innate 
cytokines are being produced, there is substitution of the 
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three proteolytic subunits in each inner ring of the 
proteasome by alternative subunits known as LMP2 (for β1), 
LMP7 (for β5) and Mecl-1 (for β2) (Beninga and Goldberg, 
1998).  These are IFNγ inducible and when these are 
incorporated into proteasomes, they are termed 
‘immunoproteasomes’ (Monaco and McDevitt, 1986).  These are 
strongly enriched in activated dendritic cells and 
constitutively expressed in B-lymphocytes. LMP2 and 7 are 
encoded within the MHC super-complex (Goldberg and Rock, 
1992) whereas Mecl-1 is not (Cruz et al., 1997).   
 
These subunits have a specialised role in antigen 
presentation as LMP7 deficient mice had a marked reduction 
in surface MHC Class I density and were unable to present 
the minor histocompatibility antigen H-Y (Fehling et al., 
1994). 
 
However, epitopes more efficiently generated by 
immunoproteasomes are mainly viral, rather than tumour, 
derived.  In fact, there is evidence that immunoproteasomes 
destroy epitopes from several melanoma associated antigens 
including gp100, tyrosinase and Melan-A and are less 
efficient than standard proteasomes at generating these 




The presence of Mecl-1, LMP2 and 7 favours cleavage after 
basic and hydrophobic amino acids rather than acidic ones 
(Gaczynska et al., 1993).  However, production of peptides 
with basic and hydrophobic C-termini optimises binding 
stability with Class I molecules (Akiyama et al., 1994).   
 
MoDC constitutively express all three inducible subunits, 
although prior to exposure to an activation stimulus roughly 
equal amounts of ‘standard’ and ‘immuno’ proteasomes were 
present, whereas after activation only immunoproteasomes 
were detected (Macagno et al., 1999).     
 
The other unique features of Class I processing in DC is the 
existence of dendritic cell aggresome like induced 
structures (DALIS).  It was first demonstrated (Lelouard et 
al., 2002) that in mouse Langerhans cells and CD34 derived 
human DCs that exposure to LPS causes an accumulation of 
peripheral ‘aggregates’ of ubiquitinated proteins.  DALIS 
appear within 4 hours of LPS exposure and staining is 
maximal around 8 hours.  By 36 hours of ‘maturation’, most 
aggregates have dispersed.  Forced translational errors 
increased the number and size of DALIS, linking them tightly 




These structures may act as antigen depots, and by delaying 
the presentation of Class I restricted epitopes by 24-36 
hours they allow coordination of the arrival of the DC in 
draining lymph nodes with the presentation of immunogenic 
epitopes.  It would be wasteful for epitope display to begin 
immediately as time is required for the cells to migrate via 
lymphatics to secondary lymphoid tissue (Lelouard et al., 
2004). This cellular ‘sink’ for ubiquitinated proteins in 
DCs may make room within the Class I loading compartments 
for peptides derived from the endocytic pathway destined for 
‘cross-presentation’. 
 
Finally, in DC the Class I and II pathway are not mutually 
exclusive and cross-presentation can occur.  This process is 
vital in the initiation of immune responses as most directly 
infected cells are poorly immunogenic and lack the necessary 
costimulation to drive the expansion of naive T-cells.   
 
 
1.4. The MHC Class II pathway. 
 
 
The Class II pathway is only constitutively active in B-
lymphocytes, macrophages and DC.  In the presence of IFNγ, 
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endothelial, epithelial and tumour cells can express Class 
II molecules (Watts, 2004).    
 
It protects against extracellular pathogens unlike the Class 
I pathway. The extracellular environment is sampled by APCs 
and epitopes derived from internalised proteins are 
presented to CD4 positive (helper) T-cells (Vyas, Van den 
Veen and Ploegh, 2008). This is illustrated in Figure 1.2.   
 
Extracellular material is taken up by macropinocytosis, 
receptor mediated endocytosis and enters the phagosome 
(Henry et al., 2004).  This structure is formed from 
invagination of the plasma cell membrane and it eventually 
fuses with endo-lysosomes (Blander and Medzhitov, 2006).   
 
Class II molecules consist of an αβ heterodimer (Janeway et 
al., 2005).  Nascent Class II heterodimers in the ER 
interact with the chaperone invariant chain.  The invariant 
chain molecule functions to block the peptide binding cleft 
of Class II molecules and prevents premature binding of 
peptides in the ER and also targets the molecules to late 
endosomal compartments (Cresswell, 1996).  In late 









chain occurs, leaving only CLIP (Class II invariant-chain 
associated peptide) in the peptide groove.  The intersection 
between endolysosomes and phagosomes is known as the MHC 
Class II loading compartment.   
 
 
The presence of CLIP stably bound to Class II molecules, 
means that many molecules do not acquire exogenous peptide 
before transport to the cell surface (Hiltbold and Roche, 
2002).  This problem is circumvented by the ‘peptide-
editing’ molecule HLA-DM.  Interactions between CLIP loaded 
Class II molecules and HLA-DM facilitate the release and 
subsequent binding of peptides (Zarutskie et al., 2001).  
HLA-DM favours removal of CLIP, protects the ‘empty’ Class 
II molecule from destruction and selects high binding 
affinity peptides that form long-lived complexes with MHC-II 
and are therefore highly immunogenic (Anderson and Gorski, 
2003 and Carven and Stern, 2005).  Typically Class II 
molecules bind stably with peptides 13-15 amino acids long.  
Most evidence suggests that long polypeptide chains bind to 
Class II molecules, endowing them with some degree of 
protection from the hostile environment of lysosomes.  
Further trimming by endo and aminopeptidases reduces the 





Peptide-loaded mature Class II molecules then traffic to the 
cell membrane, possibly through a direct route (Wubbolts et 
al. 1996) but more likely they are carried to the membrane 
by specific vesicles derived from early endosomes (Turley et 
al., 2000).   
 
A negative regulator of the function of HLA-DM exists and in 
humans is known as HLA-DO (Liljedahl et al., 1996).  It is 
encoded within the MHC super-cluster and like HLA-DM is non-
polymorphic.  It colocalises with HLA-DM in Class II loading 
compartments but its role in DC appears unclear. (Fallas et 
al., 2004).  
 
The supply of peptides for Class II loading is dependent on 
lysosomal processing.  Lysosomal proteases include cysteine, 
aspartate and serine proteasomes and metalloproteases.  
Cathepsin D is an aspartic protease and the cysteine 
proteases are Cathepsins B,F,H,L,S and Z (Riese and Chapman, 
2000).  Most enzymes have broad substrate specificity and 
include a mixture of those with endopeptidase and 
exopeptidase activity (Turk et al., 2001).  Cathepsins S and 




A highly acidic pH in lysosomes compartments is vital for 
protein digestion.  The acidic environment encourages 
breakage of disulfide bridges and unfolding of proteins, 
allowing access of proteolytic enzymes (Collins et al., 
1991).  There may also be active participation in this 
process by IFNγ inducible lysosomal thiol reductase 
(Arunachalam et al., 2000). 
It is not uncommon for long polypeptide chains to interact 
with MHC II molecules and be trimmed at either end to the 
typical 13-15 amino acids length (Castellino et al., 1998).   
 
 
Although most peptides bound to MHC Class II molecules are 
derived from exogenous proteins, senescent membrane proteins 
also contribute to the Class II peptide pool.   
 
It was demonstrated that in human B-lymphoblastoid cell 
lines, peptides eluted from surface HLA-DR molecules were 
derived from over 170 core protein sequences and 
approximately 40% of these proteins were membrane bound, but 
25% were intracellular proteins including cytoplasmic and 
nuclear ones.  Macroautophagy was involved in mobilising 
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intracellular source proteins for MHC Class II presentation 
(Dorfel et al., 2005).   
 
Autophagy is a bulk, non-selective process involving the 
degradation of senescent cellular organelles into their 
constituent amino acids for re-building of new structures 
(Klionsky and Emr, 2000).  The best characterised is 
macroautophagy, although chaperone-mediated autophagy and 
microautophagy exist (Strawbridge and Blum, 2007).  The rate 
of macroautophagy is low in resting cells and is upregulated 
in times of cellular stress and starvation (Crotzer and 
Blum, 2008).  During amino acid deprivation, signalling via 
PI-3 kinase is decreased and this removes the break on 
macroautophagy inhibition by the mammalian target of 
rapamycin (mTOR) and increases autophagy (Klionsky, 2005).   
 
There is now a body of convincing evidence that autophagy 
can supply substrate proteins into the endolysosomal pathway 
for subsequent MHC Class II restricted presentation (Crotzer 
and Blum, 2009) and that proteins from almost all cellular 




In macroautophagy, parts of the cytoplasm are gathered up 
within double membrane structures called autophagosomes that 
can eventually engulf whole organelles.  Central to this 
process are a set of autophagy-related gene products (Atg) 
that are found in yeast and mammals.  (Klionsky, 2005).   
 
Several antigens found in the nucleus or cytoplasm have been 
shown to be presented via the MHC Class II pathway including 
neomycin resistance protein (Nimmerjahm et al., 2003), the 
Epstein Barr Virus Nuclear Antigen-1 (Paludan et al., 2005) 
and the tumour antigen mucin-1 (Dorfel et al., 2005).  In 
all cases, an extracellular route has been excluded and 
inhibitors of autophagy such as 3-methyadenine or wortmannin 
or specific inhibition with Atg12 siRNA have reduced 
recognition by CD4 T-cells.   
 
Macroautophagy is constitutively active in DC and B-
lymphocytes, diverting some intracellular proteins into the 
Class II pathway (Schmid, Pypaert and Munz, 2007).  In  
human DCs 40% of MHC Class II loading compartments were 
positive for autophagosome markers after chloroquine 
exposure to inhibit lysosomal acidification.  Additionally, 
DCs expressing Flu-MP as a fusion protein with LC3 were more 
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strongly recognised by Flu specific CD4 T-cell clones than 
those expressing untagged Flu-MP.   
 
These insights into ‘novel’ sources of Class II ligands are 
important in terms of DC vaccine design.  As discussed in 
subsequent sections the generation of CD4 and CD8 T-cell 
responses simultaneously is a desired goal of vaccination 
and knowledge of how endogenously produced proteins may 
access the Class II machinery allows rational vaccine 
design.     
 
1.4.1. The MHC Class II pathway in dendritic cells. 
 
 
The key specialisation of the Class II pathway is that it is 
tightly regulated and this regulation is linked with the 
nature of activating, environmental stimuli received by the 
DC (Thery and Amigorena, 2001).   
 
Activated DC possess an unusually high density of cell 
surface MHC Class II molecules. The strength of expression 
of costimulatory molecules such as CD86 is also 




In DC, newly formed Class II molecules associated with the 
invariant chain are exported to the cell surface where they 
are internalised into the lysosomal system for peptide 
loading.   
 
Also, lateral clustering of peptide-MHC complexes on the 
surface of DCs leads to high local densities of p-MHC for 
interactions with cognate T-cells and a high likelihood of 
formation of a tight immunological synapse (Turley et al., 
2000).   
 
Prior to receipt of activating signals, the majority of MHC 
Class II molecules are found in intracellular vesicles that 
co-stain with lysosomal markers such as LAMP-1.   
 
On receipt of TLR agonist stimulation or T-cell derived 
signals (such as CD40 ligation or IFNγ) and to a lesser 
extent proinflammatory cytokines such as TNFα, there is an 
initial further burst of macropinocytic activity followed by 
rapid downregulation.  This makes sense, as it forms a 
positive feedback loop to allow maximal antigen uptake when 
pathogens are present.  Transport of MHC Class II molecules 
from the Class II loading compartments to the cell surface 
20 
 
occurs and there is dramatic stabilisation of cell surface 
p-MHC-II complexes for several days.  The rate of synthesis 
of Class II peptide complexes does not increase 
dramatically, and stabilisation of surface complexes is most 
important (Cella et al., 1997). DCs can present epitopes 
from antigens that have been captured up to several days 
before maturation.  
 
There is also controlled and less complete degradation of 
antigens with the endocytic compartment in DCs as opposed to 
other phagocytic cells, preserving more information for 
antigen presentation. DC activation leads to an activation 
of lysosomal functions and there is an overall increase in 
proteolysis. The mechanism of upregulation of lysosomal 
processing is not straightforward however.  There is no 
increase in expression of any lysosomal protease in the 
mature state.  However, two cathepsins were found in a pro-
enzyme (immature) state in immature DCs. The crucial step 
appears to be endolysosomal acidification with an 
intralysosomal pH of 5.4 in immature DCs falling to 4.6 
after exposure to LPS.    Acidification influences all key 
process of Class II loading including the activity of gamma 
interferon inducible lysosomal thiol reductase and HLA-DM 




An alternative Class II loading pathway may operate in some 
DC.  DC express significant numbers of empty MHC Class II 
molecules at the cell surface (Santambrogio et al., 1999).  
Cell surface HLA-DM is present (Andersson et al., 1998) and 
immature DCs are able to secrete lysosomal proteases 
(Amoscato et al., 1998).  This raises the possibility of 
extracellular peptide loading of Class II molecules 







1.5. Human dendritic cell physiology 
 
 
Langerhans cells were identified in the skin as a cell 
exhibiting extensive ramifications (Becker, 2003).  They 
were considered neural cells (Bloch, 1929) and later 
senescent melanocytes (Billingham, 1948).  With time, their 
central immune function has become apparent (Becker, 2003). 
 
Human DC are found in the interstitium of almost all organs, 
in the blood and in secondary lymphoid tissues.  Bronchial 
and gastrointestinal epithelia are especially DC rich. This 
makes sense as these are the areas where environmental 
antigens and pathogens come into contact with the immune 
system.   
 
Within secondary lymphoid tissues, interdigitating DC, a 
miniscule fraction of the total cellular population, form a 
vast interconnected network with an enormous capability to 
survey lymphocytes trafficking between lymphoid tissues and 
the blood.  This maximises the likelihood of the successful 
selection of individual antigen specific clones that are 
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extremely infrequent by activated DCs (Lindquist et al., 
2004).   
 
DC are the ‘conductor’ of the immune ‘orchestra’.  The DC 
network bridges innate and adaptive immunity and DC are able 
to interact with the full range of immune cells including 
granulocytes, T and B lymphocytes, natural killer and 
natural killer T cells and cells of monocyte-macrophage 
lineage.   
 
When the immune system is challenged by antigen, whether a 
self-antigen such as a tumour-associated-antigen or an 
antigenic determinant of a foreign pathogen, the nature of 
the antigen itself and also the attendant innate immune 
response determine the characteristics of the ensuing 
adaptive immune response.  DC are critical in ensuring that 
the information on the nature of antigenic challenge is 
relayed through to adaptive immunity to ensure a response 
that is appropriate and effective.   
 
In the steady state DC mediate immune tolerance.  The thymus 
produces naive T-lymphocytes and these cells have newly 
assembled T-cell receptors – some of which are self-
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reactive.  A process of negative selection occurs in which 
cells with high avidity receptors recognising self antigens 
are deleted.  Both thymic epithelial cells and mature DC 
display self-peptides and are involved in this process – 
‘central’ tolerance.  However, whilst central tolerance is 
effective in removing high-avidity self-reactive T 
lymphocytes, it is an imperfect process and some escape into 
the periphery.   
 
In the absence of infection, inflammation or cellular stress 
DC continually sample self tissues and present self-derived 
peptides in a tolerogenic fashion to T-cells.  Antigen 
presentation in the absence of costimulatory molecules on 
the DC surface and in the presence of immunosuppressive 
cytokines leads to either functional unresponsiveness of 
specific T-cells or their deletion.  Alternatively, it can 
generate T-cells with regulatory and suppressive 
capabilities that actively attenuate antigen specific T-
cells.  DC in this condition are described as tolerogenic, 
resting, or sometimes ‘immature’.   
 
However, when the immune system receives activating stimuli, 
the DC undergo a ‘metamorphosis’.  The activation programme 
involves a loss of adhesion and cytoskeletal 
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reconfiguration, increased motility, reduction in phagocytic 
and endocytic receptor expression (Steinman and Swanson, 
1995), upregulation of costimulatory molecules, 
stabilisation of surface MHC Class II molecules (Mellman, 
2005), secretion of T-cell polarising cytokines (Heufler et 
al., 1996) and induction of immunoproteasome subunits. 
 
DC activation takes place either on direct recognition of 
foreign microbes or indirectly via the innate immune system.  
DC possess pattern-recognition-receptors (PRRs) that 
interact directly with conserved molecular patterns (PAMPs) 
that are shared between pathogens.  There are ten toll-like 
receptor genes (TLRs) in humans.  These have different 
ligands and cellular localisations.  The particular TLR that 
is engaged by a pathogen can determine the nature of the 
adaptive response engendered (O’Neill et al., 2004).   
 
C-type lectin receptors interact with the carbohydrate 
moiety of bacterial glycoproteins and include Blood 
dendritic cell antigen 2 (BDCA2) and DC-SIGN.  They are 
found on many pathogens and ligation of the receptor leads 
to internalisation of the microbe.  CLRs also function as 
adhesion molecules and the interactions between DC-SIGN and 
MAC-1 and CEACAM1 on neutrophils are important in innate 
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activation of DCs, between DC-SIGN and ICAM2 and ICAM3 play 
a role in endothelial egress and stabilisation of the DC-T 
cell interaction.   
 
NOD like receptors sense intracellular microbial components 
and respond to proinflammatory cytokines.  NOD1 and 2 and 
NALP3 interact with muropeptides that are fragments of 
peptidoglycans derived from bacterial cell walls. 
 
DC can receive indirect signals of tissue damage and 
cellular stress – danger associated molecular patterns 
(DAMPs).  DAMPs include heat-shock or stress proteins such 
as gp96 and HSP70 (Somersan et al., 2001) that encourage DC 
cross-presentation, high mobility group box protein-1 
(HMGB1) that is a cytokine like molecule released from dying 
cells that induces macrophages to release IL-6 and TNFα, and 
β-defensins that are small peptides with antimicrobial 
activity released by neutrophils and epithelial cells in 
response to infection.  Other DAMPS include endogenous 
molecules such as hyaluronic acid (Do et al. 2004) a 
component of the extracellular matrix and uric acid (Shi et 
al., 2003) that is increased in conditions of high cellular 




DC can conserve exogenously acquired antigens and present 
intact antigen to B-lymphocytes.  They can initiate T-cell 
dependent antibody responses (Qi et al., 2006).   
 
DC are the most professional of the professional APCs and, 
for several reasons, they are ideal candidates for cellular 
cancer vaccines.   
 
First, DC have the near-unique ability to cross present 
antigen.  In this process peptides derived from exogenous 
antigens are presented at the cell surface bound to MHC 
Class I molecules.  This process was first observed in mice 
(Bevan, 1976), although DC involvement was only recently 
demonstrated (den Haan et al., 2000).  The importance of 
cross priming is in the generation of immune responses 
against organisms that do not directly infect DCs, and also 
in tumour immunity where cancer cells are extremely poor 
antigen-presenting cells incapable of initiating T-cell 
expansion.  In mice, only the CD8α+ splenic DC subset has 
been shown to have cross-presenting ability (den Haan et 
al., 2000), although B-cells and macrophages may cross-
present at low efficiencies in vitro (Reis e Sousa and 
Germain, 1995).  DC are able cross-present at high 
efficiencies – DCs capturing apoptotic or necrotic vaccinia 
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virus infected cells in vitro were able to present Class I 
epitopes at an equivalent level to cells pulsed with 10-7 to 
10-8 M exogenous peptide (Larsson et al., 2001). This is 
especially remarkable as it is thought that Class I 
presentation is often highly dependent on DRiPs and ongoing 
protein synthesis.  The efficiency of the process is 
increased if DCs are activated by TLR agonists, immune 
complexes, dying cells or uptake via the DEC205 receptor.  
The efficiency of cross-presentation is far higher when 
antigen is delivered in particulate rather than soluble form 
(Rock et al., 1993).  There are two putative mechanisms of 
cross-presentation that are not mutually exclusive and the 
relative importance of each depends on the DC subset and 
type of antigen (Rock and Shen, 2005).  In one, there is 
phagosome to cytosol transport and then proteasomal 
processing and translocation of the peptides to the ER via 
TAP.  In the other processing occurs in the phagosome 
followed by MHC Class I loading in the phagosome – MHC 
complexes recycling from the plasma membrane may intersect 
with phagosomes.   
Second, DC are able to stimulate the expansion of naive T-
lymphocytes.  By virtue of interactions between CD86 and 
CD28 and DC-SIGN and ICAM3 (Bhardwaj, 2001) and the 
formation of a very tight immunologic synapse between T-
lymphocyte and DC (Benvenuti et al., 2004), these cells are 
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responsible for priming the majority of cellular immune 
responses.  However, suboptimally mature cells only promote 
2 to 4 rounds of T-cell division.  Mature DCs, in contrast 
to other APCs, have the ability to adhere to T-cells even in 
the absence of antigen.   
 
Third, the efficiency of antigen processing in DC is greater 
than other APCs.  This is not surprising as DC are the only 
APC whose exclusive function is antigen.  DC in contrast to 
macrophages or B-cells are found in the naive T-cell zones 
of lymphoid organs.  The extensive ramifications of DC 
increase the surface area for display of peptide-MHC 
complexes to T-cells and allow multiple simultaneous T-cell 
contacts.  The number of peptide-MHC complexes generated per 
unit of antigen is also extremely high and surface MHC 
complexes, particularly Class II, are extremely stable and 
may persist for several days – greater than other APCs (Zehn 
et al., 2004).   
 
Fourth, DC are distinguished by a very controlled and well 
regulated rate of lysosomal proteolysis and hydrolysis.  In 
contrast to other cells types, DCs preserve a larger amount 
of antigenic ‘information’ for internalised proteins.  The 
controlled lysosomal degradation increases the likelihood of 
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formation of small peptides for MHC loading (Delamarre et 
al., 2005). DC possess a range of cathepsin inhibitors for 
this purpose (Pierre and Mellman, 1998). 
 
Fifth, the establishment of T cell memory depends on DC 
function. The development of cytotoxic T-cell memory/recall 
responses seem to be dependent on the presence of CD4 T-
cells at the time of infectious challenge (Sun and Bevan, 
2003).  Zammit et al (2005) selectively depleted CD11c 
dendritic cells in transgenic mice and this attenuated the 
development of HSV specific CTL responses and recall 
responses.   
 
Memory T-cell responses are characterised by their 
longevity, more rapid expansion and development of effector 
function and a greater frequency than naive T-cells.  In 
terms of cancer immunotherapy the generation of a long-lived 
T-cell response is vital as complete eradication of the 
clone of cancerous cells by immune responses remains 
unlikely and so durable responses are needed to maximise 




CTL memory responses are partly dependent of the recruitment 
of CD4 T-cell help (Bevan, 2004).  There is evidence that  
initial CD8 priming can occur in the absence of CD4 T-cells, 
on subsequent re-encounter with antigen T-cells primed in 
the absence of CD4 cells die rather than proliferate in a 
TRAIL dependent fashion (Janssen et al., 2005).  In fact, 
the continued presence of CD4 T-cells is vital in order for 
maintenance of CTL responses over time (Sun et al., 2004).  
During the CTL priming phase, exposure of CD8 T-cells to IL-
2, the main source of which is activated CD4 T-cells, is 
vital in order to programme the cells to be able to respond 
to subsequent antigenic re-challenge (Williams et al., 
2006). There are two main groups of theories of memory cell 
differentiation.  The first suggests that the strength or 
quantitative differences in infectious stimuli determine 
memory polarisation – if high and prolonged antigen 
presentation occurs cells are driven towards an exhausted 
and fully differentiated ‘effector’ phenotype, whereas when 
antigen presentation is more restrained or controlled there 
is more of an opportunity for memory differentiation to 
occur.  Alternatively, specific signals such as cytokines or 
subsets of DCs may encourage memory differentiation, and 
this possibility is supported by the fact that there is no 
difference in TCR specificity between effector and memory 
clones (Prlic et al., 2007).  The maintenance of memory CTL 
populations in the absence of antigen requires IL15 and this 
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is produced by DCs upon CD40 ligation (Kennedy et al., 
2000). 
 
Memory CTL responses therefore depend upon the formation of 
a three-way immunological conjugate of antigen-presenting DC 
and cognate CD4 and CD8 T-cells.  The consensus view has 
been that the requirement of CD4 augmentation of CTL 
responses varies according to the nature of the immune 
stimulus – in particular how ‘inflammatory’ it is.   
 
However, numerous studies report that the expansion of 
memory CTLs to second and subsequent antigenic challenges is 
blunted or even abolished if the response was primed 
initially without CD4 ‘help’ (Janssen et al., 2003 and 
Shedlock and Shen, 2003).   
 
CD4 help is clearly antigen specific and CTL memory 
differentiation requires that the same antigen-presenting-
cell interacts with cognate CD4 and CD8 T-cell (Cassell et 
al., 1988 and Bennett et al., 1997).   
 
The critical cellular interaction in memory CTL priming is 
that between CD40 on the APC and CD40 ligand on CD4 T-cells.  
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The evidence for this was the loss of memory responses if 
either molecule was removed (Ridge et al., 1998).   
 
Other downstream effector molecules that may amplify the 
effects of the CD40-CD40L interaction include IL2, IL12, 
IL15 and 4-1BBL.   
 
DC are the ideal APC to participate in this process as their 
ability to cross-present allows them to simultaneously 
present Class I and II restricted epitopes, they strongly 
express CD40 on activation and controlled lysosomal 
hydrolysis (compared with, for example, macrophages) permits 
generation of Class II epitopes.  
 
DC can programme T-cells to home to particular anatomic 
sites.  Skin derived DCs ‘imprint’ the ability to home into 
cutaneous tissues on the induced effector T-cells, and 
Peyer’s patch derived DCs generate DCs with the ability to 






1.6. In vitro derived DC for vaccination.  
 
 
DC are bone marrow derived antigen-presenting-cells.  Their 
development is encouraged by granulocyte-monocyte colony 
stimulating factor (GM-CSF) and by the fms-like tyrosine-
kinase 3 ligand (Flt3L) (O’Neill, Adams and Bhardwaj, 2004).  
Administration of synthetic Flt3L expands circulating DC 
populations at last 100 fold (Pulendran et al., 2000) and 
Flt3L double knockout transgenic mice are deficient in DCs 
(McKenna et al., 2000).  All DCs are HLA DR positive and 
negative for other lineage markers (e.g. CD3, CD14, CD19, 
CD56). 
 
Methods for generating cells with DC like properties in 
vitro are well established (Sallusto and Lanzavecchia, 1994) 
and this has spawned interest in the use of in vitro 
generated DC as vaccines in infectious and malignant disease 
and to downregulate T-cell responses in autoimmunity 
(Steinmann et al., 2000). 
 
1.6.1. CD34 stem cell derived DCs 
 
DCs can be produced from CD34 positive haematopoietic stem 





The use of CD34 positive haematopoietic stem cells as a 
substrate for DC generation is well established.  The 
frequency of stem cells in peripheral blood is extremely low 
- it is necessary to either use bone-marrow samples or to 
mobilise peripheral stem cells using G-CSF or GM-CSF 
injection.  There are concerns regarding promotion of tumour 
growth with these drugs.  The key advantage of using CD34 
stem cells for DC culture is that there is abundant evidence 
suggesting that culture with GM-CSF, TNFα and Stem-cell 
factor or Flt3-L generates a population of cells 
recapitulating several characteristics of Langerhans cells 
(Ueno et al., 2007).  This is ideal for immunotherapy as LCs 
drive powerfully cytotoxic CD8 T-cell responses.  There is 
evidence of clinical efficacy of this approach in metastatic 
melanoma (Banchereau et al., 2001).   
 
1.6.2. Monocyte derived DCs. 
 
 
This has been the most used platform for DC generation.  
Culture of blood monocytes, easily obtainable either at low 
purity after plastic adherences or high-purity by 
immunomagnetic selection, with a cytokine-cocktail leads to 
cells with excellent antigen-presenting properties.   
Exposure of monocytes to GM-CSF and IL4 generates a 
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heterogeneous population of large, veiled cells that have 
lost CD14 expression and gained expression of CD1a.  They 
are semi-mature or immature DCs as they express only low 
levels of costimulatory molecules, molecules involved in 
migration and MHC Class II molecules and when pulsed with 
peptides these cells tend to lead to the generation of 
regulatory T-cells or anergy of T-cell responses (de Vries 
et al., 2003 and Dhodapkar and Steinman, 2002). 
 
However, exposure of cells to macrophage conditioned medium 
or to recombinant TNFα upregulates costimulatory molecules, 
class II molecules and receptors involved in lymphokine 
driven chemotaxis to lymph nodes and generates cells capable 
of priming effective T-cell responses (Sallusto and 
Lanzavecchia, 1994).   
 
 
1.6.3. Activation and maturation of monocyte derived DCs. 
 
DC are typically generated from monocytes by 5-7 days 
differentiation in GM-CSF and IL4 followed by ‘activation’ 
with TNFα, IL1β, IL6 and prostaglandin E2 (PGE2) (Jonuleit 
et al., 1997).  Such DC have been convincingly shown, in 
proof-of-principle experiments, to be able to activate T-
cell responses in healthy human volunteers.  Dhodapkar et al 
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(2000) showed that intradermal administration of macrophage 
conditioned medium matured DCs loaded with either tetanus 
toxoid or keyhole-limpet haemocyanin led to the generation 
of durable (approximately 6 months durable) CD4 responses 
against these antigens in a specific fashion (i.e. no 
responses were seen in patients given tetanus toxoid or KLH 
alone or unloaded DCs).  In addition, DCs loaded with an 
influenza matrix protein CD8 epitope were able to expand the 
epitope specific CTL population in vivo, and in fact in 
responding volunteers DC vaccination seems to increase the 
peptide sensitivity of these cells.  However, the ability of 
MoDC to cross-present in less certain.  The ability to 
cross-present is of paramount importance in cancer 
vaccination strategies when antigen is delivered as a 
tumour-lysate or recombinant protein.  MoDCs ability to 
cross-present is critically dependent on the nature of the 
antigen presented.  Certainly capture of apoptotic cells 
(Albert et al., 1998) and immune complexes (Dhodapkar et 
al., 2002) can lead to presentation of Class I restricted 
epitopes.  Conjugation of antigens to the uptake receptor 
DEC205, expressed on moDCs, can ensure access to the Class I 
pathway for exogenous antigen (Bozzacco et al., 2007).   
 
 
A major criticism has been that the phenotype of moDCs does 
not closely resemble any in-vivo subset and the cells seem 
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to be ‘hybrids’ with features of interstitial and dermal 
DCs, specialised for humoural rather than cellular response 
induction (Palucka, 2007).   
 
 
The method of monocyte selection from peripheral blood 
mononuclear cells – elutriation, plastic adherence or 
immunomagnetic selection does not have a major effect on the 
function of the DCs.   
 
The 7-9 day culture period is not ideal for clinical 
purposes and the yield and purity of DCs is higher and more 
highly avid CTL responses are induced by DCs differentiated 
in 24-48 hours (Tuyaerts et al., 2007).  
 
 
Fast DC generated within 48 hours have a fully mature 
phenotype with MHC Class II, CCR7, CD40, and CD83 expression 
and are able to respond with migration to the lymphokine 
ligands.  The minimal cytokines required for phenotypic 
maturation appear to be PGE2 and TNF (Dauer et al., 2005).   
 
GM-CSF is essential to programme differentiation towards 
macrophage lineage cells but IL4 can be replaced by other 
cytokines.  In a comparison of IL-4 and IL-15 moDCs loaded 
with Melan A 26-35 peptide, it was shown that comparable 26-
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35 specific CD8 populations were induced but IL-15 DCs 
achieved this at lower peptide concentrations.  Also, the 
induced CTL population had higher IFNγ release, stronger 
perforin and granzyme expression and crucially was able to 
lyse targets physiologically expressing antigen (Melan A 
positive melanoma cell line) – something that IL4 DC driven 
cultures were not capable of (Dubsky et al., 2007).  IL15 
DCs display some of the desirable features of Langerhans 
cells including Langherin, CCR6 and E-cadherin but not 
Birbeck granules (Mohamadzadeh et al., 2001).   
 
A ‘supplemented’ cytokine cocktail includes T-cell derived 
signals and Type I interferons like IFNα (Lapenta et al., 
2006).  The impetus for such enhanced cocktails was the 
observation that cytokine matured moDC were deficient in 
IL12p70 production (Sporri and Reis e Sousa, 2005).  This is 
the biologically active IL12 heterodimer that is essential 
for Th1 polarisation and development of long lived and avid 
T-cells (Trinchieri, 2003).  Toll like receptor stimulation 
via MyD88 is important for IL12p70 secretion (Warger et al., 
2006) and various compounds have been used including CpG 
oligodeoxynucleotides, Poly I:C (Rouas et al., 2004) and 
imiquimod.  Adapting these compounds for clinical use is 
difficult, although a clinical study in metastatic breast 
cancer using IFNγ and LPS matured moDCs showed powerful 
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induction of CD4 and CD8 responses and reductions in disease 
volume (Czerniecki et al., 2007) 
 
Addition of IFNα or T-cell derived signals - CD40 ligand and 
IFNγ - boosts the immunostimulatory properties of moDC in 
vitro (Dauer et al., 2008).  This fits with the two-step 
model of T-cell activation.  Activation begins on receipt of 
proinflammatory signals from bystander cells and direct 
pathogen recognition by DCs.  Later, these activated DCs are 
‘licensed’ to ‘full’ effector in the T-cell areas of lymph 
nodes by T-cell signals – this forms a positive feedback 
loop to amplify T-cell activation.    
 
Although megacytokine cocktails seem optimal in in vitro 
assays of T-cell stimulation (Giermasz et al., 2009), a 
closer examination of the kinetics of the process in vivo 
raises questions about whether these findings will apply for 
clinical DC vaccination.  Maturation stimuli including T-
cell signals may lead to functionally exhausted DCs.  The 
early release of IL12p70 is disadvantageous when the further 
48 hour delay from administration to arrival in lymph nodes 
is considered.  The more desirable property is to arrived 
‘licenced’ and able to respond to T-cell signals in vivo 
with a further burst of IL12p70 secretion (Langenkamp et 





Despite these advances, activation of monocyte derived DCs 
in-vitro attempts to model an extremely complex in-vivo 
process that has evolved over millions of years of the 
pathogen-host interaction (Gilboa, 2007) 
 
1.6.4. Migration of monocyte derived DCs. 
 
A critical property of DC vaccines is their ability to 
migrate from the injection site to secondary lymphoid 
tissue, as initiation of T-cell responses locally in the 
skin is unlikely.  Only 5-10% of administered cells reach 
lymph nodes (Morse et al., 1999 and Adema et al., 2005).  
Although intralymphatic or intranodal injection of DCs 
should enhance migration, this has been difficult to 
demonstrate and there are concerns that intranodal injection 
could destroy the important micro-architecture of the node 
(Kyte et al., 2006).   
 
An alternative perspective is that the low proportion of the 
vaccine reaching lymph nodes is advantageous as it may 
reflect a process of selection with only the most ‘mature’ 




Expression of the CCR7 chemokine receptor has dominated 
thought in this area.  Most studies of DC vaccines have 
either not addressed the question of migration or simply 
used expression of surface CCR7 as a surrogate marker.  
Whilst the presence of CCR7 may be necessary for migration, 
it is not necessarily sufficient (Quillien et al., 2005).   
 
Differential expression of chemokine receptors occurs in 
maturing DCs, with interactions between, for example, CCR1 
and CCL3 and CXCR1 and CXCL8 in the early phase allowing DCs 
to home to sites of inflammation (Sallusto et al., 1998) and 
after activation these receptors are downregulated and 
interaction between the lymphokines CCL19 and CCL21 and 
their receptors CCR7 and CXCR4 becomes relevant (Cyster, 
1999).  CCR7 deficient mice show defective movement of skin 
DCs to draining superficial lymph nodes.  However, movement 
of Langerhans cells can be CCR7 independent and may rely on 
the CCR6-CCL20 interaction instead (Ohl et al., 2004). 
 
Important additional steps in this system downstream of 
either CCR7 or CXCR4 in particular leukotrienes LTD4 and 
LTDE4 (Randolph et al., 2005), expression of matrix 
metalloproteases 2 and 9 (Ratzinger et al., 2002) and lipid 




The rationale for inclusion of PGE2 in maturation cocktails 
has largely related to its effects on promoting CCR7 
expression and migratory capacity on maturing DCs (Scandella 
et al., 2002 and Jonuleit et al., 1997).  There was also 
some evidence that PGE2 in addition to TNFα in the 
maturation cocktail generated a high level of CD4 and CD8 
stimulation than TNFα alone (Rubio et al., 2005).   
 
However, IL12p70 production is attenuated by PGE2 (Kalinski 
et al., 2001) and induction of indoleamine 2,3 dioxygenase 
(IDO) is encouraged.  It is suggested that the IL10:IL12p70 
ratio and hence the balance between Th2 and Th1 responses is 
skewed in favour of humoural responses by PGE2 matured DCs 
(Jongmans et al., 2005). Other results suggest that the 
ability of PGE2 matured DCs to respond to subsequent CD40 
ligation with IL12p70 secretion is compromised.  
 
However, in the presence of powerful activating signals such 
as CD40L, IFNγ or Toll-like receptor ligands, the use of PGE2 
in maturation cocktails may not have a profoundly negative 
effect on IL12p70 production. 
 
 
However, more concerning is the recent realisation that 
inclusion of PGE2 in the maturation cocktail leads to 
generation of DCs that express the enzyme indoleamine 2,3 
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dioxgenase (IDO).  IDO expression can also be linked to 
upregulation of CD25 (Von Bergweld-Baildon et al., 2006).   
 
IDO catalyses the degradation of tryptophan to kyenurine and 
was discovered in the placenta (Munn et al., 1998).  Here it 
plays a permissive role in the immunodeficiency of pregnancy 
and it suppresses T-cell responses against fetal allo-
antigens (Mellor et al., 2001).  T-cell activation and 
proliferation are dependent on adequate concentrations of 
tryptophan and are inhibited by kyenurines and IDO positive 
DCs constitute an immunoregulatory subset (Munn, 2002).   
 
The coexistence of upregulation of CD25 and IDO on maturing 
DCs may also endue an immunosuppressive phenotype on the T-
cell response as there is evidence that increased surface 
CD25 expression, once considered a marker of ‘mature’ DCs, 
correlates the secretion of soluble IL2 decoy receptors that 
can reduce local concentrations of IL2 and thus impair CD4 
responses (Popov and Schultze, 2008).   
 
Strategies for enhancing the migration of DC vaccines 
include pre-condition of the injection site with TLRs (Nair 
et al., 2003) and use of multiple, small DC inoculums 
(Gilboa, 2007).   




1.6.5. Antigen transfer by vaccine-grade dendritic cells. 
 
 
It is assumed that vaccine DC migrate to draining lymph 
nodes and form immunological synapses with T-cells to 
initiate expansion of T-cell populations.  However in a 
mouse model of cutaneous HSV infection the cells responsible 
for presentation of a Class I restricted epitope did not 
originate from the infected epidermis (Allan et al., 2003).   
 
It is currently thought that there is a lymph node resident, 
CD8α positive dendritic cell subset in mice  that is 
entirely non-migratory and functions to acquire antigen from 
mobile DCs and cross-present it via the Class I pathway 
(Carbone, Belz and Heath, 2004).  
 
Antigen likely accesses these cells either by direct 
carriage by the afferent lymph which may be relatively less 
immunogenic (Itano et al., 2003), or by active antigen 
transfer from migratory DC populations.    
 
Clearly thse findings have implications for vaccine design.  
Monocyte derived DCs are known to be highly interactive 
cells forming gap junctions and transferring intact melanoma 
antigens to one another which amplifies the immune response 
(Mendoza-Naranjo et al., 2007).  Alternatively exosomes 
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could be responsible for antigen transfer (Thery et al., 
2002).   
 
1.6.6. Antigen loading of vaccine-grade dendritic cells. 
 
There are numerous methods for loading vaccine DCs with 
tumour associated antigens.  These can be broadly divided 
into those in which antigen is produced endogenously within 
the cell and those where there is exogenous acquisition of 
antigen.  The key disadvantages and benefits are summarised 




Most early studies, whether clinical or pre-clinical, 
utilised peptide pulsing of DCs with exogenous peptides.  
The advantages of this approach include the simplicity of 
peptide manufacture of peptides and their ease of use and 
stability.  However, peptide based approaches require 
determination of patient HLA haplotypes and are often 
restricted to patients with common HLA alleles – typically 
HLA-A2 for Class I loading in Caucasian patients.  
Additionally, whilst the number of Class II binding peptides 
is expanding these are still relatively limited in number 
and induction of CD4 responses is vital to success of DC 









peptide approaches are limited in the specificity of T-cells 
that they are likely to induce.  Use of peptide pools is 
hindered by competition and inadequate T-cell stimulation 
(Dieckmann et al., 2005). It is difficult to determine the 
appropriate dose of peptide with which to pulse cells.  
Typically high doses are used in the micromolar range. 
However, there may be an inverse correlation between antigen 
dose and the T-cell receptor avidity of the induced T-cell 
populations.  Using a model of latex beads coated with co-
stimulatory molecules as artificial APCs, it was shown that 
Melan-A 26-35 specific T-cell populations induced with 10uM 
peptide were 1000 fold less avid than those induced with 
10nM peptide (Walter et al., 2003).  Finally, it is thought 
that peptide-MHC complexes formed by passive pulsing have a 
limited duration at the cell surface and it has been shown 
that protein loaded DCs cross-present a Class I restricted 
epitope for a longer period that peptide-pulsed cells 
(Schnurr et al., 2005).  It is important to bear in mind the 
requirement for the peptide-loaded vaccine cells to migrate 
to lymph nodes.  Despite all these concerns, meta-analyses 
of the clinical trials performed to date suggests that 
peptide-loaded DC vaccines give the highest objective 
response rates in metastatic melanoma (Nakai et al., 2010) 
 




Other exogenous approaches include co-incubating DC with 
recombinant proteins or tumour lysates.  Most studies have 
been performed with tumour cell lysates rather than 
recombinant proteins as these are difficult to produce for 
clinical application.  Additionally, the desired outcome – 
presentation of Class I and II restricted epitopes is highly 
dependent on the presence of ‘danger signals’ and often 
apoptotic or necrotic cell lysates will be rich in heat 
shock proteins and these have maturation enhancing effects 
on DCs (Somersan et al., 2001).  However, all tumour 
associated proteins are transferred and whilst this has the 
advantage of including mutated tumour specific proteins, the 
possibility of exposing maturing DCs to tumour derived 
immunosuppressive substances remains.  Also, obtaining 
sufficient quantities of tumour material for autologous 
lysates is not straightforward.  Uptake of exogenous 
proteins by DCs is thought to favour the Class II pathway, 
particularly as the ability of monocyte derived DCs to 
cross-present is highly dependent on the activation stimulus 
used.  
 
1.6.6.3. Endogenous antigen production. 
 
Methods to endogenously produce within the DCs the antigen 
of interest have been developed.  These include viral 
transduction and non-viral transfection.  Viral vectors 
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typically encode specific pre-defined tumour antigens, 
whereas nucleic acid transfection can encompass either pre-
defined antigens or bulk tumour-derived cDNA or mRNA.   
 
Currently, favoured approaches centre on expression of full 
length, intact tumour-associated-antigen within the DC.  
Viral transduction with recombinant viruses, such as 
poxviruses (Kim et al., 1997) and adenoviruses (Butterfield 
et al., 1998) and is highly efficient in terms of transgene 
expression and leads to the robust generation of Class I, 
and in some cases Class II restricted epitopes.  However, it 
can lead to non-specific immune effects, deleterious T cell 
responses to viral antigens expressed in the DC and is less 
easily applicable to clinical trials owing to regulatory 
issues.  There are also safety concerns with regard to 
virally induced genomic mutagenesis. The preparation of 
plasmid cDNA or in-vitro transcribed RNA is more 
straightforward than generation of recombinant viruses which 
can take months. 
 
1.6.6.4. Non-viral transfection: plasmid DNA. 
 
 
Like other primary, non-dividing cells human dendritic cells 
were extremely resistant to transfection with plasmid cDNA 
constructs.  Transfection techniques used have included 
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cationic lipids, nucleofection and electroporation.  In the 
vast majority of studies, there was negligible transgene 
expression. 
 
Rughetti et al (2000) demonstrated 10-20% transgene 
expression in human MoDC after cationic lipid transfection 
of Mucin-1 cDNA.  However, cell viability was as low as 50% 
- although transfection appeared to have ‘maturation-
inducing’ effects on the DCs and proliferative T-cell 
responses in the autologous system were observed despite low 
transfection efficiency.  Landi et al (2007) showed 
transgene expression levels of 20% with cationic lipids.  
 
 
Although transfection efficiency remained unassessed, 
Alijagic et al (1995) showed that MoDC transfected using 
lipofectamine with cDNA encoding tyrosinase were able to 
reactivate tyrosinase specific CD8 T-cells in autologous 
PBMCs.   
 
A comprehensive analysis of various cationic lipids for 
transfection of human monocyte derived or CD34 stem cell 
derived DCs using eGFP as the reporter gene (Van Tendeloo et 





Electrical methods of cell transfection work by passing a 
current through the cells leading to the transient formation 
of membrane pores for entry of nucleic acids.  Significant 
impairment of cell viability after 24 hours is usual. 
 
Using GFP, it was shown that electroporation of plasmid DNA 
into stem cell derived DC did lead to expression levels of 
up to 15%, although 30% cell viability was typical.  There 
was a wide range of fluorescence intensities in the 
transfected DC. It was also observed that moDC were 
relatively resistant to DNA electroporation (Van Tendeloo et 
al., 1998). 
 
Although CD34 stem cell derived DC can be successfully 
electroporated with plasmid DNA, Melan A transfected HLA A2 
positive CD34 DC were not recognised by a Melan A specific 
CD8 T cell clone by IFNγ ELISA due to non-specific 
stimulation in cells transfected with control plasmid (Van 
Tendeloo et al., 2001). 
 
Amaxa nucleofection is a form of electroporation that uses 
buffer solutions and electrical parameters that are 
proprietary and vary according to the cell type being 
transfected.  Expression levels of up to 50% can be achieved 




Nucleofection of immature human moDC with eGFP cDNA led to 
acceptable cell viability (37%) and good GFP expression 
(55%) at 24 hours.  However, the cells’ ability to 
upregulate co stimulatory molecules CD80 and CD83 in 
response to the lipopolysaccharide maturation stimulus was 
impaired after nucleofection.  Production of inflammatory 
cytokines IL1B, TNFa and IL6 was diminished in nucleofected 
DC, although IL12 secretion was slightly enhanced.  
Nucleofection of mature DC, however, appeared to be the 
optimal approach as 39% of cells were GFP positive and 
retained their mature phenotype (Lenz et al., 2003). 
 
 
As part of a systematic comparison of moDC generation 
protocols and transfection methodologies, Landi et al (2007) 
found that nucleofection of immature DC (differentiated from 
CD14 positive monocytes positively selected from PBMC) could 
be effectively utilised with transfection efficiency 
approaching 40%, but significant reduction in viability was 
seen after 24 hours.  Ability of the DC vaccine to present 
antigenic epitopes was not assessed in this study.  
 
In summary, T cell recognition of DC nucleofected with cDNA 
has not been demonstrated and negative effects on the 
ability of DC to functionally mature have been noted, 





A novel technique uses a 35 amino acid cationic peptide 
(CL22) (rather than lipid) to condense the DNA into 
particles for cellular uptake.  The presence of the 
lysosomal acidification inhibitor chloroquine during 
transfection maximises DNA delivery into the cytoplasm and 
nucleus by preventing lysosomal degradation.  Percentages of 
cells expressing the transgene ranged from 80 to 20% for 
cell lines (monkey, human and mouse) and around 15% for the 
two primary cells tested (human DC and human umbilical vein 
endothelial cells).  
 
An optimised procedure for human moDC was developed with 
transfection efficiencies ranging from 1-54% with an average 
of 17%.  Transfection of human DC was shown to lead to the 
presentation of Class I restricted viral epitopes and, in 
mice, the development of a cellular (CD8 T cell) and 
humoural immune response.  Presentation of Class II 
restricted epitopes to CD4 T cells was not specifically 
investigated (Irvine et al., 2000). 
 
CL22 based transfection was taken forward into the clinical 
setting of metastatic melanoma (Steele et al., 2011) and 




1.6.6.5.  Non-viral transfection – in-vitro transcribed RNA. 
 
 
Endogenous production of whole antigen mainly directs the 
resultant epitope peptides into the Class I-CD8 pathway and 
in order to generate a complete cellular immune response 
presentation of Class II restricted peptides is crucial.  
For this reason, many antigens are expressed as fusion 
proteins alongside key components of the endolysosomal Class 
II pathway (e.g. invariant chain, LAMP) or autophagosomes 
(e.g. Atg8).  A particularly interesting strategy to achieve 
this is co-transfection with antisense oligodeoxynucleotides 
directed again the invariant chain to increase the 
likelihood of endogenous produced peptides interacting with 




The use of mRNA rather than cDNA for DC transfection has 
several putative advantages including a need for translation 
only and a requirement to only traverse one cell membrane.  
(Ponsaerts, 2003).  RNA cannot be integrated into host 
genomes.  However, RNA is highly prone to RNAase digestion 
ex vivo if not handled carefully and has a short 
intracellular half life which could lead to very transient 
protein expression.  In vitro transcribed RNA must closely 
resemble physiologically produced mRNA and to bind stably to 
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ribosomes, and be translated efficiently it requires 5’ 
methylguanosine capping and the additional of a Poly A tail 
(Colgan and Manley, 1997). 
 
Van Tendeloo et al (2001) showed, using GFP, that 
transfection efficiencies of 63% for immature moDC and 33% 
for mature moDC could be achieved using electroporation of 
in-vitro transcribed RNA at 24 hours post transfection.  The 
electroporated DC were able to upregulate CD80 and CD83 and 
MHC Class II molecules in response to TNFα and 
lipopolysaccharide (LPS), and stimulate IFNγ secretion from a 
Melan A specific cytotoxic T lymphocyte (CTL) clone.   
 
 
RNA electroporation of tumour and viral antigens, including 
influenza matrix protein, Melan A, human telomerase reverse 
transcriptase, HIV GAG, human papilloma virus E6 and E7 and 
CEA, as well as whole tumour RNA into DC has been shown to 
lead to T cell recognition and activation (Ponsaerts, 2003).   
 
Generally the focus has been on Class I presentation to CTL 
clones although CD4 T cell recognition of transfected cells 
has also been demonstrated (Dorfel et al., 2005 and Su et 
al., 2005).   
 
In the work of Grunebach et al (2003), there was no apparent 
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correlation between transgene expression levels after RNA 
transfection and the ability of the DC to expand a specific 
CTL population in vitro – suggesting that even barely 
detectable antigen levels may be sufficient for epitope 
presentation.   
 
RNA transfected DC stimulated up to 80% of maximal (i.e. 
peptide stimulated) IFNγ release, indicating the potential 
utility of RNA electroporation (Bonehill et al., 2004). 
 
 
1.7. Malignancy as a target for immune responses. 
 
1.7.1 Immune surveillance. 
 
 
Administration of bacterial extracts to advanced sarcomas 
leads to transient tumour regressions – linking cancer and 
immunity (Coley, 1891).  The tumour immunosurveillance 
hypothesis proposes that the adaptive immune system can 
recognise transformed cells as foreign antigenically and 
that immune function restrains the early stages of neoplasia 
(Burnet, 1967).  This was based on the observation that 
irradiated cancer cell lines, derived from sarcomas in mice, 
when delivered to syngeneic mice as a vaccine, led to 
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protection from subsequent tumour challenge (Basombrio et 
al, 1970, Pellis et al, 1974).   
 
There was also circumstantial evidence.  Very occasionally 
spontaneous tumour regressions do occur and they are often 
accompanied by evidence of autoimmunity as in the case of 
melanoma and vitiligo (Cunha et al, 2009).   
 
Necropsies suggest that the frequency of asymptomatic, 
microscopic foci of neoplasia far exceeds the frequency of 
known, symptomatic malignant disease (Ashley, 1965) and this 
raised the possibility that endogenous, perhaps immune, 
processes were able to prevent progression of premalignant 
lesions. 
 
In paraneoplastic syndromes, neurological dysfunction occurs 
in the absence of demonstrable infiltration of neural tissue 
by tumour, and may happen even when tumours are completely 
undetectable clinically (Mathew et al, 2006). These 
syndromes are caused by cellular and humoral immune 
responses against antigens that are shared between tumours 




However, epidemiologic studies on cancer in immunosuppressed  
patients failed to provide evidence of increased incidence 
of non-virally driven malignancies (Penn and Brunson, 1988).  
The finding that nude, athymic mice did not have increased 
incidences of cancer questioned the tumour-
immunosurveillance concept (Rygaard and Povlsen, 1974).  
Although experiments were performed using chemical 
carcinogens over a relatively short period of time – unlike 
the natural history of most cancers in humans, there was no 
difference in incidence of any cancer between the two groups 
(Stutman, 1974) and it was confirmed that the nude mice were 
severely immunodeficient and accepted allogeneic skin 
grafts. 
 
Recent experiments have resurrected the tumour immuno-
surveillance hypothesis.  Transgenic mice lacking both 
copies of the recombinase-activating gene (RAG) were 
engineered.  These animals lack all lymphocyte subsets that 
require somatic rearrangements of genes encoding antigen 
receptors – namely T cells, natural killer T cells and B 
cells.  Such mice did show increases in incidence of 
spontaneous and induced cancers compared to littermates that 
were wild-type for the recombinase activating genes 




Nude, athymic mice do possess very low levels of specific 
lymphocytes.  In particular, very low levels of alpha-beta T 
lymphocytes were present (Ikehara et al., 1984) and other 
subsets such as NK T cells and gamma-delta T-cells were 
replete in these mice.  This allowed the two sets of results 
to be reconciled.   
 
Modern epidemiologic studies reveal a two to five fold 
increase in non-viral malignancies in renal transplant 
recipients whose T-cell function is suppressed by drugs such 
as cyclosporine (Birkeland et al, 1995); although the 
majority of cancers in this population are sill associated 
with viral infection.   
 
1.7.2. Efficacy of immune-based therapies for malignancy. 
 
The efficacy of immune-based therapeutics for cancer implies 
an underlying immune control of malignancies. Intravesicular 
BCG is effective for superficial bladder cancer (Alexandroff 
et al, 1999).  BCG is an attenuated form of Mycobacterium 
bovis and acts by inducing local non-specific immune 
stimulation.  Non specific immune-stimulatory treatments, 
such as IL-2 (Atkins, 2002) and IFNα/β (Belardelli et al, 
2002), are established therapies for advanced renal cell 
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carcinoma and malignant melanoma.  The TLR7 agonist 
imiquimod is used for early skin cancers (Gaspari, 2007). In 
metastatic melanoma, an immunomodulatory drug – ipilimumab – 
has recently been shown to prolong overall survival (Hodi et 
al, 2010). The drug antagonises the function of CTLA4.  
 
1.7.3. Tumour-infltrating lymphocytes 
 
Histological studies of most tumours, including melanoma 
(Hom et al, 1991) show a T-cell infiltrate.  This is 
unlikely to be an epiphenomenon as the density of the 
tumour-infiltrating-lymphocytes correlates with a favourable 
prognosis in a wide range of cancers:- head and neck 
squamous cell carcinoma (Pretscher et al., 2009), 
oesophageal cancer (Schumacher et al., 2001), squamous 
cervical carcinoma (Nedergaard et al., 2008), malignant 
melanoma (Taylor et al., 2007), ovarian cancer (Tomsova et 
al., 2008) and colorectal cancer (Katz et al., 2009). 
 
The functionality of infiltrating lymphocytes is suggested 
by the observation that they only confer a better outcome if 
they are seen in an intratumoural rather than peritumoural 
location (Naito et al., 1998).  Only TILs possessing 
activation markers (such as granzyme B (Van Houdt et al., 
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2008) or CD69 expression (Badoual et al., 2006)) conferred a 
favourable prognosis. Analysis of TILs by gene expression 
profiling, in the setting of colorectal cancer, has proven 
to be more informative in terms of prognosis and need for 
adjuvant chemotherapy than the widely used TMN 
classification system (Galon et al., 2006).   
 
1.7.4. Importance of the CD4 response in anti-tumour immunity 
 
The anti-tumour immune response is an integrated and 
coordinated response that involves the full range of immune 
cells.  The prime effector cell in immunosurveillance has 
been thought to be the cytotoxic CD8 T lymphocyte, as it 
possesses intracellular machinery that allows killing of 
target cells. 
 
However, in the priming phase of the immune response the 
position of the CD4 helper T lymphocyte is a central one, 
and TH cells may execute several effector functions of their 
own. 
 
Mouse tumour vaccination-challenge models have demonstrated 
that depletion of the CD4 T lymphocyte subset at the time of 
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vaccination markedly attenuates the subsequent protection 
against tumour challenge. 
 
Vaccination of B6 mice with autologous DC transfected with a 
gp100 plasmid using lipofectamine mediated protection 
against challenge with a gp100 transfected tumour 
(fibrosarcoma and plasmacytoma).  However, CD4 depletion pre 
immunization abrogated protective responses.  This suggests 
that CD4 cells may be involved in priming of the CD8 
cytotoxic response (Yang et al., 1999). 
 
The importance of CD4 T-cells is illustrated by findings 
that CD8 double knockout mice are able to mount a protective 
response to subcutaneous challenge with irradiated GM-CSF 
transduced B16 melanoma cells which,was significantly higher 
than that seen in CD4 -/- mice.  Eosinophil recruitment 
requires CD4 help and the presence of tumour infiltrating 
eosinophils, and more specifically secretion of the toxic 
cationic basic protein, may be correlated with a less 
aggressive clinical course in several cancers including 
squamous cell carcinoma of the oral cavity (Falconieri et 




Production of IFNγ from activated TH cells leads to increased 
expression of inducible nitric oxide synthetase (iNOS) in 
tumour associated macrophages.  NO has anti tumour effects 
in vivo and in vitro, some mediated by effects on the tumour 
vasculature.  Secretion of highly toxic H2O2 or superoxide by 
macrophages is also TH cell dependent and may have a role in 
antitumour immunity (Hung et al., 1998). 
 
It is noted that many melanoma cells express very low levels 
of MHC Class I molecules but most do express MHC Class II 
molecules, at variable levels.  This may make them more 
susceptible to Class II effectors.   
 
The anti-tumour T helper response is interesting because, 
unlike the response to infectious pathogens which normally 
commits to either TH1 or TH2 pathways after 7-10 days post 
infection, it combines features of both (e.g. secretion of 
gamma interferon and IL4) for a prolonged period.  This is 
sometimes known as the TH0 response.   
 
CD4 help also boosts opsonising antibody responses, and in 
DC, there is evidence that the unique ability to cross-
present exogenously acquired antigen via the MHC Class I, 
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proteasomal pathway is dependent on the form of antigen that 
is available for uptake.  Antigen as immune complexes is 
taken up more efficiently and leads to the generation of 
more Class I and II restricted peptide epitopes than 
free/soluble antigen (Schnurr et al., 2005). 
 
It can also be envisaged that a humoural response against 
cell surface oncogenic proteins such as altered adhesion 
molecules or secreted molecules like matrix 
metalloproteases, involved in invasion and metastasis may 




There is evidence that a subset of CD4 T helper cells may 
possess cytotoxic functions that are independent of CD8 T 
lymphocytes.  Such cells have been detected in response to 
viral infections such as cytomegalovirus, human 
immunodeficiency virus and Epstein-Barr virus.  The 
cytotoxic mechanism appears to be granule exocytosis of 
perforin and granzyme B.  It is possible that cytotoxic CD4 
cells represent a subset highly differentiated subset of 
frequently activated TH1 cells.  Of particular relevance to 
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immunotherapy, EBV Latent Membrane Protein 1/2 specific CD4 
T cell clones, with demonstrable cytotoxic activity in 
vitro, when administered to patients with EBV positive 
lymphomas resulted in durable disease remissions (Haigh et 
al., 2008 and Bollard et al., 2008). 
 
 
Initiation of a cytotoxic T lymphocyte response requires the 
presence of CD4 helper T lymphocytes at the priming stage.  
There is a requirement for the CD4 T cell to recognise 
epitopes from the same antigen on the same antigen-
presenting-cell as the CD8 cell receiving ‘help’.  However, 
the epitopes recognised are often different and CD4/CD8 
recognition can be temporally and spatially distinct.  
Following dendritic cell capture of antigen, presentation of 
peptide-MHC complexes to CD4 T cells leads to enhanced CD40 
ligand expression.  Engagement of CD40 on DC stabilises and 
boosts the DC-CD8 interaction, allowing clonal expansion and 
development of effector functions.   
 
 




The presence of a chronic inflammatory infiltrate, 
characterised by cells of the innate immune system, is 
associated with a poorer outcome in cancer (Coussens and 
Werb, 2002).  Tumour-associated macrophages secrete 
immunosuppressive cytokines (such as IL10 and IL4) that can 
inhibit tumour antigen specific Th1 responses, and proteases 
that aid tumour invasion and metastasis (Allavena et al., 
2008).  They also release pro-angiogenic factors. Myeloid 
derived suppressor cells also mediate a similar effect 
(Ostrand-Rosenberg and Sinha, 2009).  MDSCs recruit 
regulatory T-lymphocytes and secrete soluble 
immunosuppressive cytokines. MDSCs also attenuate T-cell 
activation in the milieu of the tumour.   
 
1.7.6. Tumour-associated antigens 
 
A detailed analysis of TILs (in particular T-lymphocytes), 
circulating T-cells and of humoral responses to malignancy 
(often using the serological analysis of recombinant cDNA 
tissue libraries (Chen, 2000)) has led to the identification 
of numerous tumour-associated-antigens (Disis and Cheever, 
1996).  Despite the undeniable presence of T-cell responses 
to these tumour antigens, their overall efficacy must be 
modest, as eventually tumour escape and progression occurs 




One simple reason relates to the nature of the antigens.  
Viral tumour antigens (such as EBNA1 of Epstein-Barr Virus 
and human papillomavirus E6/E7 proteins) are foreign and 
therefore highly immunogenic, but other TAAs are self-
proteins.  A small proportion of these are oncogenic 
proteins by virtue of activating (e.g. k-RAS) or 
inactivating (e.g. p53) mutations.  Mutated oncogenic 
proteins may also arise from chromosomal translocations 
Although the immune responses only occur in the presence of 
mutated proteins, the individual epitopes recognised are 
often from non-mutated, ‘self’ portions of the proteins.   
 
However, most TAA are normal self-proteins that may be 
overexpressed or aberrantly expressed in malignancy; 
examples of these include differentiation antigens such as 
Melan-A, tyrosinase and gp100 in melanoma and cancer-testis 
antigens such as MAGEA1,2,3.    
 
Thus, in view of immune tolerance, these TAAs are unlikely 
to elicit powerful immune responses.  In fact, peripheral 
tolerance is mediated largely by regulatory T-cells.  These 
cells, characterised by a CD4, CD25, FOXP3 positive 
immunophenotype, are able to actively suppress immune 
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responses against self-antigens in both contact dependent 
and independent manners (Waldmann and Cobbold, 2009).  In 
the context of cancer, inverse correlations between T 
regulatory cell infiltrates and prognosis have been observed 
in numerous tumours – gastric cancer (Shen Z et al, 2010), 
chronic lymphocytic leukaemia (D’Arena et al, 2010), and 
colorectal cancer (Deng et al, 2010).   
 
The categorisation of tumour-associated-antigens is 
summarised in Table 1.1. 
 
1.7.7. Melanoma antigens 
 
The melanoma differentiation antigens are present on both 
normal and malignant tissue (including retinal pigment 
epithelium) of the melanocytic lineage.  CTL responses to 
these antigens recognise transformed and normal melanocytes 
(Anichini et al, 1993). The antigen group includes proteins 
with known enzymatic functions (tryosinase, tyrosinase-
related-proteins 1 and 2), those with likely structural 
roles within melanosomes (gp100/PMEL17) and those without 








Melan A is a small, type 1 transmembrane protein expressed 
in normal and malignant melanocytes.  It is one of the most 
immunogenic melanocyte-differentiation antigens with T-cell 
responses being detectable in melanoma patients (Kawakami et 
al., 1994) and healthy donors (Pittet et al., 1999).  The 
protein is found particularly in immature (Stages 1 and 2) 
melanosomes.  It has no known enzymatic function, but may 
act as an escort or chaperone protein for other melanosomal 
protein including gp100 (Hoashi et al., 2005) and OA1 
(Giordano et al., 2009).   
 
 
A more detailed analysis of peptide epitope responses to 
this antigen in melanoma patients, using T2 cells pulsed 
with synthetic overlapping peptides as targets for CTL 
recognition, revealed that there was a highly immunodominant 
epitope spanning amino acids 26 to 35 of the protein 
sequence.  Two HLA A-2 restricted epitopes 26-35 EAAGIGILTV 
and AAGIGILTV (27 to 35) are highly immunodominant (Kawakami 
et al, 1994). In direct ex-vivo analyses, Romero found that 
up to 30% of CD8 positive cells in tumour infiltrated lymph 
nodes (in metastatic melanoma) were Melan A 26-35 positive 
as assessed by tetramer staining.  These cells were capable 
of in-vitro expansion upon cytokine exposure and the 
resultant cell lines were highly lytic against matched 
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targets including peptide-pulsed cells and autologous tumour 
cells (Romero et al., 1998).   
 
Analysis of peptides that bind to HLA-A2 molecules (the 
commonest Class A haplotype in Caucasian populations) 
suggests that the optimum peptide length is 9 or 10 
residues, and that important anchor residues are methionine 
or leucine at position 2 and valine at position 9 or 10. The 
26-35 epitope (EAAGIGILTV) is therefore rather atypical, 
particularly with the negatively charged glutamic acid 
residue at position 1. Valmori et al (1998) demonstrated 
that HLA-A2 restricted TIL derived T cell clones specific 
for Melan A recognised the 27-35 epitope an order of 
magnitude less efficiently than the 26-35 epitope.  
Moreover, by making individual amino-acid substitutions it 
was shown than the 27 AL peptide analogue had the highest 
HLA-A2 binding affinity in functional competition assays.  
The ELAGIGILTV analogue also had superior HLA binding 
kinetics and the peptide-HLA complex was stable over 6 hours 
as opposed to 1 hour for the unsubstituted 26/27-35 
peptides.  Functionally, the ability of Melan A specific TIL 
clones to recognise target cells pulsed with ELA was higher 
than when targets were pulsed with EAA, and the ability of 
the modified peptide to induce Melan A specific CTL in a 
PBMC population was also superior.  Whilst the ELA analogue 
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may be useful for immunotherapeutic and vaccination 
purposes, it should be borne in mind that it does not exist 
in-vivo.   
 
The immunodominance of the 26-35 epitope is striking and 
Melan A specific CD8 responses, whether in peripheral blood, 
metastatic lymph nodes or tumour itself are dominated by 
this epitope.   
 
 
Gp100/PMEL17 is also a melanosome-associated protein.  It is 
highly expressed in later stage melanosomes (Hoashi et al., 
2005), where it forms a structural, fibrillar framework for 
the subsequent deposition of melanin pigment.  In contrast 
to the immunodominance of Melan A 26-35, several HLA A2 
restricted epitopes have been discovered.  Although T-cell 
responses to gp100 are common in melanoma patients, they are 
very rare in healthy donors.  Sequences within gp100 that 
lead to the melanosomal or endolysosomal localisation of the 
protein have been identified (Lepage and Lapointe, 2006).  
MHC Class II restricted presentation of gp100 epitopes is 





1.7.8. Tumour-mediated immunosuppression. 
 
Active tumour-driven immunosuppressive mechanisms do exist.  
The tumour microenvironment, which encompasses endothelial, 
vascular, immune and stromal cells as well as malignant 
cells themselves, actively produces immunomodulatory 
substances that can have negative effects on both 
infiltrating T lymphocytes and on local dendritic cells 
(Gajewski et al., 2006). 
 
An important mediator of immunosuppressive effects in the 
tumour microenvironment is transforming growth factor beta 
(TGFβ) (Disis, 2009).  It favours the generation of 
regulatory T cell responses over cytotoxic T cell responses 
(Li and Flavell, 2008) and may blunt high avidity CTL 
responses by reducing IL12 and 15 production (Sanjabi et al, 
2009).    
 
In antigen-specific vaccination for cancer, it is often 
observed that an expansion of CD4 or CD8 T cells specific 
for the antigen can be achieved in blood. However, the 
frequency of clinical responses is much lower.  This may 
relate to suboptimal recruitment and movement of T 
lymphocytes from the circulation or lymphatic system into 
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tumour masses (Lee et al, 1999).  Aberrant patterns of 
expression of chemokines and adhesion molecules may be 
responsible (Adams et al., 1997).   
 
Despite these numerous impediments to T-cell recruitment to 
tumour sites, Tumour-Infiltrating-Lymphocytes are readily 
detected in almost all tumour types.  However, the cells 
generally show multiple functional deficits compared to 
circulating lymphocytes and are blunted in effector function 
(Appay et al., 2006). 
 
 
In the same context of metastatic melanoma, Zippelius et al 
(2004) show appreciable frequencies of Melan A 26-35 specific 
CD8 T cells in three locations – in increasing order – 
peripheral blood, metastatic lymph nodes and visceral 
metastases.  The majority of cells were antigen experienced, 
in contrast to the naive cells found in PBMC of healthy 
donors.  T-cell clones derived from metastatic lymph nodes 
demonstrated high T-cell receptor avidity.  However, 
crucially, in both metastatic lymph nodes and visceral 
metastases specific T-cells showed reduced IFNγ release in 
short term stimulation assays compared with circulating 
cells, even though the response to non-specific stimulation 
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was preserved.  Cells from metastatic lymph nodes 
additionally displayed deficient perforin expression.  When 
cells were cultured in the presence of IL2 or IL7 in-vitro, 
cytolytic capacity was rapidly restored. 
 
The widespread expression of programmed death ligand-1 (PD-
L1) on various cancer cells leads to engagement of the PD-1 
receptor on T-lymphocytes (Dong et al, 2003).  This receptor 
is upregulated on activated T-cells and functions as a brake 
on immune responses (Latchman et al, 2001) 
 
The enzyme IDO is overexpressed in the tumour 
microenvironment, although the cell of origin remains 
unclear and malignant, vascular, stromal, myeloid-derived 
suppressor (Meisel et al, 2004) and immature dendritic cells 
(Munn et al, 2002) may all make a contribution.  IDO 
catalyses the degradation of the amino acid tryptophan to 
catabolites including quinolinic acid, L-kynurenine and 
picolinic acid.  These metabolites have a pro-apoptotic 
effect on T-cells and tryptophan depletion places a 
proliferative block on activated T-cells (Frumento et al, 
2002).  In colorectal cancer, high IDO expression by tumour 
cells correlated inversely with overall survival and density 
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of CD3 positive T-cell infiltrate and positively with 
likelihood of metastatic disease (Brandacher et al, 2006).   
 
 
Most tumours are poorly immunogenic by virtue of 
downregulation of surface HLA molecules and lack of co-
stimulation (Gilboa, 1999).  Epigenetic changes, for example 
in promoter methylation state, may drive HLA downregulation 
(Nie et al., 2001).  Aside from HLA molecules themselves, 
loss of the Class I associated protein β2M and mutations of 
LMP2/7 and TAP can be associated with tumour immune escape 
(Restifo et al., 1996 and Marincola et al., 2000).   
 
Other important tumour derived substances that have 
suppressive effects on DC maturation or T-cell activation  
include Suppressor-of-Cytokine signalling-1 (SOCS-1) (Evel-
Kabler et al., 2006), STAT3 (Cheng et al., 2003) and L-
galectin (Perillo et al., 1995). 
 
In summary, as discussed above, tumour antigen specific T-
cell responses are detectable ex-vivo from the blood of 
cancer patients.  However, due to tumour driven 









these responses are not highly efficacious in eradication of 
established malignancy. The partial and incomplete 
activation of tumour infiltrating DC plays a key role in 
this.  This forms the rationale behind the development of 
immunotherapeutic approaches to cancer that attempt to 
enhance and augment tumour-specific immune responses.  These 
specific immunotherapies include: adoptive transfer of T-
lymphocyte clones and antigen specific vaccination. 
 
 
1.7.9. Clinical studies of DC vaccination  
 
 
As discussed earlier, in-vitro derived DC can be loaded with 
antigens in many ways.  Here, the focus is on clinical use 
of nucleic acid transfection with defined, rather than bulk, 
tumour antigens. 
 
A summary of clinical trials of DC vaccination for cancer 
with vaccine cells transfected with nucleic acid encoding 




















Several observations can be drawn from these studies.  
First, these are all exploratory Phase I and II trials and 
the absence of a matched, untreated control group makes it 
impossible to draw definite conclusions regarding clinical 
efficacy.  Second, immunologic responses to vaccination have 
been more impressive than clinical responses.  Third, in 
terms of vaccine characterisation, all studies report the 
immunophenotype, yield and viability of cells prior to re-
administration.  However, only two of the studies measure 
the level of transgene expression in transfected DCs and the 
importance of this parameter in determining vaccine 
immunogenicity remains unexplored.  Fourth, not all studies 
specifically address the enhancement of CD4, MHC Class II 
restricted responses.  Finally, a plethora of different 
transfection strategies have been employed and there is no 
consensus over which method is the most effective, although 
most recent in-vitro studies of DC vaccination focus on RNA 
electroporation.   
There was a recent breakthrough in the field of ex-vivo 
generated DC vaccines for cancer with the approval by 
regulatory authories in the United States of ‘Sipuleucel-T’ 
for prostate cancer.  This is an autologous cellular product 
designed to stimulate protective T-cell immunity against 
prostatic acid phosphatise, an enzyme only expressed in 
prostatic tissue.  It is a vaccine approach although the 
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nature of the vaccine is essentially uncharacterised.  It is 
prepared from autologous PBMCs co-incubated with a fusion 
protein of GM-CSF with prostatic acid phosphatise, making it 
likely that the differentiation of antigen-presenting-cells 
is encouraged (Small et al., 2000).  These may be DC like 
cells.  Unlike other vaccination approaches, randomised 
Phase III trials have been carried out and meaningful 
endpoints including progression free and overall survival 
have been studied, rather than surrogates such as PSA 
velocity (Higano et al., 2009).  Sipuleucel-T treatment is 
associated with an overall extension of survival of 4-5 
months (Small et al., 2006).   There was an 8 fold 
amplification of T-cell responses to PAP, although only a 
small subset of patients were analysed.  Whilst not strictly 
speaking a DC vaccine, this approach paves the way for the 
expansion of DC vaccination and testing in randomised 











1.8. Rationale and Aims 
 
Methods for in-vitro generation of DCs from peripheral blood 
monocytes have been available for well over a decade 
(Sallusto and Lanzavecchia, 1994).  During this time, DCs 
have been used in the clinical context as cellular vaccines 
for many, usually advanced, malignancies (Nestle et al., 
2005).  
 
The outcome of clinical trials of DC vaccination has not 
been overwhelmingly encouraging.  On the one hand, 
monitoring of immune responses against vaccinated antigen 
has generally shown upregulation of responses and sometimes 
epitope spreading.  In contrast, long-lived, durable 
objective tumour regressions have been very rare (Rosenberg 
et al., 2004). This may reflect the advanced stage of tumour 
growth, where the balance is heavily in favour of the tumour 
cells in tumour immunosurveillance.  Also, in these trials 
DC vaccination has been used in isolation, and combination 
with other immunomodulatory strategies such as CTLA-4 
blockade (Hodi et al., 2010 and Phan et al., 2003) or 
selective depletion of regulatory T-cells may improve 




Individual clinical-grade DC vaccines have been highly 
variable in terms of DC generation method, selection of 
antigen and antigen loading strategy, maturation stimulus 
used and route of administration; perhaps contributing to 
the heterogeneity of observed outcomes (Figdor et al, 2004).    
Quality control of DC vaccines is therefore a crucial aspect 
of the development pathway and for transfected DC vaccines 
expressing whole antigen the importance of whole antigen 
detection remains uncertain.   
 
  
1.8.1 Phase I/II trial of a dendritic cell vaccine transfected with DNA 




Recently, metastatic (Stage IV) melanoma patients were 
treated with an autologous DC vaccine expressing whole 
antigen following transfection of plasmid DNA using a novel 
cationic peptide – CL22 (Steele et al., 2011).  Clinical 
responses were observed in a small subset (approximately 
15%) of patients.  Overall, T-cell responses to a range of 
Class I and Class II restricted epitopes from the two 
antigens (Melan A/MART-1 and gp100/PMEL17) increased in 
frequency across vaccination cycles.  This was antigen-
specific as IFNγ responses to viral recall epitopes remained 
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static in comparison.  The DC vaccine was characterised by 
assessment of surface markers of maturation and 
intracellular antibody staining for Melan A and gp100 
protein 48 hours after transfection (just prior to re-
administration).   
 
The proportion of DCs expressing either antigen was highly 
variable both between and within patients as shown in Figure 
1.5 for gp100 and Melan-A. The key observation was that, on 
a patient-by-patient basis, there was no evidence of 
correlation between antigen-positivity of DCs and subsequent 
clinical or immunological outcomes.  The question therefore 
arises whether whole antigen detection at 48 hours after 
transfection is a surrogate marker of DC immunogenicity or 
not, and if not, what other possible markers might be of 
use.    
 
As mentioned above, IFNγ ELISPOT assays demonstrated an 
overall increase in frequency of responses to Class II 
restricted epitopes from both antigens.  It should be noted 
that the number of know Class II restricted peptide epitopes 
was relatively modest. Pre-clinical work using the 
transfection system used in this trial had only formally 






epitopes by DCs in-vitro.  There was circumstantial, 
indirect evidence for Class II presentation however as mice 
immunised with transfected DCs mounted IgG responses to the 
antigens, suggesting T helper cell involvement (Irvine et 
al., 2000).   
 
1.8.2.  Aims 
 
The aims of the project were as follows:- 
 
1. To investigate antigen presentation in DC using CL22 
peptide mediated transfection of plasmid DNA 
a. Determine whether or not vaccination as part of 
the clinical trial led to upregulation of IgG 
responses against gp100 and Melan-A 
b. Determine the presence and level of Melan A 26-35 
and gp100 280-288 HLA A2 restricted peptide display 
on patients’ transfected DC preparations 
c. To demonstrate whether or not simultaneous 
presentation of Class I and II restricted epitopes 
from endogenously produced antigen in CL22 
transfected DCs occurs 
d. To ascertain whether or not plasmid transfection 
into DCs using CL22 peptide leads to activating or 
maturation-enhancing effects on DCs. 
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e. To determine the relative immunogenicity of CL22 
peptide transfected in comparison with other 
nucleic acid transfection methods. 
 
2. To investigate the relationship beween epitope 
presentation focussing on Class I restricted epitopes 
and whole antigen detection in transfected vaccine DCs. 
a. To determine the importance of whole antigen 
detection in immunogenicity and antigenicity 
b. To determine, if whole antigen detection seems 
irrelevant, what other measurements might be 
suitable surrogate markers of immunogenicity 
c. To determine whether or not this relationship 
between antigen detection and epitope presentation 
is a general feature of DC biology or is antigen-
specific 
 
3. To investigate the relationship between the properties 
of antigen and its ability to be presented via the MHC 
class II pathway in transfected vaccine DC 
a. To determine if the nature of antigen – viral 
(EBNA1) or self antigen (Melan-A, gp100) affects 
Class II presentation 
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b. To determine whether or not cellular localisation 
of antigen (EBNA1) affects the ability to access 
the Class II pathway 
c. If Class II presentation of endogenously 
synthesised antigen is detectable – determine the 
mechanism (secretion and reuptake, autophagy) 
d. To determine whether the kinetics of Class II 
restricted epitope presentation differ from those 
of Class I presentation 
e. To determine whether mode of transfection or 










CHAPTER 2: METHODS 
 
2.1.  Generation of immature dendritic cells 
 
Blood was drawn from laboratory volunteers into heparinised 
syringes (10 units unfractionated heparin per ml).  Donors 
had previously had HLA haplotyping performed by PCR.  Blood 
was mixed in a 1:1 (v/v) ratio with warm RPMI 1640 medium 
(Invitrogen).  After thorough mixing, diluted blood (30ml 
per tube) was carefully layered on top of 15mls of Ficoll- 
lymphoprep (Axis-Shield) in 50ml centrifuge tubes.  Tubes 
were centrifuged at 300G rpm with the brake off for 30 
minutes.  Using Pasteur pipettes, the interface cells were 
aspirated and transferred to new tubes.  PBMC were washed 
three times with RPMI 1640 medium.  PBMC were resuspended in 
a small volume of standard medium (RPMI 1640 supplemented 
with 10% v/v fetal calf serum, 1% v/v penicillin-
streptomycin and 1% L-glutamine (both Invitrogen), filter-
sterilised before use). Viability counts were performed 
using Trypan blue exclusion.  Typically, 0.75-1.5 x 106 PBMC 
were obtained per ml of whole blood.  Up to 6 x 107 PBMC were 
resuspended in 20 mls of standard medium, mixed well by 
pipetting and added to 75cm2 tissue culture flasks which were 
incubated flat for 2 hours at 37°C and 5% CO2.  Flasks were 
removed from the incubator and loosely adherent cells were 
gently removed by gentle pipetting and collected in a 
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separate 50ml tube.  The base of the flask was rinsed gently 
with 10ml warm standard medium twice to minimise 
contamination of adherent monocytes with lymphocytes.  The 
non-adherent cell fraction was either discarded or 
cryoperserved .  20ml of cytokine supplemented standard 
medium (500 IU/ml recombinant human IL4 (R and D systems) 
and GM-CSF (Queen Elizabeth Hospital Pharmacy)) was added to 
each 75 cm2 flask and these were then returned to the 
incubator for 5 days.   
 
Buffy-coat samples from the National Blood Service were 
occasionally used for DC generation, particularly when 
knowledge of HLA haplotypes was unnecessary and larger DC 
yields were required.  PBMC isolation was performed as 
described above with the addition of sterile filtering (0.33 
µM) to remove clumps of cellular debris.   
 
On day 5, cells were harvested thoroughly.  Viability counts 
were performed and an estimate was made of the relative 
proportion of dendritic cells and contaminating lymphocytes 
by morphology.  The percentage of lymphocytes ranged from 
20-40%.  At this point, cells were used for nucleic acid 
transfection.  However, in most experiments, a small 
proportion of immature DCs were transferred directly to DC 
maturation medium (standard medium supplemented with GM-CSF 
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and IL4 (500 IU/ml) and TNFa and IL1b).  After transfection, 
all DC were transferred into maturation medium before 
incubation for 24-48 hours prior to further assays.   
 
2.2.  Dendritic cell transfections 
2.2.1. CL22 mediated transfection 
 
This technique was identical to Steele et al (2011), except 
that fewer DC were used per transfection.  Transfection 
reagents were unused clinical grade products and had been 
stored at -80°C.   Immature DCs were washed twice with RPMI 
1640 and resuspended in RPMI medium at 1.2 x106 cells/ml.  
Hepes Buffered saline (HBS) was used dilute the CL22 peptide 
to a concentration of 92 µg/ml and plasmid DNA was diluted 
to 40 µg/ml.  Concentrations were verified by 
spectrophotometry (Nanodrop).  Diluted DNA and CL22 peptide 
were gently mixed by pipetting and DNA:peptide complexes 
were allowed to form for 1 hour at room temperature.  
Depending on the number of DCs available for transfection, 
the DNA:peptide mixture was added to multiwell plates: 1.5 x 
106 DC/transfection – 12 well plate – 250ul DNA:peptide and 
1.25ml of cellular suspension, 7.5 x 105 DC/transfection – 24 
well plate – 125 ul DNA:peptide and 750ul cellular 
suspension.  Cells were added dropwise to DNA:peptide mix.  
Chloroquine (QE Hospital Pharmacy) was added to each well at 
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a final concentration of 40µM.  Plates were gently agitated 
before being centrifuged at 150G for 5 minutes.  Plates were 
transferred to the incubator for 90 minutes post 
transfection.  Transfection medium was gently removed and 
maturation medium (see above) was added (1.5ml for 12 well 
plates, and 750 ul for 24 well plates), and plates were 
incubated until further analysis.   
 
2.2.2. Nucleofection of plasmid DNA or RNA. 
 
This was performed as per the manufacturer’s instructions.  
DC (mature or immature) were counted and 0.5-2 x 106 DCs per 
nucleofection were centrifuged and the supernatant was 
completely removed.  Human DC nucleofector solution was 
mixed with nucleofector supplement (18µl supplement and 82 
microlitres nucleofector solution per nucleofection) and 
left to warm to room temperature for at 30 minutes.  The DC 
pellet was resuspended in supplemented nucleofector solution 
and plasmid DNA or in-vitro transcribed RNA (1µg nucleic 
acid per 0.5 x 106 cells) was added.  Cells and nucleic acid 
were mixed and transferred to the Amaxa cuvettes.  Cells 
were nucleofected using the U-02 programme on the 
Nucleofector I device.  After nucleofection, cuvettes were 
very gently removed and 500 µl prewarmed maturation medium 
was gently added on top of the cell pellet.  Cells were then 
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carefully transferred to either 12 or 24 well plates pre-
filled with warm maturation medium (500ul for 24 well plate, 
1ml for 12 well plates).    Cells were transferred to the 
incubator prior to further analysis.   
 
2.2.3. Electroporation of in-vitro transcribed RNA. 
 
In vitro transcribed RNA was stored in 2 µg aliquots at -
80°C.  For each RNA transfection, a single aliquot was thawed 
at room temperature immediately before use.  Concentration 
of RNA was re-checked by spectrophotometry.  DC for 
transfection (typically 0.5-2 x 106 cells) were washed once 
with warm sterile phosphate-buffered-saline (PBS) and then 
with warm serum free medium (OPTImem, Invitrogen).  Cells 
were resuspended in 300µl OPTImem and RNA was added (2µg per 
106 DC).  After mixing, DCs and RNA were transferred to 4mm 
electroporation cuvettes (Cell Projects).  Cuvettes were 
placed into a Genepulser electroporation machine (Biorad) 
and electroporated (square wave) at 300V and 500µF.  The 
typical time constant obtained for DCs was 15-20 
milliseconds.  These electrical settings were obtained from 
the methods of Landi (2007) and did not require further 
optimisation as initial experiments with GFP encoding RNA 
showed high GFP expression and excellent cellular viability 
(>90%).  After electroporation, 300 µl prewarmed maturation 
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medium was added to cuvettes dropwise and cells were gently 
transferred to wells prefilled with maturation medium (total 
volume 1.6ml in 24 well plates).  Transfected DC were 
incubated until further analysis was performed.     
 
2.3.  Peptide loading of dendritic cells 
 
Alongside transfection of DCs, loading of mature DC with 
exogenous peptide was performed as a positive control for DC 
integrity and T-cell functionality.  DC were washed twice 
with RPMI 1640 (serum free) and resuspended in 100µl of 
RPMI.  Previous work at this institution had suggested that 
peptide loading is most efficient in serum-free conditions 
(G.Taylor, personal communication).  Synthetic peptide 
epitopes (dissolved in dimethylsulphoxide (DMSO)) were 
available in-house.  They were stored at -20°C.  Peptides 
were added to cells at a final concentration of 5µg/ml 
(≈5µM).  As a negative control, an equivalent volume of DMSO 
was added.  DCs were returned to the incubator for 90 
minutes, during which time, tubes were agitated every 30 
minutes.  At 90 minutes, cells were washed with standard 
medium twice to remove unbound peptide before use in assays.   
 




Cells were frozen at a maximum density of 2 x 107 cells/vial.  
Cells were centrifuged and resuspended in 500µl fetal bovine 
serum per vial.  They were then placed on ice for 10 minutes 
alongside freezing mix (20% DMSO in FCS (v/v)).  An 
equivalent volume of freezing mix was added dropwise and 
cells were transferred to cryotubes (Nunc, Denmark) – 1ml 
cell suspension per tube.  Tubes were transferred to 
isopropanol filled containers and then to a -80°C freezer for 
short-term storage.  If long-term cryopreservation was 
needed, tubes were moved to liquid nitrogen storage (-180°C).   
Cells were thawed as follows.  Vials were placed in a 37° 
waterbath for 2-3 minutes.  Just before the last ice crystal 
melted, they were removed and warmed standard medium was 
added dropwise with continual agitation.  Cells were washed 
twice with standard medium to remove excess DMSO before use.  
 
 
2.5. Generation of in vitro transcribed RNA. 
2.5.1. Linearisation of plasmid DNA 
 
Plasmid DNA was the substrate for RNA synthesis.  Plasmid 
maps were inspected for unique restriction sites just distal 
to the inserted DNA coding sequence.  Plasmid DNA was then 
digested with the appropriate enzyme.  Typically, digests 
were set up in 100µl microcentrifuge tubes as follows: 4µg 
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plasmid DNA, 20 units of restriction enzyme, 4µl buffer 
(x10) and sufficient ultrapure water to make a total 
reaction volume of 40µl.  Reagents were mixed and incubated 
in a 37°C waterbath for 90 minutes.  Control digests (lacking 
enzyme) were set up in parallel.  Approximately 8µl was used 
for analysis.  The reaction products were separated by 
electrophoresis on an agarose gel (0.8%) and were stained 
with ethidium bromide for visualisation.  If a clear 
difference in electrophoretic mobility (reflecting 
linearised versus circular plasmid) was observed, DNA was 
purified with the use of a PCR clean up kit (Roche) 
according to manufacturer’s instructions.  DNA was eluted in 
100µl elution buffer (DNAase and RNAase free). DNA was 
quantitated on a Nanodrop spectrophotometer.  Typically, the 
yield was 75%.   
 
2.5.2. RNA synthesis 
 
10µl 3M sodium acetate (pH 5.5 – RNAase free, Ambion) was 
added to DNA.  250µl absolute ethanol (pre-cooled at -20°C) 
was added and the solution mixed well.  The tubes were 
centrifuged at 13,000 rpm for 15 minutes at 4°C.  Supernatant 
was very carefully removed and 500µl 70% v/v ethanol (with 
DEPC-treated water) was added.  Tubes were centrifuged at 
13,000 rpm for 3 minutes, supernatant were removed and 
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pellets were allowed to air dry.  DNA pellets were 
resuspended in 18µl RNAase-free water.  The in-vitro 
transcription reaction was set up as follows: 
 
Reagent Volume (µl) 
DNA 18 
NTP/CAP (nucleotides, capped) 30 
10x reaction buffer 6 
RNA polymerase enzyme mix 6 
 
All in-vitro transcription reagents were part of the 
mMessagemMachine kit from Ambion.  Kits had been stored at -
20°C.  After reactions had been set up and mixed, tubes were 
incubated at 37°C for 60 minutes.  3µl TURBO DNAase enzyme 
was then added to destroy template DNA and tubes were 
incubated for a further 15 minutes. RNA was purified from 
the reaction using the RNEasy Mini Kit (Qiagen).  At the RNA 
elution stage, to maximise RNA concentration, RNA was eluted 
twice in the same 30µl of elution buffer.  RNA yield and 
purity were determined by spectrophotometry.  Typical yields 
of RNA from 4ug of plasmid DNA ranged from 20-80µg.   
 
2.5.3. Polyadenylation of in-vitro transcribed RNA 
 
RNAs were polyadenylated using the USB Yeast Poly (A) 
polymerase kit, as per manufacturer’s instructions.  The 
reaction was carried out for 20 minutes at 37°C.  275µl DEPC-
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treated water were added to the 25µl polyadenylated RNA.  An 
equivalent volume of phenol-chloroform was added and after 
brief vortexing to mix, tubes were centrifuged at 13,000 rpm 
for 10 minutes at 4°C.  The aqueous layer was aspirated off 
into a new tube.  10% (v/v) 3M sodium acetate was added, 
followed by 250% (v/v) absolute ethanol (pre-cooled to -
20°C).  After mixing, samples were cooled for 30 minutes at -
80°C. They were centrifuged at 13,000 rpm for 20 minutes at 
4°C, pellets were washed with 500µl 70% (v/v) ethanol and 
then air-dried. RNA was resuspended in 20µl of DEPC-treated 
water and quantitated on a spectrophotometer, before being 
stored in small aliquots.  As a check on polyadenylation and 
integrity of RNA, pre and post polyadenylation RNAs were 
separated by electrophoresis on 0.75% agarose gels.  In all 
cases, there was a difference in mobility after 
polyadenylation and discrete bands were seen.  
 
2.6 Surface and intraceullar staining of dendritic cells – flow cytometry 
  
For surface staining, 104-105 DC were used per stain.  The DC 
were washed once with FACS buffer (PBS with 1% BSA and 0.05% 
sodium azide).  The pellet was resuspended in 480ul FACS 
buffer and mixed with 120ul purified polyclonal mouse IgG 
(Serotec).  Cells were then left on ice for 30 minutes to 
block surface Fc receptors.  50µl cell suspension was 
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transferred to each well on a V-bottomed 96 well plate.  5ul 
of antibody solution was added per well and cells and 
antibody were mixed by pipetting.  Antibodies used are 
summarised below: 
 
Specificity Conjugate Isotype Supplier 
Human CD1a Phycoerythrin IgG1 BD Pharmingen 
Non-specific Phycoerythrin IgG1 BD Pharmingen 
Human CCR7 Phycoerythrin IgG2a R and D systems 
Non-specific Phycoerythrin IgG2a R and D systems 
Human CD14 Phycoerythrin IgG1 Serotec 
Human CD83 Phycoerythrin IgG1 Serotec 
Human CD86 Phycoerythrin IgG1 Serotec 
Human CD25 Phycoerythrin IgG1 Serotec 
Non-specific Phycoerythrin IgG1 Serotec 
 
 
Cells and antibodies were incubated for 30 minutes at room 
temperature.  Cells were washed twice with cold FACS buffer 
and resuspended in 150 µl sterile PBS.  Cells were 
transferred into 7ml tubes containing 350µl sterile PBS and 
500ul samples were used for flow cytometric analysis.  
Phycoerythrin fluorescence was measured on the FL1 channel 
and background fluorescence was set as 1-2% PE positive 
cells on DCs stained with isotype-matched non-specific 
antibodies.  At least 5000 gated events were counted.  For 
intracellular staining, after incubation with purified mouse 
IgG, cells were resuspended in 50ul FACS buffer and 100ul of 
Reagent 1 (IntraPrep permeabilisation kit, Beckman Coulter) 
before immediate vigorous mixing and incubation for 15 
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minutes at room temperature.  Cells were washed with sterile 
PBS before 100ul reagent 2 was gently added on top of cell 
pellets.  After 5 minutes, tubes were gently agitated and 
stained proceeded as above.   
 
 
2.7. Intracellular staining of dendritic cells – fluorescence microscopy 
 
2-3x105 DC were used per stain.  DC were washed with PBS 
twice to remove medium.  Cells were resuspended in 50µl PBS 
and incubated on ice for 15 minutes.  The DC suspension was 
added to warm (37C) polyethylene coated microscopy slides; 
these were returned to 37C for 15 minutes.  This maximises 
DC adherence.  Cells were fixed with 4% v/v paraformaldehyde 
for 10 minutes at room temperature, washed once with PBS and 
then permeabilised with 0.1% v/v Triton X100 for 5 minutes.   
Non-specific reactivity was blocked with 50µl 20% HINGS 
(heat-inactivated-normal-goat-serum) per spot for 15 minutes 
at room temperature.  HINGS was removed by pipetting and 
primary antibody (EBNA1 – R4 rabbit polyclonal antibody at 
1/1000 dilution, Melan-A and gp100 – A103 and HMB45 mouse 
monoclonal antibodies at 1/100 dilutions) was added at 30µl 
per spot.  Primary antibody incubation was for 1 hours in 
humidified chambers at 37C as was secondary antibody 
incubation  (EBNA1 – 1/1000 goat anti rabbit Alexa 594, 
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Melan-A and gp100 – goat anti mouse Alexa 488).  After 
extensive washes, cell nuclei were stained with DAPI (4',6-
diamidino-2-phenylindole) and single drops of 90% v/v 
glycerol were added to spots before viewing under a 
fluorescence microscope (Nikon E600).  Representative images 
are presented for red/green (antibody) and blue (DAPI) 
fluorescence filters.   
 
2.8. Measurement of IFNγ release: ELISPOT assays. 
 
The human IFNγ ELIspot kit (Mabtech, Denmark) was used 
according to manufacturer’s instructions.  PBS was syringe 
filtered.  ELISPOT plates (Mabtech, Denmark) were filled 
with 50 µl/well of 70% ethanol for 1 minute at room 
temperature and then washed twice with 200µl per well 
filtered PBS.  Diluted capture antibody (human IFNγ specific, 
1D1K) at 7.5µg/ml in PBS was then added - 50µl per well. 
Plates were incubated at 4C overnight.  Primary antibody was 
removed and wells were washed with pre-warmed RPMI 1640 
medium 6 times.  Wells were filled with 200µl complete 
medium (10% FCS) and incubated for 3 hours at 37C to 
minimise non-specific binding.  During this time, target and 
effector cells were prepared in complete medium at the 
required cell density (typically 103-104 cells/well) and 
added to ELISPOT plates.  Plates were incubated overnight at 
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37C.  Cells were removed and wells were washed 6 times with 
PBS-Tween (PBS with 0.005% Tween-20).  Second antibody 7B61-
biotin was diluted to 1µg/ml and 50µl per well was added.  
After 3 hours at room temperature, second antibody was 
removed and wells were washed again.  50µl per well diluted 
alkaline-phosphatase-streptavidin conjugate (1:1000) was 
added for 90 minutes at room temperature.  Colour reagent A 
and B were mixed in a 1:1 (v/v) ratio and AP colour 
development buffer was diluted 1:25 (v/v) with sterile 
water.  These two were mixed and were added at plates at 
100µl/well.  After 15 minutes, colour reagents were removed 
and the reaction was stopped with tap water.  Plates were 
fully dried.  Spot counts were enumerated on an automated 
ELISpot reader (AID).  Results are presented as individual 
spot counts per well.   
 
2.9. Measurement of IFNγ release: ELISA assay. 
 
IFNγ in culture supernatants was quantified by ELISA.  Assays 
were assembled in triplicate with effectors being T-cells 
and targets were either DC or LCLs/B-cell blasts.  96 well 
Maxisorp plates (Nunc) were coated with 50ul/well mouse 
anti-human IFNγ antibody at 0.75ug/ml in coating buffer (0.1M 
Na2HPO4, adjusted to pH 9 with 0.1M NaH2PO4) and were 
incubated at 4C overnight.  Primary antibody was removed and 
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non-specific binding was blocked with 200ul/well of blocking 
buffer (PBS with 1% w/v bovine serum albumen and 0.05% v/v 
Tween 20) for 1 hour at room temperature.  After six washes, 
50ul culture supernatant or diluted recombinant human IFNγ 
(doubling dilutions from 2000pg/ml to 31.25 pg/ml) were 
added to wells for 3 hours at room temperature.  After six 
hours, 50ul per well of biotinylated anti-human IFNy 
antibody was added per well at 0.75ug/ml and incubation was 
at room temperature for 90 minutes.  After 6 further washes, 
50ul per well of ExtrAvidin peroxidise (Sigma) was added at 
1:1000 in blocking buffer for 30 minutes.  After 8 washes, 
80ul per well of substrate (3’,5,5’-tetramethylbenzidine 
solution containing peroxide – TebuBiotech) was added; after 
15 minutes the reaction and colour development was stopped 
with 1M HCl.  Absorbance was measured at 450nm using an 
automated plate reader (Bio-Rad).  IFNy release was 
determined using a linear equation derived from the standard 
curve of recombinant IFNy concentration and absorbance.   
 
 
2.10. Measurement of cytokine release by dendritic cells: ELISA 
 
The Ebioscience ‘Ready-Set-Go’ cytokine ELISA kits – 
IL12p70, IL12p40 and IL10 were used as per manufacturer’s 
instructions.  Plates were 96 well NUNC (Denmark) Maxisorp 
plates.  Coating antibody (IL10, IL12p40 or IL12p70) was 
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diluted according to the Certificate of Analysis in coating 
buffer and was added at 100µl per well.  Plates were 
incubated overnight at 4C.  Wells were washed 5 times with 
wash buffer and were then blocked with assay diluent 
(diluted 1:5 in sterile water) .  Assay diluent was removed 
and 50µl/well of dendritic cell supernatant (directly 
removed from culture wells, spun at 10,000 rpm for 5 minutes 
to pellet any cellular material) was added to wells for 2 
hours at room temperature.  After 5 washes with wash buffer, 
diluted capture antibody was added at 100µl/well for 1 hour 
at room temperature.  Diluted Avidin-horseradish peroxidase 
conjugate was added at 100µl per well for 30 minutes at room 
temperature.  After further washes, substrate solution was 
added at 50µl per well for 15 minutes and the reaction was 
stopped with 50µl/well stopping solution.  Absorbance was 
measured at 450nm wavelength on a multiplate 
spectrophotometer.  To determine cytokine levels, a standard 
curve was constructed for these assays using recombinant 
cytokines provided.  A best-fit line was determined using 
Microsoft Excel and the equation for this line was used to 
calculate cytokine levels in unknown samples.  The standard 
curves generated for IL10, IL12p40 and IL12p70 are presented 







2.11. ELISA for anti Melan-A IgG. 
 
96 well flat bottomed ELISA plates (Falcon) were coated with 
recombinant Melan-A protein (ProSpecTany Technogene, Israel) 
at 5µg/ml in coating buffer (Na2CO3/NaHCO3 buffered at pH 
9.6) overnight at 4C.  Wells were washed with PBS three 
times before being blocked with PBS containing 5% (w/v) non-
fat dried milk for 2 hours at 37C.  Wells were washed thrice 
with PBS containing 0.05% (v/v) Tween-20 (Sigma) and samples 
were added.  Plasma samples were either used fresh (lab 
donors) or gently thawed at 37C for 5-10 minutes followed by 
gentle mixing by pipetting.  They were diluted to 1:50, 
1:250 and 1:500 (v/v) in PBS-Tween-5% milk and were added to 
wells at 50µl/well for 1 hour at room temperature.  After 
further washing of wells with PBS-Tween, the detection 
antibody (goat anti human IgG-alkaline phosphatase, Sigma) 
was added at 50µl per well at a dilution of 1:1000 in PBS-
Tween-5% milk for 1 hour at room temperature.  After further 
washes, the substrate (p-nitrophenyl-phosphate, Sigma) was 
added at 100µl per well and after 30 minutes the reaction 
was stopped with 0.1M H2SO4 and the absorbance was determined 
on a spectrophotometer at 450nm.  Assays were set up in 
triplicate, and in initial optimisation assays, the plasma 
samples were replaced with primary Melan-A specific 
antibodies (mouse anti-human Melan-A, A103).  In experiments 
to determine the effect of preincubation of plasma with 
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recombinant Melan-A, plasma samples were pre-incubated with 
either bovine serum albumen (Sigma) or Melan-A protein prior 
to analysis as above.   
 
2.12. Staining with HLA 35-HPV tetramer 
 
This tetramer (Khan et al., 2004) was a kind gift from Dr 
Andrew Hislop, Institute for Cancer Studies.  It is 
conjugated with a phycoerythrin tag.  Cells (at least 105 
per stain) were washed twice and suspended in PBS containing 
2% fetal calf serum and 1:50 (v/v) HPV specific tetramer.  
Cells and tetramer were mixed well and left at room 
temperature for 15 minutes.  Cells were washed twice with 
10ml 2% FCS/PBS and pellets were suspended in 500ul PBS 
before flow cytometric analysis on the FL2 channel.  
Negative control was unstained cells and cells lacking the 
HLA B35 epitope; background fluorescence was set at 1-2%.   
 
2.13. Western blotting – EBNA1 and Melan-A. 
 
Transfected HEK293 cells were approximately 70% confluent 
and culture medium was removed followed by two washes with 
sterile PBS.  Lipofectamine 2000 (24ul) was diluted in 
OptiMEM (800ul).   1.6µg plasmid DNA (encoding Melan-A ELA 
variant) was diluted in 100ul of OptiMEM.  As a control 
pcDNA3.1 (empty plasmid) and the Melan-A WT plasmid were 
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also used.  DNA and lipofectamine 2000 were combined and 
200ul per well was added.  Cells and DNA were incubated for 
1 hour. Transfection was terminated by adding 2ml DMEM 
containing 10% FCS per well.  After 72 hours, cells were 
harvested.  140µl of 9M urea were added per tube and cells 
were resuspended by pipetting. From this point samples were 
maintained on ice.  Urea lysates were sonicated briefly for 
5 seconds and samples were centrifuged at 13,000 rpm for 5 
minutes at 4C.  Protein containing supernatants were 
aspirated carefully and cellular debris was discarded.  
Protein content was determined using a Biorad Bradford 
assay.  After protein determination, 15ug protein was added 
to sterile distilled water for a total volume of 20ul and an 
equivalent volume of Laemelli sample buffer was added (950ul 
buffer with 50ul B-mercaptoethanol).  Samples were boiled at 
98C for 3 minutes and cooled rapidly on ice. Running buffer 
was made – 100ml Tris-Bicine at 1M was added to 10ml 20% SDS 
and made up to 1 litre with sterile distilled water.  The 
gel for electrophoresis was prepared – 13.3ml of 30% 
polyacrylamide contain 0.4ml 20% SDS and 4ml 1M Tris-Bicine 
made up to 40ml with sterile distilled water.  
Polymerisation was induced with Tetramethylethylenediamine 
and ammonium persulphate.  35ul of each sample and adjacent 
protein ladders were loaded and electrophoresis was 
performed for 2.5 hours at 40mA.  Proteins were electro-
blotted onto a nitrocellulose membrane overnight at 13V.  
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Blotting buffer was 43g glycine and 9g Tris dissolved in 
600ml methanol and made up to 3l with distilled water.  
Proteins were stained with Ponceau S.  Non specific antibody 
binding was blocked with PBS containing 5% non-fat milk and 
0.1% Tween (20ml) for 90 minutes at room temperature.  Mouse 
anti Melan-A monoclonal antibody (Dako, A103) was diluted to 
1ug/ml in 20ml of blocking buffer and blots were stained 
with regular tilting for 2 hours at room temperatures.  
Blots were washed three times with 50ml PBS for 10 minutes 
and then stained with goat anti-mouse IgG-HRP (1:1000 in 
blocking buffer).  After three further washes, 
chemiluminescent substrate was added and films were 
developed and exposed. 
 
For EBNA1, transfection of HEK293 cells was performed 
exactly as above, with approximately 75,000 cells per 
transfection at  confluency of 70-80%. The pcDNA3.1 plasmid 
(Invitrogen) containing inserts encoding EBNA1 (full 
length), EBNA1∆GAr, EBNA1∆GAr-NLS mutation and pcDNA3.1 with 
no insert and no DNA controls were used.  After 48 hours, 
some cells were removed for immunofluorescence microscopy 
studies and the remainder were left for 24 hours for use in 
Western blotting.  The only differences in method were that 
urea lysates were sonicated twice for 10 seconds and 50ug of 
protein was loaded per lane and electrophoresis was 
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performed for 3 hours at 40mA.  As a positive control, 
lysates of EBV transformed B-LCLs were also used.  Primary 
antibody was anti EBNA1 rat monoclonal (1H4) at 1/50 and 
secondary antibody was goat anti rat IgG-HRP conjugate at 
1/1000.   
 
2.14. Immunofluorescence staining of EBNA1 in transfected HEK293 cells 
 
This was performed as for dendritic cells with some 
modifications.  HEK293 cells were plated onto microscopy 
slides at 30,000 cells per spot and were allowed to adhere 
for 4 hours at 37C.  After fixation and permeabilisation, 
antigen retrieval was performed.  Citric acid buffer was 
made up with 2.1g citric acid in 100ml of distilled water, 
the pH was adjusted to 5.8 with 1M NaOH and the total volume 
made up to 1L with water.  Slides were placed in a plastic 
container and covered with citric acid buffer, and were 
heated in a microwave for 30 minutes.  After cooling at room 
temperature, slides were gently washed with tap water and 
staining proceeded as above.  The 1H4 antibody was used at 
1:50 dilution and secondary antibody was goat anti rat Alexa 
594 conjugate at 1/500 dilution.   
 




The starting point for these experiments was the Melan-A 
wildtype (EAA) plasmid (Plasmid Factory).   The strategy 
used was PCR based site-directed mutagenesis.  Mutagenesis 
primers were designed flanking the site of the EAAELA 
mutation and included a single mutated codon which encodes 
leucine rather than alanine.  Two sequencing primers 
flanking the entire Melan-A coding sequence were also 
purchased.  Melan-A plasmid DNA was diluted to 1ng/ul in 
distilled water and mutagenesis primers 1 and 2 were diluted 
to 10uM concentrations in water. Polymerase chain reactions 
were set up  with 12ul of Phusion HF buffer, 1.2ul of 
dinucleotidetriphosphates at 10mM, 3ul primer 1 and 2 and 
37.2ul of distilled water with 0.6ul of Taq DNA polymerase 
enzyme.  19ul of reaction mix were added to 1ul of diluted 
plasmid DNA.  Thermal cycling conditions were as follows – 
98C for 1 minute and then 35 cycles of 98C for 20 seconds, 
60C for 20 seconds and 72C for 150 seconds followed by 5 
minutes at 72C and reaction products were held at 4C.  PCR 
products were analysed by gel electrophoresis  - 9ul of 
reaction product were added to 2ul loading buffer (x5) and a 
1.5% agarose gel was poured.  10ul samples were loaded into 
each lane alongside DNA markers and electrophoresis was 
performed for 45 minutes at 110V.  This result is 
illustrated in Figure 2.2.  The reactions showing a strong 
band at approximately 4kb were taken forward.  Appropriate 
bands were cut from the gel and extraction of DNA from the 
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gel was undertaken using the Qiagen gel extraction DNA 
purification kit according to manufacturer’s instructions.  
DNA was eluted in 30ul buffer and DNA concentrations were 
4.9ng/ul for reaction 1 and 10.1ng/ul for reaction 3.  The 
ends of linear DNA produced were ligated – 50ug DNA with 
10ul ligation buffer (x2) and 1ul DNA ligase enzyme.  
Reactions were mixed and left at room temperature for 25 
minutes.  As a control, reactions lacking ligase enzyme were 
also assembled.  2ul of each reaction was transferred to 
eppendorf microtubes and 50ul of XL1Blu bacterial cells were 
added per tube.   As a control for the transformation 
process, circular plasmid DNA (encoding Melan-A WT) was also 
used.  Bacteria and DNA were left together on ice for 30 
minutes and were rapidly heated to 45C for 45 seconds before 
being returned to ice.  At this point, 200ul warm super 
optimal broth medium was added per tube.  Transformed 
bacteria were shaken at 2000 rpm at 37C for 90 minutes.  
Bacterial suspensions were spread onto agar plates at either 
50 or 150ul per plate.  Plates were incubated overnight at 
37C and individual colonies were selected with a pipette.  
There were over 200 colonies per plate with the Melan-A 
plasmid DNA, at least 50 with the ligation reactions and 
less than 10 with ‘no ligase’ controls.  In total, 16 
colonies from Melan-A ELA ligation DNA were selected and 5ml 
LB medium was added to each before overnight incubation at 
37C.  DNA was purified from bacteria using the QIAprep Spin 
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MiniKit (QIAGEN) according to manufacturer’s instructions 
and DNA was eluted in 50ul buffer.  Resultant plasmid DNA 
was analysed by Sanger dideoxy sequencing as described here.  
Per reaction, 1ul ‘Big-Dye’ enzyme mix (ABI PRISM), 4ul 
buffer (x5), 1ul sequencing primer at 3.2uM and 10ul of 
distilled water were combined.  16ul of reaction mix was 
added to 4ul of DNA and the PCR was performed overnight 
using the following cycles: 95C for 15 seconds, 50C for 15 
seconds, 60C for 150 seconds for 25 cycles.  2ul 0.25M EDTA 
was added to 18ul reaction products.  60ul absolute ethanol 
was added and reactions were left at room temperature for 15 
minutes.  After centrifugation at 13,000 rpm for 30 minutes 
at 4C, supernatants were carefully removed leaving 1-2ul.  
100ul 70% v/v ethanol were added and further centrifugation 
at 13,000 rpm for 10 minutes was performed.  Supernatants 
were removed as completely as possible and pellets were air-
dried before being resuspended in 10ul formamide. After 
brief vortexing, they were heated for 2 minutes at 96C and 
rapidly cooled on ice.  10ul was loaded onto an ABI PRISM 
machine for sequencing.  Sequencing data were analysed using 
the Chromas software package.  In-silico translation was 
performed in all three reading frames.  Results indicated 
that several clones had alterations around the ELA encoding 
codons.  4 clones containing DNA encoding the ELA sequence 
were sequenced again using a reverse sequencing primer and 
fidelity of the sequence was confirmed.  These plasmids were 
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introduced into HEK293 cells and Melan-A protein detection 
was performed by Western blotting (see above).   
 
2.16. Generation of EBNA1 encoding plasmid DNA. 
 
Plasmids encoding EBNA1 were a gift from Dr Graham Taylor, 
Institute for Cancer Studies.  However, different EBNA1 
isoforms were available in varying plasmid backbones.  For 
comparative experiments, all isoforms were required in the 
same vector.  The starting point was pCGC vector containing 
an EBNA1∆GAr and EBNA1∆GAr-NLS mutation insert, alongside 
rat CD2 cytoplasmic domain and eGFP sequences.  The EBNA1 
insert sequence is flanked by Not1 and Xho1 restriction 
sites.   These are also present in the pcDNA3 cloning site.  
Reactions were assembled: 
 
pcDNA3 (360 ng/ml) pcGC-EBNA1 (1.5mg/ml) 
Plasmid DNA – 6ul Plasmid DNA – 2ul 
2ul buffer H 2ul buffer H 
11ul distilled water 15ul distilled water 
0.5ul (5 units) Not1 enzyme 0.5ul (5 units) Not1 enzyme 




Reactions were performed overnight at 37C.  1µl of shrimp 
alkaline phosphatase was added per reaction for 5 minutes at 
37C and it was then inactivated at 65C for 20 minutes.  Gel 
electrophoresis of reaction products revealed an 
approximately 4kb band for linearised pcDNA3 and a 4kb and 
1.2kb band for pCGC-EBNA1.  The 4kb pcDNA3 band and 1.2kb 
EBNA1 insert band were excised from the gel and DNA 
extraction was performed using the QIAGEN Gel extraction 
kit.  DNA concentrations were: pcDNA3 – 43 ng/ul, EBNA1∆GA – 
16.6 ng/ul, EBNA1∆GA-NLS mutation – 25.5 ng/ul.  DNA 
ligation was performed – A)pcDNA3 alone 1ul with 9ul water 
B)pcDNA3 (1ul) and EBNA1∆GA (3ul) with 6ul water C)pcDNA3 
(1ul) and EBNA1∆GA-NLS (2ul) with 7ul water.  10ul ligation 
buffer (x2) was added to each tube and 1ul fast DNA ligase 
was added.  After 15 minutes, reactions were cooled on ice.  
Agar plates containing 100mg/ml ampicillin were poured and 
XL1Blu bacterial cells were thawed.  2ul of each ligation 
reaction was added to 50ul XL1Blu cells and these were 
incubated on ice for 45 minutes.  Bacterial transformation, 
selection of colonies and DNA extraction were performed as 
above.  Restriction digest with Not1 and XhoI confirmed the 
presence of the EBNA1 inserts in these plasmids.   
 
The puc19 vector containing a full length EBNA1 encoding 
sequence was a gift from Dr Graham Taylor.  The pcDNA3-
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EBNA1∆GA and puc19-EBNA1 vectors were digested with Not1 and 
Xcm1 enzymes and the linearised pcDNA3 vector was treated 
with shrimp phosphatase.  Successful DNA cleavage was 
confirmed by gel electrophoresis and the bands representing 
full length EBNA1 insert and linearised pcDNA3 were excised 
and DNA extraction was performed.  Ligation and 
transformation of XL1Blu were performed as above.  There 
were no bacterial colonies from reactions lacking ligase 
enzyme.  5 colonies were selected and these were digested 
with Not1 and Xho to confirm correct insert sizes 
(approximately 1.8kb).  For final checks, digests were 
performed with an enzyme that does not cut the full length 
but does cut the ∆GA sequence, and it was also verified that 
the insert size was greater for full-length EBNA than ∆GA.  
However, all plasmids were sequenced for final confirmation 
of correct coding sequence.  Results revealed correct 
sequence alignments with long open reading frames encoding 
the known sequences of EBNA1. 
 
For the EBNA1∆GAr-invariant chain fusion protein the 
starting point was pcDNA-invariant chain plasmid, a kind 
gift from Dr Graham Taylor.  This encodes the cytoplasmic 
domain of the human invariant chain (Ii) – approximately 80 
amino acids. Primers flanking the Ii sequence were designed 
and sequences are given in Appendix 1.  PCR was assembled as 
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follows (per reaction): 1ul template DNA (at 10ng/ul), 2.5ul 
magnesium containing PCR buffer, 1.25ul of each primer (at 
10uM), 0.5ul dNTPs and 0.2ul HiFi DNA polymerase.  Thermal 
cycling was as follows: 94C for 2 minutes, then 40 cycles of 
94C 20 seconds, 55C for 20 seconds, 72C for 30 seconds, 
followed by 7 minutes at 72C and a hold a 4C.  The results 
of PCR with and without template DNA were analysed by gel 
electrophoresis: reactions without template showed faint 
bands at 150bp (primer-dimers) but reactions with template 
showed a strong band at 250bp.  This is the expected size of 
the Ii fragment.  PCR product was purified using the Roche 
PCR clean up kit as per manufacturer’s instructions. The 
concentration of invariant chain PCR product was 4000ng/ul.  
4ug of DNA (pcDNA3.1-EBNA1∆GA and Ii DNA were used for a 
Not1 digest.  After gel electrophoresis, relevant bands were 
excised and DNA was purified.  The EBNA1 digest was 
dephosphorylated with shrimp alkaline phosphatase.  DNA was 
diluted to 10.4ng/ul (EBNA1∆GAr)  and 5.2 ng/ul Ii.  50ng of 
vector was combined with 10ng of insert DNA.  The total 
reaction volume was 20ul – 5ul vector, 2ul insert, 3ul 
water, 10ul 2x buffer and 1ul ligase enzyme.  After 20 
minutes at room temperature, XL1Blu bacteria were 
transformed with ligation and control reaction products by 
heat-shock.  Individual colonies (10) were selected and 
expanded, followed by DNA purification with the QIAGEN 
MiniPrep kit.  DNA from these colonies was analysed by 
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digestion with Not1 enzyme.  6 of 10 DNA preparations 
contained an approximately 250bp fragment on gel 
electrophoresis.      As the cloning process was bi-
directional, these six clones were taken forward to DNA 
sequencing to ascertain the orientation of the insert.  DNA 
concentrations ranged from 130 to 240 ng/ul.  Sequencing PCR 
reaction utilised a T7 primer and a total of 400-50-ng DNA 
was used per reaction.  Per reaction – 1ul BigDye, 4ul 5x 
BigDye buffer, 1ul T7 primer (3.2uM) and 12ul distilled 
water with 2ul template DNA.  Thermal cycling was as per 
BigDye protocol.  Reaction products were added to 2ul 0.25M 
EDTA and 60ul absolute ethanol.  After centrifugation (13000 
rpm for 30 minutes at 4C), supernatants were aspirated and 
after a wash with 70% ethanol, pellets were air-dried and 
suspended in 10ul formamide.  One plasmid contained the Ii 
insert in the correct orientation.   
 
2.17. Staining of cells with recombinant T-cell receptors – flow cytometry. 
 
Cells were washed with PBS-0.5% FCS and were resuspended at 
105 cells/ml.  90ul cell suspension was added to each FACS 
tube (9x104 cells).  Soluble TCR (Immunocore Ltd, Abingdon) 
was diluted in PBS/FCS and added at 100nM.  Cells and TCR 
were mixed by gentle ‘flicking’ and left at room temperature 
for 10 minutes.  After 1 wash, supernatants were fully 
removed and cells were resuspended in 90ul of buffer. 
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Streptavidin-phycoerythrin conjugate (Promega) was prepared 
and added at 10µg/ml.  After 10 minutes at room temperature, 
cells were washed twice and resuspended in 500ul PBS before 
immediate analysis by flow cytometry.  The negative control 
was streptavidin-PE only (i.e. no TCR).  PE fluorescence was 
measured by flow cytometry and background fluorescence was 
set at 1-2%.   
 
2.18. Staining of cells with recombinant T-cell receptors – fluorescence 
microscopy. 
 
Staining was performed on cryopreserved DC.  DC were thawed 
and kept on ice during transport.  Cells were resuspended in 
imaging medium (RPMI medium without Phenol red, 10% FCS 1% 
glutamine and 1% penicillin/streptomycin).  5 x 104 to 105 
cells were used per stain and viability as ranged from 50-
75%.  Cellular pellet was suspended in 200ul  recombinant 
TCR (at 10µg/ml in BSA/PBS) for 30 min at 4oC.  Cells were 
washed twice with PBS and the pellet was resuspended in 
200ul of Streptavidin/PE (at 10µg/ml) for 20min at room 
temperature in the dark.  Cells were washed twice with 10ml 
PBS, with complete removal of media.  Pellets were 
resuspended in 50ul imaging medium and were transferred to 8 
well chamber coverslips for analysis.  Single-molecule wide 
field fluorescence microscopy  was performed on a Zeiss 
200M/Universal Imaging system with a 63x objective. PE 
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fluorescence was detected using a 535/50 excitation, 610/75 
emission,and 565LP dichroic filter set (Chroma). Given that 
staining of cell surface-bound biotinylated complexes with 
an excess of streptavidin-PE has been shown to result in 
monomeric association of streptavidin-PE with target protein 
(Purbhoo et al., 2004), a single detected PE signal 
corresponds to a single TCR-peptide-HLA complex. To cover 
the entire three-dimensional surface of the cell, z-stack 
fluorescent images were taken (21 individual planes, 1 µm 
apart). Data were evaluated for at least 30 cells in each 
experimental condition.  Spot counts were enumerated 
manually.  This work was performed in close collaboration 
with Dr Giovanna Bossi, Immunocore Ltd at Abingdon.   
 
 
2.19. Epitope detection using soluble TCR-anti CD3 fusion protein. 
 
 
A fusion protein comprising the gp100 280-288  (YLE) specific 
T-cell receptor and an anti human CD3 antibody was a kind 
gift from Dr Rebecca Ashfield (Immunocore Ltd). Engagement 
of the TCR with the epitope leads to CD3 ligation and T-cell 
activation.  Only effector memory cells becomed rapidly 
activated (R.Ashfield, personal communication).  T-cell 
activation was detected by IFNγ ELISPOT assay.  Patient DC 
were thawed, washed twice and resuspended in 10% FCS/RPMI 
and were added to ELISPOT wells at 5 x 103 cells/well.  HLA 
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A2 positive LCLs were loaded with GLC (BMLF-1, negative 
control), and YLE peptide as described above and were also 
used as targets at 5 x 103 per well.  Effector cells were the 
EBNA1 HPV specific clone c47.  DC are EBV negative cells and 
should not display this epitope, minimising background 
recognition.  Targets and effectors were combined and the 
fusion protein was added in 10%FCS/RPMI at 10-8, 10-9 and 10-
10M.  These concentrations were recommended by the 
manufacturer with the caveat that the highest and lowest 
concentrations may lead to non-specific and low signals 
respectively.  Since the strongest specific signal was 
obtained with 10-9M fusion protein on peptide-loaded LCL 
target cells, patient data from 10-9M concentration is 
presented.   
 
2.20. Cytotoxicity assays. 
 
 
Cytolytic ability of T-cells (clones or polyclonal 
populations) was assessed by the 51Chromium release assay.  
Target cells were labelled with 15ul of 51Cr sodium chromate 
solution (Amersham) – 50-100 uCi – for 90 minutes at 37C in 
serum-free medium.  If peptide-loaded targets were required, 
peptide-loading was performed simultaneously.  After washing 
to remove unbound peptide/sodium chromate, cells were used 
as targets.  Targets were plated at 105 cells per well into 
V-bottomed 96 well plates.  Effector cells were added (at 
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various E:T ratios) and plates were centrifuged at 500rpm 
for 5 minutes to increase cell-cell contact.  After 6 hours 
at 37C, plates were centrifuged at 600G for 5 minutes and 
50ul supernatant was transferred to mini-tubes for gamma 
counting.  Positive control was targets lysed with 1% SDS in 
water and negative control was targets alone (background 
release).  Percentage specific lysis was calculated as 
specific lysis/maximal lysis x 100.   
 
2.21. Proliferation assays.  
 
Cellular proliferation was measured by determination of 
thymidine incorporation, a well-established technique (Kern 
et al., 1987).  For proliferation assays with bulk 
populations of T-cells, U-bottomed 96 well plates were used, 
whereas for T-cell clones, flat bottomed 96 well plates were 
utilised.  For allogeneic mixed lymphocyte reactions (effect 
of plasmid DNA on DC maturation) – 4 x 104 DCs (irradiated at 
4000 rad) were plated per well in 10% FCS/RPMI without 
cytokines with responder cells – 2 x 105 allogeneic PBMCs per 
well.  Total volumes were 200ul per well.  Negative control 
was stimulator cells alone and assays were set up in 
quadruplicate.  After 6 days incubation at 37C, 1µCi 3H 
methyl thymidine solution (Amersham) – 10ul per well – was 
added.  16 hours after this, cells were harvested using 
sterile distilled water and were passed through glass fibre 
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filters under suction.  The filters were removed and allowed 
to fully air-dry at room temperature.  Liquid scintillation 
cocktail was added (30µl per well) by pipetting and filters 
were loaded into cassettes for counting.  Radioactivity was 
measured (counts per minute) on a liquid scintillation 
counter.  Plate temperature was monitored.  For assays using 
T-cell clones (Melan-A specific) as responders, 104 T-cells 
per well were used with equivalent numbers of stimulator DCs 
(non-irradiated).  After 72 hours, 1µCi 3H thymidine was 
added per well and assays were completed as above.   
 
2.22. Generation of B-cell blasts. 
 
 
The starting point for this work were L-cells.  These were a 
kind gift from Dr Heather Long, Institute for Cancer 
Studies.  They are mouse fibroblasts that are transfected 
with human CD40 ligand cDNA (Van Kooten et al., 1994).  L-
cells were cultured in DMEM (Gibco) containing 10% heating 
inactivated fetal calf serum and 1% penicillin-streptomycin 
and 1% L-glutamine.  They are adherent cells and were sub-
cultured by detachment with 2% trypsin-EDTA and re-plating.  
After trypsinisation, cells were irradiated at 4000 rad, 
counted and plated into 6 well plates.   Freshly isolated 
non-adherent PBMCs were resuspended at 1.5 x 106 in IMDM 
containing 5% pooled human serum with 0.7 ug/ml cyclosporin 
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A (Queen Elizabeth Hospital Pharmacy) and 5ng/ml recombinant 
human IL4 (R and D systems).  Medium was aspirated from L-
cells, and 3ml PBMC suspension was added per well.  After 2-
3 days, when medium was yellow, non-adherent cells were 
stripped off by vigorous pipetting, resuspended and counted 
and re-plated onto fresh irradiated adherent L-cells.  This 
process was repeated 6-7 times and at that point B-cell 
blasts were frozen for immediate use subsequently.  
 
2.23. Statistical analysis 
 
Where indicated, the Student’s T-test was used to assess the 
significance of the difference of mean values of 
experimental groups.  The paired t-test was performed using 
the statistical package GraphPad Prism for Windows.  P-
values are shown to 3 decimal places.  For correlation 
coefficients, again GraphPad Prism software was used and the 
Pearson correlation coefficient (R2) is given to 3 decimal 




3. Melanoma DC vaccine trial and CL22 mediated DC transfection. 
 
3.1 Humoral responses to DC vaccination in melanoma clinical trial. 
 
In the melanoma trial (Steele et al., 2011), although the 
frequency of Class II restricted T-cell responses increased 
with vaccination, there were few Class II epitopes known.  
Hence, a more broadly applicable method of assessing CD4 
responses was sought. 
 
Since IgM to IgG isotype switching is dependent on helper T-
lymphocyte responses (Parker, 1993), IgG responses are an 
indirect marker of CD4 responses.   Therefore, these 
experiments aimed to measure IgG responses against Melan-A 
in patients.    
 
A two-step ELISA was developed.  Initial experiments 
determined the optimal concentration of recombinant Melan-A 
protein to coat wells within the ‘capture’ stage. As shown 
in Figure 3.1A, the optimum signal was achieved with 5µg/ml 
Melan A protein for primary antibody concentrations of 1 in 
1600 and 1 in 6400.  When primary antibody was used at 1 in 
400, the best protein concentration appeared to be 2.5µg/ml.  






plasma samples were expected to be very low, 5µg/ml was 
taken forward in further experiments. 
 
Using a mouse antibody, the ability of the assay to quantify 
a range of antibody concentrations was determined.  There 
was an approximately linear relationship between the 
measured absorbance and antibody concentration (Figure 
3.1B).   
 
Having detected mouse monoclonal antibodies against Melan-A, 
experiments moved onto the use of donor plasma samples.  To 
verify the specificity of the assay, plasma samples were  
pre-incubated with Melan-A and an irrelevant protein (BSA).  
The Melan-A specific signal (i.e. absorbance in the presence 
- absence of Melan-A protein) was diminished after pre-
incubation with Melan-A but not BSA (Figure 3.1C): 
suggesting specificity.  
 
 
This assay was then used to measure anti Melan-A IgG 
responses in clinical trial plasma samples (pre vaccination 
and post Cycle 4).  Since it was not possible to determine 
the exact relationship between observed absorbance and 
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antibody concentration, trial patient plasma was diluted to 
three different concentrations for the assay. 
 
As shown in Figure 3.2, there were detectable levels of 
anti-Melan-A IgG in most patients and levels were widely 
variable.  However, there was no overall change in antibody 
levels after vaccination.   
 
Two of twenty patients analysed demonstrated an increase in 
Melan-A specific absorbance at all dilutions tested after 
vaccination (Figure 3.3). One of these had a prolonged 












3.2. Presentation of HLA-A2 restricted gp100 and Melan A epitopes by 
patient DCs from the melanoma vaccine trial. 
 
 
The antigenic epitopes studied here are summarised in Table 
3.1 below: 
 
Table 3.1. MHC Class I restricted peptide epitopes from Melan-A and gp100 







et al., 1994) 
ELAGIGILTV (Valmori 












gp100/PMEL17 YLEPGPVTA (Cox et 
al., 1994) 












3.2.1. Clinical material 
 
In the trial, a maximum of 5 x 106 DC were administered per 
cycle.  If DC culture was particularly efficient, there were 
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excess DC for cryopreservation. There were 18 HLA-A2 
positive patients with excess transfected DC.  These were 
used for analysis of HLA A2 restricted epitope presentation.   
 
3.2.2. Presentation of Melan A 26-35 epitope by patient DCs. 
 
For the Melan-A 26-35 epitope, a CD8 positive T-cell clone was 
used as a cellular readout of epitope presentation.  This T 
cell clone specific for the Melan-A 26-35 epitope 
(E(AL)AGIGILTV) was a kind gift from Immunocore Ltd.  This 
clone, Mel c5, was generated from PBMC of a laboratory 
donor.  Melan A specific CD8 T cells were initially selected 
using IFNγ capture and cells were expanded using autologous 
APC pulsed with ELA peptide (R.Ashfield, Immunocore Ltd, 
Abingdon, personal communication).    
 
The peptide-sensitivity and specificity of the clone are 
shown in Figure 3.4.  Target cells were HLA A2 positive B-
cell blasts loaded with ELA, EAA and GLC (A2, BMLF1,control) 
peptides.  There is clearly recognition of A2 positive B-
cell blasts loaded with ELA peptide.  This appears to be a 
bi-phasic response: there is recognition above background 
levels (GLC peptide) down to 10-7 M, this reappears at 10-11 






very low level of recognition of EAA peptide – at 6 of 8 
peptide concentrations tested, spot counts with EAA loaded 
B-blasts are slightly higher than with GLC. Thus, this 
appears to be a T-cell clone with relatively low avidity for 
ELA peptide and barely detectable activity against the 
native peptide.   
 
The plasmid DNA (CTL901) used in the clinical trial encodes 
the wild-type Melan A protein (i.e. 26-36: EAAGIGILTV), and 
the ability of the T-cell clone to recognise EAA peptide was 
very limited.  However, it was decided to proceed with the 
use of the clone as a cellular readout as in vivo the ELA 
epitope does not exist and there may well be differences 
between the passive process of coating surface HLA molecules 
with exogenous peptide at high concentrations and the 
physiologic, active process of proteolysis and HLA loading 
intracellularly.  Thus, the fact that responses to exogenous 
EAA peptide are very weak does not necessarily mean that the 
same will hold true for intracellularly generated epitopes.  
In fact, work presented in Chapter 5 strongly suggests that 
this is indeed the case.  
 
Since the aim of the clinical trial was to generate the most 
effective cellular vaccine possible, all immature dendritic 
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cells were transfected with plasmid DNA.  Therefore, there 
were no cryopreserved untransfected DCs available.  These 
would, as antigen negative cells, have been ideal control 
cells in the ELISPOT assays using the Melc5 clone.  However, 
their absence does not preclude a comparative analysis 
between patients.   
 
Patient DC preparations were used as targets in overnight 
IFNγ ELISPOT assays with Mel c5 effector cells.  As a control 
HLA A2 positive LCLs were loaded with GLC (negative control) 
and ELA (positive control) peptides at 5µM.  The viability 
of DC preparations ranged from 50-80% after thawing.  One 
cryopreserved sample had compromised viability (10%) and was 
therefore not used for cellular assays.  
 
There was an unequivocal recognition of ELA-coated LCLs 
(mean 164 v 3 spots/well for ELA v GLC loaded targets); 
indicating functionality and specificity of the Mel c5 
clone.   
 
The Melan A 26-35 specific spot count (representing 
presentation of the 26-35 epitope) was calculated as IFNγ 
secreting cells in the presence of T-cell effectors and 
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their absence (i.e. dendritic cells alone).  The 
relationship between epitope presentation and whole antigen 
detection (% of DCs positive for Melan A) is presented in 
Figure 3.5A.  There is no apparent relation between epitope 
presentation and the percentage of cells that are positive 
for whole Melan A.   
 
When the one patient DC preparation with an unusually high 
percentage of Melan A positive cells (96%) is removed from 
the analysis, a modest negative correlation of –0.29 emerges 
(Figure 3.5B).  The excluded sample is highly atypical, in 
that over 90% of all DC preparations in the trial were less 
than 10% Melan A positive. This inverse correlation is in 
full agreement with the conclusions from experiments using 
laboratory donor DCs.  These experiments, presented in 
subsequent chapters, showed that Melan-A negative DCs could 
in fact present Class I restricted epitopes and that at 
early time-points after transfection when whole antigen 
positive cells were seen, epitope presentation was minimal.   
 
Additionally, in general the level of epitope presentation, 
certainly in comparison to peptide-loaded target cells, is 







of epitope presentation is only approximately 10% of maximum 
(i.e peptide-driven responses).   
 
3.2.3. Presentation of gp100 280-288 epitope by patient DCs. 
 
Experiments then moved on to assess the presentation of the 
gp100 280-288 epitope (YLE) by patient DC preparations.  
Unfortunately, a T-cell clone specific for this epitope was 
not available.  However, epitope presentation was measured 
using a recombinant human T-cell receptor-anti CD3 fusion 
protein that specifically binds to HLA A2-YLE complexes.  
This was a kind gift from ImmunoCore Ltd (Abingdon, Oxon, 
UK).   
 
3.2.4. Characterisation of gp100 280-288 specific recombinant T-cell 
receptor 
 
The ability of this reagent to detect the YLE epitope bound 
to HLA-A2 molecules in a specific fashion is demonstrated in 
Figure 3.6.  The principle of these assays was as follows – 
interaction of the peptide-HLA complex (on target cells) 
with the recombinant T-cell receptor leads to cross-linking 
of CD3 on effector cells.  The effectors can be either 
allogeneic PBMC or a CD8 T-cell clone of unrelated 






effector memory subset of T-cells and subsequent secretion 
of cytokines, including IFN-γ.  This is quantified using an  
ELISPOT assay.  It is likely that use of a T-cell clone is 
more efficient than PBMCs as all the cells are effector 
memory, allowing the use of lower numbers of effectors per 
well (R.Ashfield, ImmunoCore Ltd, personal communication).   
 
As shown in Figure 3.6, there is recognition of HLA A2 
positive targets loaded with YLE peptide at the high 
concentration of 10-6 M (mean 2 spots with GLC-loaded targets 
v 29 spots with YLE-loaded targets).  Even when target cells 
are loaded with very low concentrations of YLE peptide (down 
to 10-10M) the spot count is still slightly higher than that 
obtained with the control (GLC) peptide at 10-6M (mean spots 
– 3 versus 1).  Encouraged by the sensitivity of the 
reagent, the next question was whether it could be used to 
detect epitope presentation from endogenous gp100 protein.  
The actual spot counts in this experiment are low in 
comparison to those presented in Figure 3.7.  This reflects 
the lower number of effector T-cells (PBMC) used in this 
assay – 1000/well.   
 
The aim of the next experiment was to determine whether or 
not the T-cell receptor fusion protein was a sufficiently  
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sensitive reagent to be able to detect presentation of the 
YLE epitope when it is derived from intracellular source 
protein rather than exogenous peptide.  LCLs from an HLA-A2 
positive donor were transfected with gp100 and control (GFP) 
DNA using electroporation.  To assess transfection 
efficiency, the cells were subjected to flow cytometric 
analysis for GFP expression.  Approximately 25% of cells 
were GFP positive.  Transfected LCLs were used as target 
cells with allogeneic PBMC as responder cells.  As shown in 
Figure 3.7, there is evidence that epitope presentation is 
detectable on these cells above background levels in GFP 
expressing cells.  There is, however, a higher level of non-
specific PBMC activation with GFP-transfected targets 
compared to targets loaded with irrelevant peptide.  This 
reflects the lower viability of LCLs that have been 
electroporated with DNA (≈50% versus 90%).   
 
3.2.5. Assessment of gp100 280-288 presentation by patient DCs 
 
 
Having established the utility of the fusion protein in 
detecting YLE epitopes from transfected cells, the reagent 
was used to measure levels of epitope presentation on 







In this experiment, responder/effector T-cells were a CD8 T-
cell clone specific for the EBNA1 HPV epitope.  The use of 
an antigen-experienced clone means that all cells will be 
effector-memory in phenotype and able to secrete IFNγ on CD3 
ligation.  Importantly, monocyte-derived DCs are EBV (and 
therefore EBNA1) negative cells – minimising background 
levels of recognition by the HPV specific clone.   
 
To confirm functionality of the T-cell receptor fusion 
protein, HLA-A2 positive B-LCLs were loaded with 10-6M YLE 
(and GLC, control) peptide and also used as targets in the 
assay.  The YLE loaded cells led to strong, specific IFNγ 
responses (mean spots/well = 190 with YLE v 3 with GLC 
(control)).  In terms of patient DC preparations, a 
proportion of samples displayed a clear increase in spot 
count, in the presence of 10-9M fusion protein, over counts 
with GLC-loaded LCLs.  This is highly suggestive that the 
epitope is being presented by patient DCs.   
 
These results are presented in Figure 3.8A and B.  In Figure 
3.8A, the relationship between gp100 YLE specific spots 
(i.e. epitope presentation) and the percentage of DCs 
positive for whole antigen is illustrated.  There is no 






correlation co-efficient is -0.05. In Figure 3.8B, patient 
DC are divided into two groups – epitope positive and 
negative. Positivity is arbitrarily defined as having spot 
counts over twice those obtained with GLC peptide loaded 
target cells.  Here, there is no difference in whole gp100 
positivity between the two groups.  In fact, the only DC 
preparation with over 10% maximal responses was only 1.3% 
whole gp100 positive.   
 
These results, for both gp100 and Melan-A epitopes, strongly 
suggest low-level epitope presentation that is unrelated to 
the percentage of whole antigen expressing cells.   This 
means that whole antigen measurement is unlikely to reflect 







3.4.  Assessment of immune-stimulatory effects of CL22 transfection of 
plasmid DNA on immature dendritic cells . 
 
The aim of this set of experiments was to determine whether 
DC expressed TLR9, and if so, could transfection of plasmid 
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DNA using CL22 have immune-enhancing effects.  It was 
suspected that the non-electrical nature of CL22 
transfection might be associated with fewer negative effects 
on DC function and CL22 has been used in the clinical 
setting.   
 
DC generated from adherent monocytes after exposure to GM-
CSF and IL4 do express TLR9 (Figure 3.9).  The proportion of 
positive cells falls after exposure to TNFα and IL1β.  This 
makes physiologic sense as recognition of pathogens is 
important at the activation phase rather than T-cell priming 
phase of DC function.  The proportions of positive cells 
vary between different donors.  Since TLR9 is thought to be 
expressed on a subset of PBMCs, (particularly monocytes and 
B-lymphocytes) these cells were also included in the 
analysis.   
 
The percentages of TLR9 positive cells are tabulated in 
Table 3.2. 
 
Table 3.2.  TLR9 expression in dendritic cells and PBMCs assessed by flow cytometry.   
 % TLR9 positive  
Donor Immature DCs Mature DCs PBMCs 
1 65.8 25.6 20.3 
2 28.8 10 1.6 







This result, that moDCs appear to be TLR9 positive, raised 
the possibility that they may be responsive to plasmid DNA 
in terms of maturation and function.   To determine whether 
this was the case, immature DC were prepared from blood 
donors.  These cells were either transfected with GFP 
plasmid DNA or underwent the transfection procedure (i.e. 
exposure to CL22 and chloroquine) in the absence of DNA.  
Cells were also either exposed to proinflammatory cytokines 
or not.  This experimental design, summarised in Figure 
3.10, would allow detection of effects of DNA in the 
presence or absence of cytokines and any possible 
synergistic effects.   
 
Each of the four groups of DCs (and pre-transfection DCs – 
Day 4) was assessed for three parameters of DC function.  
The expression of maturation markers CD83, CD86 and CD25, 
the lymphokine receptor CCR7, and lineage specific markers 
CD1a (dendritic cells) and CD14 (monocytes) was measured by 
antibody staining.  GFP expression was also measured in this 
way.  The ability of these DC to stimulate allo-specific 
proliferative responses in allogeneic PBMCs was determined 
by thymidine incorporation assays.  The secretion of 
IL12p70, Il12p40 and IL10 were also determined by ELISA on 
culture supernatants.  These assays were repeated on DC from 







Transgene expression varied from donor to donor, as found in 
pre-clinical work prior to the melanoma clinical trial 
(Irvine et al., 2000 and Haines et al., 2000).  GFP 
expression is shown in Table 3.3. 
 
Table  3.3.  GFP expression assessed by flow cytometry on DCs transfected with GFP 
DNA using the CL22 peptide 
Donor TNFα, IL1β GFP DNA % GFP positive cells 
1 - - 0.09 
1 - + 0.78 
1 + - 0.06 
1 + + 0.29 
2 - - 3.06 
2 - + 8.31 
2 + - 2.4 
2 + + 10.8 
3 - - 0.19 
3 - + 1.54 
3 + - 0.17 
3 + + 0.58 
 
 
One donor shows clearly detectable GFP expression, whereas 
in the other two it is barely detectable (<1% of DCs).  It 
is also evident that the percentage of positive cells is 
lower in those DCs exposed to maturation-inducing cytokines, 
perhaps implying active processing of GFP.   
 
As shown in Figure 3.11, there are donor-to-donor variations 
in the expression of the DC marker CD1a and monocyte marker 
CD14.  Donors 2 and 3 display a ‘typical’ DC phenotype with 






expression.  However, in donor 1 CD14 is retained and only 
about a third of cells express CD1a.  This suggests that 
these DC may have retained some features of monocytes, 
supported by the finding of low CD83 expression on these 
cells. 
 
In terms of phenotypic maturation, there is no consistent 
change in expression after exposure to GFP DNA regardless of 
the presence of cytokines.  CCR7 levels are generally low 
which is expected in the absence of PGE2 (Scandella et al., 
2002).  CD25 expression is higher in DNA-exposed cells in 
all three donors.  CD86 expression is generally very high, 
and in fact it increases even on cells not exposed to DNA or 
a cytokine stimulus.   
 
The allo-stimulatory capacity of these DC is illustrated in 
Figure 3.12.  DC were irradiated prior to use, to ensure 
that measured thymidine incorporation reflected allogenic 
PBMC proliferation.  In donors 1 and 3, there are clear-cut 
increases in proliferation when stimulator DCs have been 
exposed to GFP DNA.  In donor 1 only, there are synergistic 
effects of DNA and cytokines.  In donor 2, however, this 
effect is not seen.  Additionally, in terms of fold-increase 






1 and 3 are more immunogenic than those of donor 2.  
However, in terms of absolute levels of proliferation, the 
highest levels are achieved with donor 2 DCs.   
 
Finally, cytokine secretion was measured by ELISA. The 
concentrations of IL12p40, IL12p70 and IL10 measured are 
illustrated in Figure 3.13.  Interleukin-12 p40 levels are 
two to three-fold lower in DCs from donor 1.  This is not 
unexpected as it has been found that only CD1a expressing 
DCs secrete IL-12 (Cernadas et al., 2009).  However, there 
is an effect of exposure to GFP DNA in two of three donors.  
In donor 1 this is seen in the presence or absence of 
exogenous cytokines, whereas in donor 3 it is only apparent 
in the absence of cytokines.  However, in donor 3 exposure 
to DNA in the absence of cytokines leads to almost 
equivalent IL12p40 production as exogenous cytokines.  There 
is no evidence of IL12p70 production by DCs from donor 1, as 
expected from low CD1a expression.  In donor two, there is 
evidence of IL12p70 secretion at a low level, but only in 
cells exposed to DNA and cytokines.  In donor 3, exposure to 
DNA seems to slightly increase IL12p70 release.  IL10 
release is highest in donor 1, where exposure to DNA is 
associated with increased secretion. In donor 2, IL10 is 
secreted by cells exposed to inflammatory cytokines. In 






The critical observation is probably that biologically 
active IL12 (p70) is only released by DCs exposed to a 
stimulus via TLRs (i.e. DNA) and inflammatory cytokines.  
However, the absolute levels of bioactive (i.e. p70) IL12 
release from these DCs is very low.  
 
These experiments suggest that introduction of DNA into 
immature DCs using the CL22 peptide may lead to maturation, 
particularly in terms of allostimulatory capacity and 
cytokine release.  Effects are, however, variable from donor 
to donor.  It is noted that in the donor with the highest 
transgene expression, effects are the least impressive.  In 
view of the demonstrable TLR9 expression in DCs, this may 




3.5. Simultaneous Class I and Class II restricted epitope presentation by 




Transfection of moDC using CL22 peptide and plasmid DNA has 
been shown to lead to presentation of Class I restricted 
epitopes using viral antigens in vitro (Haines et al., 
2000).  In a mouse model, vaccination with transfected DC 
led to production of opsonising antibodies against the 
antigens, suggesting helper T-cell involvement (Irvine et 
al., 2000).  This transfection methodology has been taken 
forward into the clinical arena in the setting of metastatic 
melanoma (Steele et al., 2011).  Although Class II 
restricted T-cell responses increased with vaccination, it 
has not been formally demonstrated in vitro that human DC 
transfected using this system present Class II restricted 
epitopes. 
 
The aim of this experiment was therefore two-fold.  The 
primary objective was to determine whether or not CL22 
transfected DCs present MHC Class II restricted epitopes 
from endogenous antigen. The secondary objective was to 
determine whether or not the previously demonstrated lack of 
correlation between whole antigen detection and epitope 
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presentation held true for other (i.e. non-melanoma) 
antigens. 
 
3.5.1. Antigens and epitopes. 
 
The antigens and epitopes studied in this set of experiments 
is summarised in tabular form below (Table 3.4) 
 
Table 3.4.  EBNA1 epitopes studied 








(Long et al., 
2005) 









The Epstein Barr virus EBNA1 antigen is vital for episomal 
maintenance of the viral genome in host cells and is 
expressed in all forms of latent viral infection (Leight and 
Sugden, 2000).  More pertinent to DC vaccines for cancer, it 
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is the only EBV protein expressed in all EBV driven 
malignancies including nasopharyngeal carcinoma (Young et 
al., 1988), Hodgkin’s lymphoma (Grasser et al., 1994) and 
post-transplant lymphoproliferative disease (Hopwood and 
Crawford, 2000).  Antigen processing and presentation of 
EBNA1 are relatively well-characterised.  The protein 
contains a long repetitive sequence (Glycine-Alanine repeat) 
that inhibits presentation of MHC Class I restricted 
epitopes (Levitskaya et al., 1995).  This is due to slower 
rate of translation and decreased DRiP generation (Tellam et 
al., 2007) and also resistance to proteasomal degradation 
(Tellam et al., 2001).  The natural nuclear localisation of 
EBNA1 depends upon a signal sequence.  Alteration of this 
sequence can artificially re-localise the protein into 
cytoplasmic compartments (Kitamura et al., 2006).  In order 
to get a comprehensive picture of Class II restricted 
epitope presentation from EBNA1, all three forms of the 
protein were expressed: full length EBNA1, GA repeat deleted 
EBNA1 and cytoplasmic GA repeat deleted EBNA1. As a positive 
control for MHC Class II restricted presentation, a fourth 
EBNA1 variant was included – EBNA1∆GA-invariant chain.   
   




A CD8 T cell clone specific for the EBNA1 407-417 epitope 
(HPVGEADFYEY) was a kind gift from Dr. Jill Brooks.  The HPV 
epitope is restricted through HLA B35, and the clone 
recognises B35 matched LCL (autologous and allogeneic) in 
IFNγ ELISPOT assays.  These cells endogenously express EBNA1 
from the resident Epstein-Barr virus genome.  Recognition of 
B35 positive, but not B35 negative, LCL is enhanced by 
addition of exogenous HPV peptide.  This is shown in Figure 
3.14. 
 
A CD4 positive T cell clone specific for the EBNA1 515-528 
epitope (TSLYNLRRGTALAI) was generated from a DR1 positive 
EBV seropositive donor previously demonstrated to make 
responses to this epitope, using limiting dilution cloning.  
The functional avidity and MHC restriction of clones was 
assessed using autologous B-cell blasts as target cells.  
Targets were pulsed with reducing concentrations of cognate 
peptide, in the presence or absence of anti MHC antibodies, 
in IFNγ ELISA assays.  The results of these assays are shown 
in Figure 3.15A and B.  There is evidence of HLA-DR 
restriction and a response to B-cell blasts pulsed with 1nM 
exogenous peptide.  However, it was also important to assess 
their ability to recognise cells endogenously expressing 
EBNA1 rather than merely exogenously added peptide, to gauge 









clone is able to recognise DR1 positive target cells 
endogenously expressing EBNA1.  Autologous LCL were 
transduced with a modified vaccinia Ankara (MVA) virus 
expressing EBNA1∆GAr-invariant chain (or EBNA3C negative 
control) at a multiplicity of infection of 1 and these were 
clearly recognised, at approximately 1/3 to 1/4 of peptide-
stimulated levels.   
 
The EBNA1∆GAr-invariant chain MVA virus expresses a fusion 
protein of EBNA1 and the cytoplasmic tail and transmembrane 
domain of the human invariant chain polypeptide (amino acids 
1-80, NH2 terminus))(Chaux et al., 1999).  This invariant 
chain sequence causes the EBNA1 protein to be ectopically 
localised in the endolysosomal system with resultant 
improved MHC Class II restricted presentation.  
 
3.5.3. Tools: EBNA1 plasmid DNA. 
 
To confirm functionality of EBNA1 plasmids (EBNA1 full 
length, EBNA1∆GAr, EBNA∆GAr cytoplasmic) they were 
introduced into HEK293 cells using Lipofectamine 2000.  
After 72 hours, cells were harvested and EBNA1 expression 
was assessed by immunocytochemistry and immunoblotting.  As 
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shown in Figure 3.16, all three plasmids lead to the 
production of EBNA1 species of the correct molecular 
weights.  Immunofluorescence staining of transfected cells, 
shown in Figure 3.17, indicates that EBNA1 protein is 
produced from these plasmids and that the nuclear 
localisation signal mutation does indeed relocalise the 
protein from the nucleus to the cytoplasm.   
 
In contrast to Figures 3.16 and 3.17, where functionality of 
EBNA1 plasmid DNA constructs was confirmed by expression in 
HEK293 cells followed by antibody staining, an alternative 
approach was required in the case of the EBNA1∆GAr-invariant 
chain construct.  A plasmid encoding EBNA1∆GAr-invariant 
chain in the pcDNA3.2 vector that other EBNA1 constructs are 
in was generated.  Being ectopically expressed in the endo-
lysosomal compartment, the antigen is expected to be rapidly 
degraded and in the B-cell system is barely detectable by 
Western blot (G.Taylor, University of Birmingham, personal 
communication).  Therefore, its functionality was assessed 
in T-cell recognition assays.  HLA DR11 positive LCL were 
transfected (by electroporation) with the plasmid and 
recognition by VYG specific CD4 positive T-cells (EBNA1 509-
528) was measured in IFNγ ELISA.    As shown in Figure 3.18, 












clone in response to LCL transfected with this plasmid.  
This indicates that EBNA1 is expressed from this construct 
and it is able to gain access to the MHC Class II pathway, 
as expected.   
 
EBNA1 was chosen as a model antigen for these experiments.  
The protein’s glycine-alanine repeat (GAr) provides a degree 
of protection from CTL recognition but has not been reported 
to have any inhibitory effect on MHC Class II restricted 
epitope presentation.  In vivo, CD4 T-cell responses against 
EBNA1 epitopes are particularly abundant, in constrast to 
the CD8 response.  Plasmid DNA encoding four different forms 
of EBNA1 was used: EBNA1∆GAr, EBNA1∆GAr cytoplasmic, full 
length EBNA1 and EBNA1∆GAr-invariant chain (Ii).  The 
EBNA1∆GAr cytoplasmic plasmid contains a mutation within the 
EBNA1 nuclear localisation sequence and the protein is 
therefore redistributed in nuclear and cytoplasmic 
compartments rather than being exclusively nuclear.  The 
EBNA1∆GAr-invariant chain construct encodes a fusion protein 
of EBNA1∆GAr and the cytoplasmic tail and transmembrane 
domain of the human invariant chain.  This protein is 
ectopically expressed in the endolysosomal system where MHC 




Use of the full range of EBNA1 constructs allows 
determination of the role of cellular localisation (nuclear 
versus cytoplasmic versus endolysosomal) and protein 
stability and rate of translation in generation of Class II 
restricted epitopes (full length versus GAr deleted). 
 
The aim of these experiments (Figures 3.19 to 3.21) was to 
determine whether CL22 transfection of mo-DCs with EBNA1 
encoding DNA led to presentation of MHC Class II restricted 
epitopes; and to determine the relation between whole 
antigen expression and Class I and II epitope presentation.   
 
3.5.4. Whole antigen expression in EBNA1 transfected DCs. 
 
DC were prepared from a B35 and DR1 positive donor.  These 
DC were CL22 transfected with plasmid DNA encoding EBNA1: 
EBNA1∆GA, EBNA1∆GA cytoplasmic, full length EBNA1 and 
EBNA1∆GAr-invariant chain (Ii).  All these EBNA1 constructs 
were in the pcDNA3.2 plasmid vector (Invitrogen).  After 48 
hours TNFα and IL1β exposure, cells were stained for EBNA1 
by immunocytochemistry and their recognition by EBNA1 407-417 
(HPV, Class I) and EBNA1 515-529 (TSL, Class II) specific T-
cell clones was assayed by overnight IFNγ ELISPOT assays. 













GFP expression in transfected DC was 1.5% by flow cytometry 
(Figure 3.19A).  Preliminary experiments, comparing 
transfection methods, had shown that CL22 transfection was 
highly variable in efficiency (range 0 to 11% GFP positive 
cells) in contrast to  RNA electroporation that was highly 
efficient (consistently >90% GFP positive cells).   EBNA1 
staining revealed occasional EBNA1 positive cells, with an 
frequency of 1/100-1/150 in all transfections except the 
EBNA1∆GAr-invariant chain (Figure 3.19B).  This is of the 
same order of magnitude as the GFP expression.  There is 
strong staining on EBNA1 positive EBV transformed B-LCL.   
The antibody used for EBNA1 detection (R4) has been shown to 
recognise EBNA1 expressed from these DNA constructs in 
HEK293 cells.  Additionally, DCs expressing EBNA1 from RNA 
generated using these constructs as the template, are also 
clearly stained by the R4 antibody.  This confirms that the 
antibody recognises artificially and naturally (i.e. from 
the resident EBV genome) expressed EBNA1 protein. 
 
3.5.5. Antigenicity of EBNA1 transfected DCs. 
 
In terms of antigen presentation, there was evidence of 
recognition of EBNA1 expressing DC compared to GFP 
transfected (control) DC for Class I and II restricted 
clones in IFNγ ELISPOT assays.  There was a hierarchy of  
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recognition - invariant chain tagged EBNA, then full length 
EBNA1 followed by cytoplasmic EBNA1∆GAr expressing DC - by 
the TSL specific clone as shown in Figure 3.20A.  Although 
the level of recognition was modest in comparison to 
peptide-stimulated responses (approximately 5%), these data 
show that the Class II restricted TSL epitope is presented 
to specific CD4 T cells after CL22 transfection. Full-length 
EBNA1 appears most likely to give rise to Class II epitope 
presentation, perhaps as a result of reduced proteasomal 
processing and therefore increased availability for 
endolysosomal processing.  As expected, the TSL epitope is 
presented most efficiently by DCs expressing invariant chain 
tagged EBNA1.   
 
In parallel with these experiments, presentation of a Class 
I restricted epitope (HPV) by these same DCs was also 
examined.  The HPV specific clone recognised DC expressing 
full length EBNA1 and EBNA1∆GAr (Figure 3.20B) in IFNγ 
ELISPOT assays.  Again, levels of recognition were 
relatively low in comparison to peptide-driven responses.  
Particularly in view of the low level of EBNA1 expression in 
these DC preparations, this result is important in 
confirming that successful transfection and gene expression 
was achieved.  The level of HPV epitope display from full-
length EBNA is similar to GA repeat deleted EBNA1.  This is  
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in accordance with reports that GA repeat mediated 
protection from Class I presentation is not absolute. 
 
T-cell recognition assays demonstrate that presentation of a 
Class II restricted epitope from endogenously expressed 
EBNA1 occurs.  Additionally, Class I and II epitope 
presentation takes place simulataneously despite relatively 
low proportions of DCs expressing whole antigen at 48 hours. 
 
3.5.6. Immunogenicity of EBNA1 transfected DCs 
 
However, in these experiments epitope presentation is 
measured only at a specific time-point (between 48 and 72) 
hours after transfection.  In vivo, DC migration from the 
administration site to T-cell zones of secondary lymphoid 
tissue takes 24-48 hours (Adema et al., 2005), so  
persistent epitope presentation may be more physiologically 
relevant.   
 
Experiments were therefore extended in scope.  Their aim was 
to determine whether or not DC transfected with EBNA1 
encoding DNA using the CL22 peptide can expand TSL and HPV 




This question was answered by using the same transfected DCs 
as stimulator cells and autologous non-adherent PBMC as 
responder cells in polyclonal cultures.  This method mirrors 
the clinical use of DC vaccines to stimulate T-cell 
responses in cancer patients and is therefore pertinent.  
Also, unlike T-cell recognition assays, in-vitro 
reactivation experiments gauge epitope display over a far 
longer period (7-14 days).  Once again, for transfected 
cells the negative control transfection was with GFP 
encoding DNA, and negative control for peptide (HPV or TSL) 
loaded DCs was DMSO without peptide.  An initial stimulation 
was performed, and excess transfected (and mature 
untransfected) DCs were cryopreserved.  Seven days later, 
these DCs were thawed (and untranfected DC were loaded with 
peptides) and added to polyclonal lines.  Low dose IL-2 was 
added at this time.   
 
The polyclonal T-cell lines thus generated were analysed for 
the presence of either HPV or TSL specific IFNγ secreting T-
cells by overnight ELISPOT assays on day 14.  In these, 
stimulator cells were previously cryopreserved autologous B-
cell blasts loaded with exogenous peptide (HPV, TSL) at 5µM 




Quantification of TSL and HPV specific responses is 
illustrated in Figures 3.21A and B.  Peptide-specific spot 
counts were calculated as number of spots in the presence of 
peptide-loaded versus DMSO only B-blasts.  Results are 
presented as spot count with antigen loaded DC – spot count 
with antigen negative DC (GFP or DMSO).  Peptide-loaded DC 
are able to expand the epitope specific T-cell populations, 
and in terms of absolute numbers TSL specific responses are 
increased to a greater extent than HPV (≈100 spots/well v 70 
spots/well).  In terms of transfected DCs expressing whole 
EBNA1, only full-length EBNA1 expressing cells lead to 
expansion of both HPV and TSL responses.  In both cases, 
responses with full length EBNA1 are comparable to peptide-
driven responses.  This is in marked contrast to the results 
obtained with T-cell clones as readouts.   This difference 
could reflect the importance of persistent antigen 
presentation: possibly several days with transfected DC as 
compared to 12-16 hours with peptide-loaded cells.  For HPV 
specific responses, EBNA1∆GA cytoplasmic and EBNA1∆GA-
invariant chain expressing DCs are also immunogenic, but not 
to the same extent as full-length EBNA1.  The superiority of 
full-length EBNA1 in these assays of DC immunogenicity could 
reflect the stability and long-lived nature of the protein 
in comparison to other isoforms.  Overall, these results are 
consistent with those obtained using T-cell clones in  
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showing that CL22 transfection can lead to presentation of 
MHC Class II restricted epitopes and that epitope 
presentation (Class I or II) does not depend upon high 




3.6. Systematic comparison of dendritic cell transfection methodologies. 
 
In general, CL22 transfection of DC is relatively 
inefficient in terms of transgene expression, although it 
can be variable.  Therefore, alternative DC transfection 
methodologies were investigated.   
 
Three transfection methods were used in this set of 
experiments.  In brief, CL22 based transfection utilises a 
35 amino acid cationic peptide (CL22) to condense plasmid 
DNA for cellular uptake (Haines et al., 2000).  Transient 
exposure to the lysosomal acidification inhibitor 
chloroquine minimises endolysosomal degradation of DNA.  
This system has been shown to lead to reliable transfection 
of immature human monocyte-derived DCs (Irvine et al., 
2000).  Nucleofection is a proprietary technique using 
individual electroporation settings and solutions according 
to the cell type being transfected.  The human dendritic 
cell nucleofector kit was used (Lonza Bio).  Electroporation 
of in-vitro transcribed RNA is widely considered the most 
efficient method of transfection for human monocyte DCs and 
immunogenicity of these DCs has been demonstrated in 




3.6.1. GFP expression, cellular viability and phenotypic maturation. 
 
Thus, a systematic comparison was made between CL221 
transfection, DNA nucleofection and RNA electroporation 
using GFP in DCs.  Nucleofection can be used to transfer DNA 
or RNA into DCs, however, preliminary experiments had 
indicated that RNA nucleofection of DCs was not particularly 
efficient and was poorly-sustained.  On theoretical grounds, 
nucleofection is optimised to deliver nucleic acid to the 
nucleus, which would be unnecessary for RNA that only needs 
access to the cytoplasm.   
 
Immature DC were prepared from a single donor, the yield of 
immature DC was 12 x 106 cells from 250 x 106 PBMC (≈5%).  
The phenotypic profile of these iDC was typical and is shown 
in Figure 3.22A.  24 hours after transfection, cells were 
harvested and cellular viability and GFP expression was 
measured.  GFP expression is presented in Figure 3.22B (i-
iii). 
 
Cellular viability, as assessed by trypan blue exclusion and 








Table 3.5. Comparison of DC transfection methods – transgene expression and viability 
at 24 hours. 
 % viable DC % DC GFP positive 
Transfection 
method 
mock GFP DNA/RNA mock GFP DNA/RNA 
CL22 44.7 49.3 1.03 8.1 
Nucleofection 
DNA 
36.5 36.9 0.46 48.8 
Electroporation 
RNA 




These data demonstrate that CL22 transfection leads to good 
cell viability but low levels of transgene expression, 
nucleofection of DNA has a transfection efficiency 
approaching 50% with significant impairment of viability 
whereas RNA electroporation leads to high levels of 
transgene expression with excellent viability. 
 
The ability of immature dendritic cells to upregulate 
markers of maturation (such as CD25, CD83 and CD86) in 
response to the proinflammatory cytokines TNFα and IL1β was 
demonstrated in the DC vaccine clinical trial after CTL901 
transfection (Steele et al., 2011).   
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However, this has not been established for the other two 
transfection methods.  Therefore, the phenotype of RNA 
electroporated DC was determined and this is compared to the 
pre electroporation (immature) phenotype in Figure 3.23.  
There is no evidence that the electroporation of RNA into 
immature DC impairs their subsequent ability to respond to 
proinflammatory cytokines by upregulating CD25, CD83 or 
CD86.  GFP expression was 93% in these DCs, and phenotypic 
assessment of maturation markers was performed after 24 
hours.  
 
Nucleofection of DC led to approximately half of the cells 
expressing GFP, and this provided the opportunity for 
further investigation of the effect of the nucleofection 
process on the ability of immature DC to display phenotypic 
maturation.  To separate the effect of the nucleofection 
process and the introduction of plasmid DNA into the DC, 
immature DC were nucleofected in the absence of DNA.  These 
cells showed normal maturation in response to 
proinflammatory cytokines.   
 
24 hours after nucleofection with GFP DNA, DC were 
approximately 50% GFP positive and cells were sorted on GFP 
into GFP negative and positive fractions.  These two 
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populations were then stained with antibodies against three 
key DC surface markers (CD25, CD83 and CD86) and analysed by 
flow cytometry.  The GFP negative fraction showed clear 
increases in CD25, CD83 and CD86.  In contrast, the GFP 
positive fraction failed to show upregulation of these 
markers (Figure 3.24).  This suggests that DNA nucleofection 
impairs the ability of immature DC to respond to a 
maturation stimulus.  Similar findings have been reported 
previously (Lenz et al., 2003).   
 
3.6.2.  Epitope presentation by EBNA1 expressing dendritic cells. 
 
The experiments discussed above show that all three 
transfection methods lead to detectable transgene expression 
using GFP, albeit at very different levels (7%, 48% and 93% 
GFP positive cells).  Nucleofection is distinguished by 
lower cellular viability and possible impairment of DC 
‘maturation’.    
 
These experiments were extended to determine whether or not 
differences in transgene expression, viability and 
‘maturation’ between the three transfection methods 
translated to differences in presentation of MHC Class I and 






presentation is essential for an effective DC vaccine. The 
EBV antigen EBNA1 was used for this experiment. 
 
HLA B35 and DR1 positive immature DCs were transfected with 
nucleic acid encoding EBNA1∆GA, EBNA1∆GA-invariant chain or 
GFP (negative control).  These isoforms of EBNA1 were chosen 
for study as glycine-alanine repeat deleted EBNA1 is 
efficiently processed via the proteasome for Class I 
presentation (Levitskaya et al., 1995) and co-expression 
with the human invariant chain reroutes the protein into the 
MHC Class II loading compartments (Chaux et al., 1999).  
Both antigenicity (i.e. ability to be recognised by a T-cell 
clone) and immunogenicity (i.e. ability to expand the 
epitope specific T-cell population in peripheral blood 
lymphocytes) were assessed in these transfected DCs, along 
with measurement of whole antigen expression by 
immunofluorescence microscopy.  
 
GFP expression was measured by fluorescence microscopy on 
transfected DCs:- proportion and percentage of GFP positive 
cells was 2/50 (4%), 4/58 (7%) and 80/122 (66%) for CL22 
transfection, DNA nucleofection and RNA electroporation 




Immunofluorescence microscopy for EBNA1 expression showed 
the following proportion and percentages of EBNA1 positive 
cells:- EBNA1∆GA – 0/77 (0%), 6/85 (7%) and 35/110 (32%) 
EBNA∆GA-invariant chain – 0/80 (0%), 2/80 (2.5%) and 30/115 
(26%) for CL22 transfection, DNA nucleofection and RNA 
electroporation respectively.  These data are shown in 
Figures 3.25A-C.  It is also clear that in RNA 
electroporated DCs, the EBNA1 staining intensity is clearly 
lower in cells transfected with the invariant chain tagged 
EBNA1 compared with EBNA1∆GA transfected cells.   
 
These data, concerning whole antigen expression, are in line 
with the results presented in Figure 3.22B, with a hierarchy 
of transfection efficiency with RNA electroporation being 
superior to DNA nucleofection which is superior to CL22 
transfection. 
   
3.6.2.1.  Antigenicity of EBNA1 transfected DCs. 
 
 
These cells (EBNA1 expressing) were then used as targets in 
overnight IFNγ ELISPOT assays with the EBNA1 TSL specific CD4 
T cell clone (17B) and EBNA1 HPV specific CD8 T cell clone 
(17A) as effectors.  Results of these T cell recognition 










As shown in Figure 3.26A only DC transfected using RNA 
electroporation with EBNA1∆GA-invariant chain RNA are 
recognised above background levels (i.e. GFP transfected 
DCs) by the TSL specific clone.  This level of recognition 
is still very modest compared to maximal recognition with 
peptide-loaded DCs (5 spots v 170 spots).   
 
In contrast, as shown in Figure 3.26B, there is definite 
evidence of EBNA1 407-417 HPV epitope presentation by cells 
transfected using DNA nucleofection and RNA electroporation.  
For both these transfection methods, both EBNA1 isoforms are 
clearly recognised by the HPV specific T cell clone at 
levels well above background (GFP expressing DCs).  However, 
it is interesting to note that in both cases, addition of 
the invariant chain tag enhances Class I presentation.  
There is no major difference in recognition levels between 
DNA nucleofection and RNA electroporation for the invariant 
chain tagged EBNA1∆GA.  However, cells expressing unmodified 
EBNA1∆GA after RNA electroporation are recognised at a 
higher level than those transfected by DNA nucleofection.  
CL22 transfected DC expressing EBNA1∆GA are only recognised 
at a very low level by the HPV specific T cell clone (5 spot 




3.6.2.2. Immunogenicity of EBNA1 transfected DCs. 
 
 
The ability of these transfected DCs expressing whole EBNA1 
to expand the TSL 515-529 specific T-cell population was 
assessed using in-vitro stimulations of autologous non-
adherent PBMCs.  After two rounds of stimulation, cells were 
harvested and used as effector cells in overnight IFNγ 
ELISPOT assays with autologous B-cell blasts (loaded with 
5µM TSL peptide or DMSO negative control) as target cells.  
In contrast to the results obtained in ELISPOT assays with 
the TSL specific T-cell clone, in terms of immunogenicity, 
all three transfection methodologies led to expansion of TSL 
specific T cells (Figure 3.27A).  Once again, in the case of 
RNA electroporated or DNA nucleofected DCs, there was little 
difference between immunogenicity of cells expressing 
invariant chain tagged EBNA1∆GA.  However, DCs expressing 
unmodified EBNA1∆GA were more immunogenic following RNA 
electroporation than DNA nucleofection.  There is also a 
clear increase in TSL specific T cells in cell populations 
stimulated with DCs expressing EBNA1∆GA versus GFP following 
CL22 transfection.   
 
Finally, the ability of these DCs to present the HPV 407-417 
epitope in an immunogenic fashion was determined using bulk  
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cytotoxicity (51Chromium release) assays with autologous B-
cell blasts loaded with 5µM HPV peptide or DMSO (negative 
control) as targets.  As shown in Figure 3.27B, there is 
only a minimal increase in HPV specific cytotoxic activity 
following stimulation with DCs expressing EBNA1 versus GFP 
after CL22 transfection.  However, there is a definite 
increase in HPV specific lysis when cells are stimulated 
with DNA nucleofected or RNA electroporated DC expressing 
EBNA1 versus GFP.  For both invariant chain tagged and 
unmodified EBNA1, RNA electroporated DC appear more 
immunogenic than DNA nucleofected ones.  In addition, the 
superiority of invariant chain tagged EBNA1 is less marked 








Chapter 4: CL22 peptide based transfection of dendritic cells: 
discussion. 
 
4.1. Humoral responses to vaccination with CL22 transfected DCs in 
clinical trial. 
 
Humoral responses to tumour-associated-antigens are well 
described (Reuschenbach et al., 2008) and many TAAs were 
discovered by screening recombinant expression libraries 
derived from tumour cell lines with cancer patient sera 
(Sahin et al., 1995).  Occasionally, levels of TAA specific 
antibodies provide prognostic information (Silk et al., 
2009).   
 
In tumour-antigen specific immunotherapy or vaccination, 
immune monitoring as a surrogate marker of therapeutic 
effect almost exclusively concentrates on cellular responses 
(Clay et al., 2001).   
 
 
The focus was IgG responses as they are a surrogate marker 
of cognate CD4 T lymphocyte help and indeed very few IgM 
responses to tumour antigens have been demonstrated 




Experiments demonstrated that many laboratory donors had 
detectable levels of anti Melan-A IgG, consistent with 
recent reports that Melan-A specific CD8 T lymphocytes can 
be detected directly ex-vivo (using tetramers) from lab 
donor blood (Lee et al., 1999 and Petitt et al., 1999), and 
that highly cytotoxic CD8 T-cells can be induced from PBMCs 
of lab donors (van Elsas et al., 1996).   
 
For patients, there were again detectable levels of anti 
Melan-A IgG in plasma.  However, overall, there was no 
increase or decrease in absorbance after DC vaccination at 
any of the three dilutions tested.   
 
The detection of these antibodies contrasts with the 
findings of Stockert et al (1998) who failed to detect them 
in 127 metastatic melanoma patients.  More recently, anti 
Melan-A IgG was detected in melanoma patients who had a co-
existent CD4 T cell response but not in lab donors (Bioley 
et al., 2006).   
 
Although some patients with increases in anti Melan-A levels 
had prolonged clinical responses, it is unlikely that the 
increase in antibody level had a direct therapeutic effect 
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as the protein is intracellular and inaccessible to 
antibodies.  It more likely represents the development of an 
augmented, coordinated immune response.   
 
In these experiments, plasma was used rather than serum.  
Generally, antibody assays are carried out on serum and it 
is possible that the presence of fibrinogen and other 
coagulation factors could have had an influence on the 
results obtained.   
 
The specificity of the assay for Melan-A was demonstrated by 
pre-incubating plasma with Melan-A and a control protein and 
showing that Melan-A preincubation only attenuated the 
observed responses.  However, the control protein was bovine 
serum albumen which was not produced in the same way as 
Melan-A (produced in E.Coli from recombinant DNA).  Thus, 
the possibility that some of the observed increases in 
absorbance in wells coated with Melan-A protein are due to 
antibodies reactive to contaminating (i.e. E.Coli) proteins 
cannot be totally excluded. In future, this experiment 
should be repeated using an irrelevant protein produced in 
an identical fashion from the same source.  In other 
studies, control wells (i.e. antigen-negative) have been 




Melan-A specific antibody levels did not increase after 
vaccination, possibly because cellular and humoral responses 
may have different kinetics, and assays may have been 
performed too soon to detect any possible increase.   
 
The assay may have lacked sensitivity to detect small 
changes in antibody levels.  In future, it may be preferable 
to perform serial dilutions of each plasma sample and 
determine the dilution at which there is no increase in 
absorbance between Melan-A protein coated and control wells, 
rather than simply measuring absorbance at three predefined 
dilutions. This is how antibody titres are determined and 
reported in the clinical setting.  
 
Finally, recruitment of CD4 help may have caused an 
increased in antibody affinity rather than antibody 
concentrations and future experiments should investigate the 
affinity of Melan-A specific antibodies before and after 
vaccination and also, perhaps, include later time points if 
possible.   
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4.2.  Presentation of Melan A 26-35 and gp100 280-288 epitopes by CL22 
peptide transfected DCs in melanoma clinical trial. 
 
In the clinical trial, there was no correlation between 
vaccine characteristics including markers of maturation, 
whole antigen expression or surrogate immunologic markers 
(i.e. frequency of T-cell responses in PBMCs) and clinical 
response to vaccination (Steele et al., 2011).  
 
Using a T-cell clone specific for the Melan-A 26-35 epitope, 
it was demonstrated that a proportion (5 of 18) vaccine 
preparations analysed showed a degree of recognition by the 
clone above background levels of Melan-A negative, A2 
positive cells loaded with irrelevant peptide (GLC). This 
suggested that epitope presentation was occurring despite 
very low percentages of cells expressing whole antigen.  The 
level of recognition was, however, rather low ranging from 0 
to 9% of maximal levels.  This likely reflects the 
insensitivity of the clone for native peptide; it was noted 
that even for the ELA (A27L) variant peptide, the 50% 
maximal peptide concentration is 10-6M and the recognition of 
A2 targets cells loaded with EAA peptide was barely 
detectable above background.  In future, it is possible that 
this lack of sensitivity could be improved by using a T-cell 
clone generated by antigenic stimulation with EAA (26-35) or 




There was no relation between the percentage of Melan-A 
positive cells at 48 hours after transfection and epitope 
presentation, in fact after exclusion of an outlying sample 
(where Melan- A positivity was 98%); a modest inverse 
correlation was revealed.  One explanation for this would be 
rapid degradation of the protein with subsequent appearance 
of the A2-peptide complex at the cell surface.  This would 
predict that whole antigen levels would be higher and 
epitope display less robust at early time points.  This 
prediction was tested in later experiments involving RNA 
transfection of DCs.   
 
In the case of gp100, measurement of epitope display was 
less straightforward as no gp100 280-288 specific T-cell clone 
was available.  However, a novel reagent, a biotin-tagged 
A2-YLE specific recombinant T-cell receptor was used for 
this purpose.  Preliminary experiments with the TCR showed 
that detection of TCR binding to MHC-peptide using the 
strepavidin-phycoerythrin secondary reagent followed by flow 
cytometry lacked sensitivity for detecting epitopes produced 
from endogenous antigen.  Single cell fluorescence 
microscopy may have been sufficiently sensitive, but was 
impractical owing to the large number of samples to be 




Thus, a TCR-anti CD3 fusion protein was used to detect 
epitope presentation in re-directed T-cell IFNγ ELISPOT 
assays.  Epitope display was determined as the increase in 
spot count in the presence versus absence of TCR-fusion 
protein.   
 
In terms of patient DC preparations, the majority showed 
detectable gp100 280-288 specific spots (defined as spot count 
in the presence (10-9M) of TCR-fusion protein – spot count in 
its absence).  Of the 18 vaccine preparations tested, 13 
showed spot counts at least twice that of those obtained 
with control cells (A2 positive, gp100 negative, GLC 
peptide).  However the level of epitope presentation was 
relatively modest in comparison to peptide-loaded target 
cells (0-11% maximal).  There was no relation between whole 
antigen expression and gp100 280-288 positivity. 
 
The key limitation here relates to the negative control 
group.  The best negative control to absolutely verify that 
observed increases in spot count in the presence of the TCR 
were only due to presence of the gp100 280-288 epitope would 
have been a TCR-fusion protein of irrelevant specificity or 
anti-CD3 alone rather than no TCR-fusion protein.  However, 
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the other alternate TCR-fusion protein available was Melan-A 
26-35 specific.  Since patient DCs co-expressed Melan-A and 
gp100, this would not have been a suitable negative control.  
In future, this experiment could be repeated with a TCR-
fusion protein of unrelated specificity as a negative 
control (e.g. NY-ESO). 
 
To put the results obtained into context, the average 
epitope specific spot count for patient DC preparations was 
6 spots per well.  In experiments using the fusion protein 
at 10-9M with the same number of effector cells (103/well), 
similar spot counts were obtained with target cells pulsed 
with 10-10M YLE peptide.   
 
The other concern with the results obtained using the gp100 
280-288 specific TCR-anti CD3 protein relates the actual number 
of epitope specific spots obtained.  The manufacturer of the 
fusion protein reviewed these results and felt that, whilst 
suggestive of epitope presentation, were not especially 
robust in comparison to other cell types overexpressing 
gp100 (Jakobsen B, personal communication).  It is possible 
that the number of DCs per well was not optimal, and in 
future further detailed optimisation experiments using 
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antigen-presenting-cells expressing whole antigen would be 
necessary.   
 
In both of these experiments, there was no negative control 
for the transfection process – that is, all DC vaccine 
preparations had been transfected, using CL22 peptide, with 
gp100 and Melan-A encoding DNA.  The absence of an 
untransfected control group is due to a need to maximise the 
yield of mature, transfected DCs for each patient and at the 
transfection stage it would not have been ethical to put 
aside DC as a control and potentially compromise the yield 
of cellular product available for re-administration.   
 
This appears to be the first time epitope display has been 
measured in a cellular product used therapeutically in 
patients.  In terms of melanoma antigens, adenovirally 
transduced moDC expressing full-length Melan-A have been 
used to treat metastatic melanoma patients in a Phase I/II 
clinical trial (Butterfield et al., 2008).  However, there 
was no measurement of antigen expression or epitope 




In the setting of ampullary, breast and pancreatic cancers 
expressing Mucin-1, an autologous DC vaccine expressing MUC1 
after cationic lipid transfection of plasmid DNA has been 
investigated in the Phase I/II setting (Pecher et al., 
2002).  Here, whole antigen expression was measured and was 
variable, but epitope presentation was not evaluated.   
 
 
These results are highly suggestive that Class I restricted 
epitopes are being presented, perhaps at a low level, by 
CL22 peptide transfected DCs of metastatic melanoma patients 
and this extends the initial observations made with this 
transfection system using viral antigens and laboratory 
donor DCs (Irvine et al., 2000).  
 
In terms of clinical trials of DC vaccination, these data 
raised questions regarding the importance and relevance of 
whole antigen detection 48 hours after transfection to 
vaccine antigenicity – certainly for melanoma 
differentiation antigens.  In future, the use of recombinant 
T-cell receptors specific for epitopes derived from these 
antigens should be seriously considered as a quality control 




In terms of physiological relevance, the main limitation of 
these experiments is that they are only measuring epitope 
display over a limited time-frame – 48-64 hours after 
transfection.  In vivo the subcutaneously administered DCs 
would take at least a further 48 hours (Lappin et al., 1999 
and de Vries et al., 2003) to reach T-cell zones of 
secondary lymphoid tissues and begin to interact with T-
cells.  There is also accumulating evidence that epitope 
persistence and the maturation status of DCs is equally, if 
not more, important than merely the number of peptide-MHC 
complexes per cell.   
 
4.3. TLR9 expression in monocyte derived DCs and immune-stimulatory 
effects of CL22 transfection of plasmid DNA. 
 
Initial experiments determined that immature DC did express 
TLR9 as assessed by intracellular antibody staining and flow 
cytometry.  Mature DC showed a lower level of TLR9 
expression.  Contaminating lymphocytes and undifferentiated 
monocytes showed low-level TLR9 expression.  
 
Although an isotype matched control antibody was used to 
confirm specificity of the observed staining, in future it 
would be helpful to perform the staining on a cell type 
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known or suspected to be TLR9 negative (e.g. epithelial cell 
lines) and also on cells ectopically over-expressing the 
protein, perhaps after DNA transfection to establish 
definitive positive and negative controls. 
 
Cells had been fixed and permeabilised before staining in 
these experiments.  Although TLR9 positivity was 
demonstrated, it was not possible to distinguish between 
cell surface and intracellular expression as analysis was 
performed by flow cytometry.  Future experiments should 
determine localisation, either by staining with and without 
permeabilisation or using fluorescence microscopy.   
 
Previously, there have been conflicting findings regarding 
TLR9 expression on monocyte-derived (i.e. myeloid) DCs.  In 
the murine setting, the bone-marrow derived DCs of TLR9 
double knockout mice did not secrete IL12 or Type 1 
interferon in response to hypomethylated CpG 
oligonucleotides or plasmid DNA (Tudor et al., 2004).  In 
human monocyte derived DCs, TLR9 expression was detectable 
by flow cytometry, but not by Western blotting, and levels 
of expression were significantly lower than those seen in 
plasmacytoid DCs or TLR9 transfected HEK293 cells (Hoene et 
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al., 2006).  This study additionally demonstrated that moDCs 
were response to stimulation with CpG oligonucleotides.   
 
In contrast however, Bauer et al (2001) showed that monocyte 
derived DCs were entirely unresponsive to stimulation with 
bacterial DNA and CpG oligonucleotides and did not contain 
detectable TLR9 mRNA transcripts by RT-PCR.  CD123 positive 
plasmacytoid DCs and B-lymphocytes, however, were responsive 
to hypomethylated DNA and were TLR9 mRNA positive.  The 
consensus view has been that myeloid DCs are TLR9 negative 
and plasmacytoid DCs are positive (Shortman and Liu, 2002).   
 
Encouraged by the detection of TLR9 on immature moDCs, 
experiments moved forward to determine whether or not 
introduction of plasmid DNA into DCs, using the CL22 peptide 
transfection system, could have activating and immune 
stimulating effects on the DCs.   
 
Plasmid DNA encoding GFP was used for these experiments for 
two reasons – firstly transfection efficiency can be easily 
monitored by flow cytometry, and secondly, GFP is likely to 
be a relatively non-immunogenic protein.  This is important 
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to allow separation of the effects of protein production 
from those of introduction of DNA into the cell.   
 
Exposure to DNA transfection, regardless of the presence or 
absence of proinflammatory cytokines, increased the 
proportion of DCs expressing CD25.  
 
It has been generally accepted that CD25 expression is a 
marker of ‘mature’ DCs (Steinman, Pack and Inaba, 1997) and 
in the trial, exposure to proinflammatory cytokines 
increased the proportion of positive DCs.  However, some 
work has suggested that mature, CD83 positive moDCs with 
robust T-cell stimulatory abilities only express CD25 very 
weakly (Zhou and Tedder, 1996).  Certainly, the functional 
role of the α-chain of the IL2 receptor (CD25) on dendritic 
cells remains unclear.  The β-chain is not co-expressed, 
which makes any biological effect of IL2 on the cell very 
unlikely. In fact, CD25 may distinguish tolerogenic DCs that 
coexpress the the enzyme IDO (von Bergwelt-Baildon et al., 
2006).  Surface CD25 on DCs can be cleaved to a soluble form 
which can act as an IL2 decoy receptor and lead to IL2 
sequestration and decrease T-cell activation and 




In agreement with phenotyping results from the trial, CCR7 
expression is noted to be very low in all three DC 
preparations regardless of exposure to DNA or cytokines. 
Although CCR7 expression seems to be closely linked to 
migratory ability of DCs (Ohl et al., 2004), there is some 
evidence that CCR7 independent pathways must exist as CCR7 -
/- knockout mice still exhibit resident DCs in lymph node 
tissue (Hintzen et al., 2006).   
 
In future, the scope of these experiments could be extended.  
Although CCR7 may be a marker of potential to migrate, the 
actual ability of DCs to migrate in response to a chemokine 
stimulus could be directly measured in transwell assays.  
Also, in view of the uncertain significance of CD25 
expression, further experiments could include determination 
of cleaved, soluble CD25 in culture supernatants and 
assessment of IDO expression and activity.   
 
The ability of DCs to stimulate the proliferation of 
allogeneic lymphocytes was assessed in 3H thymidine 
proliferation assays.  In two of three donors, there were 
increases in allogeneic proliferation when cells were 
tranfected with GFP DNA regardless of the presence of 
cytokines.  This likely reflects increases in MHC Class II 
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expression on the surface of DCs.  In future, these 
experiments could be extended to include assessment of other 
properties of the allogeneic responders such as cytokine 
release and Th1 (IFNγ, TNFα) versus Th2 (IL4, IL10) profiles.   
 
Cytokine production by DCs is a vitally important property 
of these cells.  Plasmid DNA transfection had unequivocal 
effects on the cytokines secreted by all three of these DC 
preparations.   
 
IL12 is produced by dendritic cells, cells of monocyte/ 
macrophage lineage and neutrophils in response to foreign 
pathogens via TLR signalling.  The main target cells are B 
cells where IgG production is enhanced and IgA and IgE 
production reduced, and T cells where Th1 cytokine 
production is increased (TNFα, IFNγ) (Trinchieri, 2003). IL12 
is a heterodimeric protein consisting of heavy (p40) and 
light chain (p35) subunits.  The expression of the p35 
subunit is almost ubiquitous amongst cell types.  IL12p40 
expression is inducible.  However, only the disulphide-
bonded heterodimer has biological activity (i.e. IL12p70).  
The p35 subunit can only be secreted as part of the p70 




IL12p40 production was increased by DNA tranfection in the 
absence of cytokines in one donor, and only in the presence 
of cytokines in another donor.  In the final donor, there 
was no effect of DNA transfection on p40 production.  In 
terms of IL12p70 release, this was essentially undetectable 
in two of three donors, but in one donor there was evidence 
of low-level IL12p70 production only in the presence of DNA 
transfection and exogenous cytokines.   
 
These barely detectable levels of bioactive IL12 release 
from dendritic cells are entirely consistent with the 
current two-signal model of DC activation.  For secretion of 
large amounts of IL12p70, the first signal necessary is 
signalling through Toll-like receptors and the second is 
receipt of T-cell derived signals such as IFNγ and CD40 
ligation (Mosca et al., 2000).  In this case, there may have 
been TLR9 stimulation by plasmid DNA but an absence of T-
cell signals prevents strong IL12p70 release.  It should 
borne in mind, however, in terms of DC vaccine design, that 
in terms of timing, high-level IL12p70 release early after 
transfection may not be necessary and such ‘hyper-
stimulated’ DCs may be functionally exhausted on reaching T-




It is also noted that the effects of transfection of plasmid 
DNA using the CL22 peptide seemed to vary according to the 
level of transgene expression.  In two donors, there is 
barely detectable GFP expression (less than 1.5% positive 
cells) and these DCs do show signs of ‘maturation’ in terms 
of phenotype, allostimulation and cytokine release on DNA 
exposure.  The other donor had more robust GFP expression 
(8%) but the only definite change upon DNA exposure was 
detectable IL12p70 release.   
 
CL22 peptide forms complexes with DNA that are actively 
taken up, by endocytosis, in immature DCs (Haines et al., 
2000).  The complexes enter the endolysosomal compartment, 
where instead of being degraded by lysosomal proteases they 
persist due to concomitant administration of chloroquine 
that inhibits acidification.  This allows access of DNA to 
the nucleus for transcription and later translation in the 
cytoplasm.  Recent evidence suggests that TLR9 is located in 
the endoplasmic reticulum in resting cells and on activation 
it translocates to lysosomes to interact with incoming 
foreign DNA (Latz et al., 2004).  It is therefore possible 
that when CL22-DNA complexes move rapidly through the 
endolysosomes to the nucleus, allowing good transgene 
expression, there is less time for interaction with TLR9 and 




In conclusion, these experiments show that TLR9 is expressed 
on monocyte derived DCs and that transfection of plasmid DNA 
using the CL22 peptide system can have immune enhancing 
effects on immature DCs.   
 
The importance of this, in the setting of clinical use of DC 
vaccines, is that it represents a further advantage of using 
methods of nucleic acid transfection to express whole 
antigen in comparison to other techniques of antigen 
loading.  Also, most known TLR ligands are difficult to 
adapt for clinical use, so delivery of TLR agonist signals 
via nucleic acids themselves would be useful way of 
circumventing this.  There are toll-like receptors that 
interact with viral RNA such as RIG-I receptors (Habjan et 
al., 2008), raising the possibility that RNA transfection 
may also possess intrinsic immune-adjuvant effects.   
 
Future experiments could usefully include knockdown of TLR9 
in DCs, for example by using anti-sense 
oligodeoxynucleotides, to determine whether or not the 
observed effects are due to TLR9 signalling or not.  It 
would also be pertinent to determine whether or not such 
immune-adjuvant effects are also observed when electrical 
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methods (i.e. electroporation) of DNA are employed, as there 
is some preliminary evidence that direct, electrically-
mediated transfer of plasmids to lung tissue bypasses the 
endolysosomal compartment and does not activate TLR9 (Zhou 
et al., 2007).   
 
4.4.  CL22 peptide based transfection of EBNA1 DNA into DCs leads to 
presentation of MHC Class I and II restricted epitopes. 
 
Transfection of human monocyte derived DCs with plasmid DNA 
encoding influenza nucleoprotein, using the CL22 peptide, 
led to presentation of the B8 restricted NP 380-388 epitope 
in the autologous system.  Transfection using CL22 was 
almost as effective as adenoviral transduction in terms of 
generating EBNA3c 258-266 specific cytotoxic T-cells in a 
B27 positive autologous system.  In the murine setting, 
vaccination with CL22 transfected DCs expressing influenza 
NP led to development of anti NP specific IgG responses, 
suggesting recruitment of CD4 T cells (Irvine et al., 2000). 
 
Here, we extend these observations by formally demonstrating 
that CL22 transfected DCs expressing EBNA1 present the HLA 
DR1 restricted TSL epitope – assessed by T-cell clone 
recognition assays and immunogenicity (bulk) assays.  In 
agreement with the work of Irvine et al., presentation of 
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the B35 restricted HPV epitope coexists with presentation of 
TSL by these transfected DCs.   
 
 
The presentation of epitopes mentioned above occurred 
despite both a very low transfection efficiency – assessed 
by GFP positivity in the control (i.e. EBNA1 negative) DCs, 
and very low proportions of EBNA1 transfected DCs being 
whole antigen positive by antibody staining at 48 hours.  
This again raises questions as to whether whole antigen 
detection in transfected DC vaccines is a useful or 
important surrogate marker of immunogenicity.  It was also 
noted that the proportion of GFP positive and EBNA1 positive 
cells at 48 hours was very similar, suggesting that EBNA1 is 
a relatively stable protein in DCs.   
 
The ability of DC preparations with low transgene expression 
to be immunogenic was also seen in the work of Irvine et 
al., where even DC vaccines with low (1-5%) transfection 
efficiencies could be highly immunogenic in vitro and in 
vivo. 
The results presented here also illustrate the importance of 
assessing both the antigenicity (short term T-cell 
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recognition) and immunogenicity (ability of DCs to expand 
epitope-specific cells in PBL) of a DC preparation.  In T-
cell recognition assays, for TSL and to a lesser extent HPV, 
peptide-pulsed target cells are recognised at levels 
several-fold higher than transfected cells.  In contrast, in 
immunogenicity assays, transfected DCs approach equivalence 
with peptide-loaded ones.  One explanation for this could 
relate to antigen persistence.  In order to stimulate 
outgrowth of T-cell clones, prolonged duration of epitope 
presentation is important particularly for CD4 cells (Obst 
et al., 2005), but also for CD8 T cells (Jusforgues-Saklani 
et al., 2008).  Pulsing with exogenous peptides leads to 
presentation of a high density of peptide-MHC complexes for 
a relatively short period (12-18 hours), whereas endogenous 
whole antigen expression likely leads to a lower peptide 
density that is maintained over several days.  It also 
possible that the concentration of peptide used for pulsing 
was supra-physiological and led to expansion of only very 
low avidity T-cell clones.  There is some experimental 
evidence of this using gp100 Class I restricted epitopes in 
the murine setting (Bullock et al., 2000).  The superiority 
of full-length EBNA1 in immunogenicity assays examining TSL 
and HPV specific responses lends support to the possible 
importance of antigen persistence as its distinguishing 
features is a slower translation rate and slower degradation 
rate in cells (Tellam et al., 2007).  In fact, antibody 
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staining for EBNA1 on these DCs shows a slightly higher 
frequency of positive cells when full-length EBNA1 is the 
transgene.  
 
That whole antigen detection in transfected DCs appears to 
be largely irrelevant to presentation of epitopes, 
particularly as assessed by the ability to expand epitope-
specific T-cell populations in PBMCs, might relate to 
antigen transfer between DCs.  However, a closer re-
evaluation of the antigen-recognition results shows that 104 
DCs were co-incubated with 103 effector T-cells.  Based on 
EBNA1 staining, approximately 1 in 100 cells were clearly 
antigen positive, this would equate to 100 antigen positive 
DC per well.  These cells directly presenting epitopes could 
still give rise to the small increases in T-cell activation 
seen – approximately 10-20 spots.  In order to determine 
whether or not antigen transfer had a role in presentation 
of these epitopes by CL22 transfected DCs, experiments could 
be conducted with reducing numbers of target DC per well to 
ascertain whether or not T-cell recognition is still seen 
even when less than 100 targets per well are present.  If 
this were the case, it would be experimental evidence of 





4.5.  Dendritic cell transfection methodologies – a systematic comparison. 
 
The CL22 peptide based transfection system is one of the 
very few DNA based whole antigen expression systems that has 
actually been used in the clinical setting.  However, both 
in the preclinical and clinical setting, this transfection 
platform is characterised by marked variability between 
individual donors and between individual DC preparations.  
There is also the important limitation that optimal 
transgene expression is only achieved when cells are 
transfected in the immature state as active endocytosis of 
peptide-DNA complexes is required.  The large majority of 
recent clinical trials of DC vaccination for malignancy have 
used RNA as the nucleic acid of choice, and typically it has 
been introduced into mature DCs using electroporation.   
 
On this background, a systematic comparison between three 
non-viral whole antigen expression methods was carried out.  
The aim of this was to determine the most efficacious method 
with which to carry out further experiments on MHC Class I 
and II restricted epitope presentation by DCs and, in terms 
of future clinical use, to assess CL22 peptide transfection 




The strengths of this experiment were the fact that all 
three transfections were performed in parallel, using 
dendritic cells derived from the same blood donation, using 
well characterised antigens (EBNA1∆GA and EBNA1∆GA-Invariant 
chain) and that immunogenicity and antigenicity of the DCs 
were measured.  There has been a paucity of reported formal 
comparisons between dendritic cell transfection techniques 
in the literature.  The work of Van Tendeloo (2001) suggests 
that human monocyte-derived DCs were far more amenable to 
transfection with in-vitro transcribed RNA using 
electroporation rather than cationic lipid preparations (85% 
versus 7.5% GFP positive viable DCs).  It was also noted 
that cell viability was higher following electroporation 
(78% versus 72%).  In terms of MHC Class I epitope 
presentation, the recognition of DCs lipofected with Melan-A 
encoding RNA by a 27-35 specific CTL clone was approximately 
half that of electroporated DCs.   
 
In stem cell (CD34 positive) derived DCs, a comparison 
between mRNA and cDNA was performed.  Interestingly, there 
was no difference in levels of recognition by the 27-35 
specific CTL clone of GFP and Melan-A cDNA transfected 




Earlier work (Van Tendeloo et al., 1998) had suggested that 
the type of in-vitro derived dendritic cell was crucial -  
monocyte derived DCs were refractory to transfection with 
cDNA regardless of whether cationic lipids or electroporaton 
were employed.   
 
A comparison of GFP expression in human monocyte derived DCs 
was carried out by Irvine et al (2000).  In line with the 
prevailing consensus view, the majority of cationic lipid 
preparations were ineffective in generating GFP positive 
DCs.  However, there was detectable, albeit minimal (<1% GFP 
positive) transgene expression using 4 cationic lipids 
including clonfectin and FUgene.  In comparison, the average 
transfection efficiency of CL22 peptide much higher at 
approximately 15% (Irvine et al., 2000). 
 
A more comprehensive analysis of amenability of DCs to 
transfection was carried out by Lundquist et al (2002).  
Stem cell and monocyte derived DCs from cancer patients and 
lab donors were subjected to viral transduction and non-
viral transfection.  60% of monocyte derived DCs expressed 
the transgene (GFP) after RNA electroporation, whereas no 
GFP expression was seen using DNA with the same electrical 
parameters and cell viability was compromised by DNA 
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electroporation.  Lipid mediated gene transfer led to low 
levels (1-10%) of GFP expression using RNA but not DNA.  In 
contrast, however, DNA delivered to DCs using particle 
bombardment (‘gene gun’) did lead to transgene expression at 
1-2% positive cells.  The analysis was extended to include 
viral transduction.  Although the percentage of GFP positive 
cells was comparable for adenovirally transduced and RNA 
electroporated moDCs, the intensity of GFP expression was 
higher with the adenovirus.  There was no deleterious 
effects of adenoviral transduction or electroporation of RNA 
on the allostimulatory capacity of DCs.     
 
In a similar vein, the percentage of transgene positive 
monocyte derived DCs was comparable after lentiviral 
infection or mRNA electroporation at 24 hours, but maximum 
fluorescence intensity was higher with the viral construct 
(Dullaers et al., 2004).  It was also demonstrated, in 
keeping with the results obtained in this work, that neither 
viral infection nor mRNA electroporation prevented 
subsequent phenotypic maturation of DCs following cytokine 
cocktail exposure.   
 
In this work, GFP expression was less than 5% with CL22 
peptide, around 40-50% with nucleofection of DNA and 90% 
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using RNA electroporation.  Nucleofection of RNA was not 
studied as part of the formal comparison, because previous 
experiments had shown a rapid reduction in the proportion of 
GFP positive cells with time and also on the theoretical 
basis that the electrical parameters of nucleofection are 
designed to deliver nucleic acid to the nucleus which would 
be unnecessary for RNA.  The reasons for this hierarchy of 
transgene expression could include: requirement of active 
endocytosis of DNA-peptide complexes with CL22 versus 
passive induction of cell membrane and nuclear pores with 
electrical methods and the lesser requirements of RNA as 
opposed to DNA – translation only rather than transcription 
and translation.   
 
The key limitations of this set of experiments relates to 
the low yield of dendritic cells.  Although the largest 
possible volume of blood was drawn, the starting number of 
monocytes was insufficient for a comprehensive analysis of 
DC function.  It was intended to perform a full phenotypic 
analysis of DCs to ascertain the effects of transfection on 
phenotypic maturation, but this was not possible as DCs had 
to be preserved for experiments on antigen expression and 
immunogenicity.  In future, this problem could be addressed 
in two ways.  The most straightforward would be to take 
blood from the same donor on several occasions a few weeks 
227 
 
apart and freeze whole PBMCs each time.  When a sufficient 
number of PBMCs were available from frozen stocks, cells 
could be thawed and used for plastic adherence to obtain the 
monocyte-enriched fraction.  It was noted however, 
throughout this work, that the final yield of immature DCs 
was always lower when frozen rather than fresh PBMCs were 
used.  This perhaps related to formation of clumps of cells 
after thawing.  An alternative would be to use leukapharesis 
or use buffy-coat PBMCs after HLA typing.   
 
In future, this comparative analysis should be extended to 
include other important DC characteristics including 
phenotypic markers of maturation, migratory capabilities, 
cytokine secretion.  In addition, if cell numbers were 
sufficient, the antigenicity and immunogenicity could be 
more completely assessed.  It would be highly informative to 
determine the functional avidity and affinity of the induced 
HPV and TSL specific T-cell populations by using a range of 
concentrations of exogenous peptide in the bulk cytotoxicity 
assays and ELISPOT assays and by altering target:effector 
ratios.  For CD8 responses, use of the HPV specific tetramer 
to stain DC-stimulated PBMC population would allow an 
assessment of functional avidity based on the intensity of 
staining.  In addition, the extent to which the induced T-
cell populations are able to lyse target cells 
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physiologically expressing EBNA1 such as B-LCL or lymphoma 
cell lines (rather than peptide-loaded target cells) would 
be a useful extension to the work.  This is particularly 
important as target cells were loaded with high, probably 
supraphysiologic concentrations of peptide in these 
experiments.   
 
In terms of clinical DC vaccine design, these results 
clearly favour RNA electroporation of dendritic cells.  This 
technique was the only one to lead to presentation of MHC 
Class I and II epitopes simultaneously as assessed by in-
vitro stimulation assays and T-cell clone recognition.  
Although DNA nucleofection was immunogenic in certain 
circumstances, the marked loss of cellular viability would 
make this technique difficult to apply in the clinical 
setting.  This difficulty is particularly troublesome when 
one considers the additional 24-48 hours migration that must 
occur from the injection site to draining lymph nodes.  
However, DNA nucleofection should not be totally discounted 
as fully mature DC can be nucleofected and could be 
immediately injected – this would possibly circumvent the 
described lack of phenotypic maturation seen in nucleofected 




In the context of this comparative experiment, CL22 
transfection was effective in generating immunogenic DCs – 
however, presentation of the HPV epitope was only seen in T-
cell recognition assays and of the TSL epitope only seen in 
in-vitro stimulation assays.   
 
Although the superiority of RNA electroporation may simply 
reflect a higher level of transgene expression, it is also 
possible that effects of the nucleic acid on DC maturation 
could be responsible.  In fact, in vitro transcribed RNA has 
been found to contain structures which can lead to formation 
of double-stranded RNA which increases Type 1 interferon 
release, MHC Class II and CD80 and CD86 expression on 
porcine monocyte derived DCs after RNA electroporation 
(Ceppi et al., 2009).   
 
These data also allowed an assessment of the importance of 
transfection efficiency to be made.  Despite an absence of 
EBNA1 positive cells by immunofluorescence, CL22 transfected 
DCs do present the HPV and TSL epitope albeit at low levels.  
Furthermore, cellular localisation of antigen seems to be 
more important than the efficiency of transfection – 
invariant chain tagged EBNA1 is presented equally well to 
TSL specific clone by DNA nucleofected and RNA 
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5. Relationship between detection of whole antigen and presentation of 
Class I restricted epitopes in RNA transfected dendritic cells. 
 
5.1 Rationale and purpose 
 
As discussed in Chapter 4, electroporation of0 in-vitro 
transcribed RNA into DCs leads to high levels of transgene 
expression and such DCs were highly antigenic and 
immunogenic for Class I and II restricted epitopes. This is 
in agreement with the recent literature on RNA 
electroporation of DCs (summarised in Ponsaerts et al., 
2003).   
 
Experiments assessing the levels of gp100 YLE and Melan A 
EAA/ELA epitope presentation by excess transfected (CL22 
peptide method) melanoma patient DCs suggested that there 
was no relationship between the ability to detect whole 
antigen at 48 hours after transfection and epitope 
presentation.  In fact, there was a modest negative 
correlation between these two variables in the case of 
Melan-A.   
 
On the basis of these results, a more detailed examination 
of the relation between whole antigen and epitope 
presentation was made using all three antigens (i.e. EBNA1, 
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gp100 and Melan A) using the most efficient transfection 
method – electroporation of RNA.  It was surmised that the 
more robust transfection method may provide more consistent 
and informative results than CL22 peptide based transfection 
or nucleofection where cell viability is poor.   
 
The primary aim was to determine whether or not detection of 
whole antigen in transfected DCs was a necessary 
prerequisite for presentation of MHC Class I restricted 
epitopes, and the secondary aim was to determine whether or 
not the relation between epitope presentation and whole 
antigen detection was dependent on the nature of the 
antigen. 
 
The overall clinical relevance of this set of experiments is 
to provide experimental evidence which can allow an informed 
decision to be taken regarding the utility of whole antigen 
detection as a surrogate marker of immunogenicity of DCs, 
and if not, to possibly suggest alternative markers of 




5.2.  EBNA1 transfected DCs are both whole antigen and epitope positive. 
 
 
Immature DC were prepared from a B35 positive donor and were 
electroporated with RNA encoding EBNA1∆GA or mock-
transfected.   
 
24 hours after transfection, epitope presentation and whole 
antigen detection were measured.  EBNA1 staining using the 
R4 antibody was performed by immunofluorescence microscopy.  
Presentation of the HLA B35 restricted epitope HPV (EBNA1 
407-417) was determined by using the DCs as stimulator cells 
in polyclonal cultures.  Responder cells in this assay were 
autologous non-adherent PBMCs that were stimulated twice 
with transfected and HPV peptide loaded DCs at weekly 
intervals.  On day 7, low dose IL-2 was added to cultures.  
On day 14, HPV specific T-cells were quantified using a PE 
conjugated B35-HPV specific tetramer.  Preliminary 
experiments had shown that a small population of tetramer 
positive cells were detected in a HLA B35 positive donor, 
whereas no such population was seen in a HLA B35 negative 
donor.  Both donors were EBV seropositive.  No tetramer 
staining was observed in a B35 positive, EBV seronegative 




In terms of whole antigen detection, there is strong, 
specific EBNA1 staining in transfected DCs (≈90%) as 
compared to minimal background staining in mock transfected 
cells.  EBV positive B-LCLs are EBNA1 positive.  These 
results are shown in Figure 5.1.  Staining intensity is 
higher in DCs than LCLs.    
 
In terms of epitope presentation, there is an expansion of 
the B35-HPV specific CD8 T-cell population in cultures 
stimulated with EBNA1∆GA transfected (≈10 fold) and HPV 
peptide loaded (≈30 fold) DCs compared to antigen-negative) 
DC.  This result is shown in Figure 5.2 and indicates that 
epitope presentation is occurring.   
 
Antigenicity was then determined.  Presentation of the HPV 
epitope was assessed using the HPV specific T-cell clone in 
IFNγ ELISPOT assays.  EBNA1 antibody staining was performed 
on transfected DCs.  Approximately 35% of EBNA1 transfected 
DCs were whole antigen positive, whereas no positive cells 
were seen in the mock transfected group (Figure 5.3).   
 
In terms of epitope presentation, the EBNA1 expressing DCs 












clone.  Levels of recognition are lower than those seen with 
exogenously added peptide alone, largely due to some 
background (non-specific) recognition of EBNA1 negative DCs 
by the T-cell clone.  However, at both target:effector 
ratios (1:1 and 10:1) there is evidence of recognition 
(Figure 5.4).   
 
It was confirmed that RNA electroporation had not impaired 
DC maturation. There is upregulation of CD25, CD83 and CD86, 
and to a lesser extent CCR7 after exposure to TNFα and IL1β 
(Figure 5.5).   
 
These experiments demonstrate that there is no disconnection 
between whole antigen detection 24 hours after RNA 
transfection and presentation of a Class I restricted 










5.3.  Melan-A transfected DCs are whole antigen negative yet are epitope 
positive. 
 
5.3.1. Background and aims 
 
 
The aim of these experiments was to determine whether there 
was a relationship between epitope presentation and whole 
Melan-A detection in DCs transfected with in-vitro 
transcribed RNA. 
 
The immunodominant HLA-A2 restricted Melan A epitope is 
EAAGIGILTV (26-35).  However, a heteroclitic variant exists 
with enhanced A2 binding stability and therefore 
immunogenicity.  This is ELAGIGILTV.  To maximise the 
likelihood of detecting epitope presentation from DCs 
endogenously expressing Melan-A, a DNA construct encoding 
the Melan-A 27AL variant was generated.  PCR-based site 
directed mutagenesis, utilising primers containing the 
desired base substitution, was used to create the new 
construct.  Sanger dideoxy sequencing was used to check for 
the presence of the mutant sequence.  Plasmids containing 
the mutant were taken forward and transfected into 
epithelial cells (HEK293).  Cell lysates were prepared after 
72 hours and were used in immunoblotting experiments to 
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detect the Melan A protein.  As shown in Figure 5.6, the 
introduction of the amino-acid substitution has no 
deleterious effect on the protein as it is still detected by 
the A103 antibody, at the expected molecular weight of 20-22 
kDa.  One of the Melan-A A27L plasmids was used as a 
substrate for RNA synthesis. 
 
5.3.2. DCs are negative for whole Melan-A after RNA transfection. 
 
The initial aim was to determine whether or not Melan A RNA 
transfected DC are Melan A positive.  HLA-A2 positive DC 
were electroporated with Melan-A RNA (wild-type and A27L 
variant), and gp100 and GFP encoding RNA as controls. GFP is 
an easily detected and its stability allows an accurate 
assessment of overall transfection efficiency regardless of 
intracellular processing.  In parallel, Melan A RNA was also 
introduced into HEK293 cells by electroporation in order to 
verify that the RNAs were functional in vitro.   
 
After 24 hours, cells stained for intracellular Melan-A 
protein using the A103 antibody in indirect 
immunofluorescence microscopy with fluorophore conjugated 
secondary antibodies.  GFP was detected by fluorescence 







As shown in Figure 4.7A, there is strong GFP expression in 
the vast majority of cells assessed by microscopy.  
Approximately 98% of cells within the dendritic cell gate 
are positive for GFP compared to 0.5% of Melan-A transfected 
DCs, shown in Figure 5.7B.  This result confirms that 
electrical settings had been optimised for DC.   
 
Moving on to Melan A expression, there was successful Melan-
A staining of HEK293 cells electroporated with Melan A RNA 
(wild-type and A27L variant).  However, there was no 
evidence of Melan A positivity in the transfected dendritic 
cells, despite obvious Melan-A detection in the Melan-A 
positive melanoma line SK23MEL.  These results are presented 
in Figure 5.8A-C.  Of note, HEK293 cells and DCs were 
electroporated with RNA from the same aliquot on the same 
day, in parallel.   
 
Thus results show that highly efficiency DC transfection has 
taken place, that RNA is functional in HEK293 cells and that 
successful Melan A staining has been performed. Despite 
this, 24 hours after transfection, dendritic cells appear to 














Melan-A transfected DCs were used as targets in overnight 
IFNγ ELISPOT assays with the Melan A 26-35 specific T-cell 
clone as effector cells. DC were loaded with ELA peptide 
(positive control) at 5µM in DMSO or with DMSO alone 
(negative control) and used as targets.  The effector to 
target ratio was 1:10 and assays were performed in 
triplicate. 
 
As shown in Figure 5.9, there is strong recognition of 
target DCs loaded with cognate peptide.  However, there is 
also evidence of specific recognition of DCs transfected 
with Melan A wild-type and A27L variant RNA above background 
levels.  The increase in average spot count with transfected 
DCs is approximately 8 fold less than that achieved with 
peptide-loaded cells.  The wild type and A27L transfected 
DCs appear equivalent in terms of epitope presentation.  
These responses were also observed at T cell: DC ratios of 












5.3.4. Melan A negative DCs are Melan A 26-35 positive as assessed by 
recombinant T-cell receptor staining. 
 
To extend these observations, that whole antigen negative 
DCs seem to be able to present a Class I restricted epitope, 
epitope presentation was assessed in a different way.  A 
recombinant T-cell receptor specific for the A2 restricted 
ELA epitope was a kind gift from Immunocore Ltd, Abingdon, 
Oxon.   
 
Initial experiments characterised the ability of this 
reagent to detect epitope presentation on cells loaded with 
cognate peptide, and expressing whole Melan-A. The aim was 
to determine the sensitivity of the reagent prior to its use 
on DC.  The TCR is biotinylated, allowing detection by two-
step staining followed by flow cytometry.  The secondary 
reagent is streptavidin-phycoerythrin conjugate.   
 
TCR staining was performed on HLA A2 positive B-cell blasts 
loaded with reducing concentrations of ELA and EAA peptide.  
These experiments indicated that the threshold of epitope 
detection was 10-7M for ELA and 10-6M for EAA peptide (Figure 
5.11). These concentrations of exogenous peptide are 







epitope densities on cells endogenously expressing and 
processing whole antigen.   
 
Melan-A positive melanoma lines were stained with the TCR.  
SK23MEL is HLA A2 positive and 888MEL is negative and serves 
as a negative control.  There was a small population of 
cells showing low-level TCR positivity with SK23MEL, whereas 
no such population was seen with the 888MEL cell line 
(Figure 5.12).   
 
HEK293 cells are HLA-A2 positive and are readily 
transfectable. Therefore, they were transfected with Melan A 
A27L plasmid DNA or empty vector using Lipofectamine 2000.  
72 hours after transfection, cells were stained for 
intracellular Melan-A protein.  Approximately 15% of cells 
were Melan A positive.  In terms of TCR staining, there was 
a small increase in TCR positive cells in the Melan-A 
expressing 293 cells. This was just above the limit of 
detection with flow cytometry (Figure 5.13).   
 
These results show that whilst use of the Melan A 26-35 
specific TCR in two-step staining and flow cytometry is able 









concentrations, it may lack sensitivity to detect the likely 
low epitope densities on cells endogenously expressing 
antigen.   
 
This lack of sensitivity may represent a technological 
limitation of flow cytometry, as it is estimated that 200-
300 phycoerythrin signals per cell are necessary for 
reliable detection, and assuming a 1:1 epitope-TCR binding 
ratio this would be 200-300 epitopes/cell.  Strategies to 
improve sensitivity have included use of additional 
amplification steps in the TCR staining procedure.  However, 
in order to maximise the ability to detect epitopes, single 
live-cell fluorescence microscopy was used to enumerate 
epitopes based on a 1:1 relationship between epitopes and 
soluble TCR binding (Purbhoo et al., 2006).   
 
Using this sensitive technique, presentation of the Melan-A 
26-35 epitope by RNA transfected DCs was assessed.  The 
negative control cells in this experiment were gp100 
expressing DCs as it was suspected that green fluorescence 
from GFP positive cells might influence detection of 




In order to ensure that any observed Melan-A 26-35 T-cell 
receptor staining was specific, a TCR of irrelevant 
specificity (HIV GAG epitope specific) was used as the 
negative control.  This was particularly important in this 
assay as DCs had previously been cryoperserved and cellular 
viability was only 60-70%.   
 
Results are presented as a histogram showing the epitope 
counts for each cell examined in each of the groups of DCs.  
A minimum of 30 cells were analysed in each group.   
 
 
As shown in Figure 5.14, there is a non-specific background 
staining of approximately 25 epitopes per cell with the HIV 
GAG TCR regardless of which transfection DCs had undergone.  
However, in the Melan-A A27L expressing DCs only, there is a 
clear and distinct population of cells displaying epitope 
counts above this background that is not seen with the 
control TCR.  This strongly suggests that these cells are 
presenting the epitope and is in concordance with the result 
obtained using the T-cell clone.  Of note, there is no 
evidence of epitope presentation on DCs transfected with 






epitope counts on positive cells ranging from 0 to 55 
epitopes.   
 
These experiments establish that, at 24 hours, Melan A 
transfected DCs are negative for whole Melan A yet they are 
able to present the immunodominant A2 restricted epitope 




5.4. gp100  negative DCs are gp100 280-288 epitope positive as assessed 
by recombinant T-cell receptor.   
 
In a series of experiments analogous to those described 
above, the relation between detection of whole gp100 protein 
in the DC and presentation of the gp100 280-288 (YLE) epitope 
was determined.  In the melanoma DC vaccine trial, gp100 was 
detectable in transfected cells 48 hours after transfection.  
However, levels were highly variable with percentages of 
positive cells ranging from 0 to 98%.  The aim of this set 
of experiments was to show whether or not detection of whole 
gp100 was a necessary prerequisite for Class I epitope 
presentation. 
 
HLA A2 positive DC were transfected with gp100 RNA or GFP 
RNA as a negative control. In parallel, HEK293 cells were 
also electroporated with gp100 encoding RNA.  At 24 hours, 
cells were analysed for gp100 protein by indirect 
immunofluorescence microscopy. As shown in Figure 5.15A-C, 
there is abundant gp100 staining in transfected HEK293 
cells, and also in SK23MEL gp100 positive melanoma cell 
line.  However, there is an absence of gp100 staining in the 








The ability of these whole-antigen negative DCs to present 
the A2 restricted YLE epitope was assessed using a soluble 
recombinant T-cell receptor-anti CD3 fusion protein.  
Previous experiments with this reagent, using a T-cell clone 
of irrelevant specificity as a cellular readout, had 
suggested that it was sensitive enough to detect epitope 
presentation on cells endogenously expressing and 
physiologically processing whole antigen.   
 
Figure 5.16 presents the number of gp100 YLE specific spots 
per well for peptide-loaded and RNA transfected DCs as a 
measure of epitope presentation.  YLE specific spots are 
calculated as the spot count in the presence of the T-cell 
receptor-anti CD3 fusion protein at a concentration of 10-9M 
– spot count in the absence of TCR-fusion protein.  It can 
be seen that there is strong evidence of epitope 
presentation from DCs loaded with exogenous YLE peptide, but 
there is also an increase in spot count with gp100 
transfected as opposed to mock transfected DCs.  This 
suggests that these DC do indeed present the gp100 280-288 
epitope, albeit at a far lower level than peptide-loaded 








5.5. Melan-A and gp100 are detectable at earlier time points after 
transfection with RNA, albeit at different levels. 
 
 
Studies have shown that antigens are expressed in RNA 
electroporated DC as soon as 30 minutes after 
electroporation (Ponsaerts et al., 2003), and the aim of 
these experiments was to determine the kinetics of antigen 
expression focussing on early time points. 
 
Non HLA typed DC were transfected with GFP, gp100 and Melan-
A encoding RNA.  Cells were returned to TNFα and IL1β 
containing medium and at 2, 4, 8, 12 and 24 hours after 
transfection, cells were harvested and fixed onto microscopy 
slides.  The next day, GFP transfected cells were 
immediately viewed under a fluorescence microscope, whereas 
the melanoma antigen expressing DCs were permeabilised and 
stained for gp100 and Melan A expression.   
 
These results are presented visually in Figure 5.17 and 
graphically in Figure 5.18.  For GFP expression, the vast 
majority of cells show strong green fluorescence at all 
times points after transfection.  However, for Melan A there 
is a detectable population of Melan A positive cells at 









and are undetectable by 24 hours.  For gp100, there are a 
very few positive cells, again only seen at earlier time 




5.6. Lysosomal acidification seems to be involved in the loss of Melan-A 
expression with time and with presentation of the Melan A 26-35 epitope 
in transfected DCs.  
 
 
The observed reduction in proportion of Melan-A whole 
antigen positive cells with time, demonstrated in earlier 
sections, could be due to instability of the RNA and 
transient expression, or relate to active intracellular 
processing of the source protein.   
 
In experiments on the kinetics of antigen expression, DCs 
were exposed to a proinflammatory stimulus (TNFα and IL1β) 
that is known to upregulate lysosomal acidification and 
enzymatic function (Amigorena and Savina, 2007).   
 
Therefore, the primary aim of this set of experiments was to 
determine whether or not lysosomal or proteasomal processes 
might be involved in degradation of Melan-A in transfected 
DC, and the secondary objective was to determine whether 
such processes are involved in generation of the 26-35 
epitope at the cell surface.   
 
To achieve this, the effect of pharmacological inhibitors 
was studied.  Bafilomycin A is a highly specific inhibitor 
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of lysosomal acidification through inhibition of the 
vacuolar H+/ATPase proton pump (Yoshimori et al., 1991).  
Epoxomycin is an inhibitor of proteasomal activity, 
specifically β5 subunit dependent chymotrysin-like peptidase 
function (Naujokat et al., 2007).   
 
HLA A2 positive DC were prepared and transfected with RNA 
encoding Melan A or mock transfected (electroporated in the 
absence of RNA) and incubated for a further 24 hours in TNFα 
and IL1β supplemented medium.  In addition, some immature 
DCs were left untransfected and transferred into maturation 
medium.  RNA transfected cells were additionally exposed to 
epoxomycin, bafilomycin, or both for 24 hours after 
transfection.  At this point, intracellular Melan-A staining 
was performed on the DCs, and they were used as targets in 
overnight IFNγ ELISPOT assays with the Mel c5 clone as 
effectors. DCs were washed extensively to remove excess 
bafilomycin or epoxomycin before cellular assays. 
 
As shown in Figure 5.19, there is no Melan-A staining in 
cells left untreated, in line with Figure 4.8.  Cells 
treated with epoxomycin are also antigen negative.  However, 
DCs treated with bafilomycin alone do show Melan-A 






(approximately 1/100).  There is successful staining of 
Melan-A in a melanoma cell line (SK23MEL).  It is also noted 
that DCs treated with epoxomycin show decreased cellular 
viability (50-60%) as compared to other DC groups (90-100%), 
and exhibit abnormal (small, irregular, fragmented) nuclei 
on DAPI staining.   
 
Moving forward to epitope presentation, there is again 
evidence that the Mel c5 T-cell clone recognises Melan A 
(wild-type and A27L variant) transfected DCs in a specific 
fashion in IFNγ ELISPOT assays.  This is shown in Figure 
5.20.  The level of recognition is approximately 7 fold 
lower than maximal levels.  The addition of epoxomycin 
and/or bafilomycin A markedly attenuates the observed 
responses.  The reduction in recognition by the T-cell clone 
is greatest with epoxomycin (whether in combination with 
Bafilomycin or not), but there is clearly an inhibitory 
effect of bafilomycin alone.  Melan A A27L variant DCs 
appear to be less affected by the pharmacological 
inhibitors, perhaps due to a greater sensitivity of the T-
cell clone to the A27L variant.   
 
These data suggest that the lysosome is involved in the 






generation of the A2 restricted 26-35 epitope may be 
dependent on both proteasomal and lysosomal processes. The 
possibility that the observed reduction T-cell recognition 
after treatment with inhibitors is partially due to non-
specific negative effects on the DCs is not totally excluded 




5.7. Lysosomal acidification does not appear to be involved in generation 
of a MHC Class I restricted epitope from EBNA1 in transfected DCs. 
 
Melan-A RNA transfected DCs treated with bafilomycin A 
do show whole antigen positivity (at a very low level) 
and this treatment attenuates recognition by an A2 
restricted T-cell clone.  The aim of thse experiments 
was to determine whether this dependence of Class I 
epitope presentation on lysosomal processing was a 
general feature of dendritic cell function or whether it 
was antigen-specific.   
  
To achieve this, the experiments detailed in Section 5.6 
were repeated using a different antigen.  EBNA1∆GA was 
chosen for these experiments as it is a viral antigen 
that is efficiently processed via the proteasome and its 





HLA-B35 positive DC were transfected with EBNA1∆GA RNA 
or mock-transfected.  After transfection, cells were 
again transferred to medium containing pharmacological 
inhibitors or not.  At 24 hours, cells were harvested, 
washed and used as targets in overnight IFNγ ELISPOT 
assays using the B35 restricted HPV specific T-cell 
clone as effector cells.  As a positive control, mature 
untransfected DCs were loaded with HPV peptide or DMSO 
(control).  Whole antigen detection was performed on 
fixed and permeabilised cells using the R4 antibody.  
As shown in Figure 5.21, in contrast to Melan-A 
transfected DCs, EBNA1 is easily detectable in all 
transfected cells except those transfected without RNA.  
The localisation appears nuclear.  The percentages of 
positive cells are as follows: mock – 0%, EBNA1 no 
inhibitors – 51%, EBNA 1 epoxomycin – 33%, EBNA1 
bafilomycin – 49%, EBNA1 both inhibitors – 44%.  There 
appears to be a slight increase in staining intensity in 
bafilomycin treated DCs.  Again, there are abnormal cell 
nuclei in epoxomycin treated cells, and cellular 
viability was reduced in this group (≈50%).  There is no 








The ability of these DCs to present the B35 restricted HPV 
epitope to a specific T-cell clone is presented in Figure 
5.22.  There was obvious recognition of DCs loaded with 
exogenous HPV peptide, although background recognition of 
DCs loaded with DMSO only was slightly higher than usual.  
In terms of transfected DCs, there is recognition of 
EBNA1∆GA expressing cells that is abrogated by exposure to 
the proteasome inhibitor epoxomycin.  In contrast, exposure 
of DCs to bafilomycin seems to somewhat increase 
presentation of the epitope.   
 
Taken together, these results (Sections 5.6 and 5.7) suggest 
that there is heterogeneity in antigen degradation pathways 
and Class I restricted epitope generation mechanisms between 
different antigens in transfected DCs.  For Melan-A, 
lysosome inhibition increases detection of whole antigen and 
reduces epitope presentation.  In the case of EBNA1, epitope 
presentation is actually increased in the presence of 
bafilomycin.  This finding also reduces the likelihood that 
observed effects are due to off-target effects of 








5.8. In transfected DCs, presentation of the Melan-A 26-35 epitope lags 
behind detection of whole Melan-A antigen. 
 
 
After considering that Melan-A RNA transfected DC are whole 
antigen negative at 24 hours yet present the 26-35 epitope, 
and the result that at earlier time-points Melan-A is 
detected intracellularly, a simple question arises – ‘Is 
epitope presentation also happening when cells are whole 
antigen positive shortly after transfection?’. 
 
The aim of this set of experiments was to answer this 
question by comparing whole antigen detection and 
simultaneous epitope presentation at 4 and 24 hours after 
RNA transfection with wild type and A27L variant RNA.    The 
maturation status of these DCs was assessed by antibody 
staining against a panel of DC.   
 
HLA-A2 positive DC were prepared and transfected with Melan-
A wild-type or Melan A A27L variant RNA or mock-transfected 
(control).  After 3 and 24 hours after transfection, cells 
were stained for Melan-A and with a panel of cell surface 
antibodies, and were used as targets for recognition by the 
Melc5 T-cell clone in IFNγ ELISPOT assays.  The same aliquot 
of T-cells was used for each assay.  Additionally, at each 
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time-point untransfected DCs were loaded with exogenous 
peptide (ELA) or DMSO alone as a positive control for T-cell 
function.   
 
For whole antigen detection, a small population of Melan-A 
positive DCs is seen at 3 hours post transfection.  
Approximately 1 in 8 cells are Melan-A positive.  In 
contrast, at 24 hours no antigen positive cells are visible.  
Successful staining of Melan-A in a melanoma cell line 
(SK23MEL) is seen.  Cells were fixed separately but all 
staining was performed in parallel.  These results are 
presented in Figure 5.23.   
 
Moving forward to presentation of the 26-35 epitope, there 
is definite evidence of specific recognition of transfected 
DCs by the T-cell clone at 24 hours, but this is not seen at 
3 hours post transfection.  Recognition appears more robust 
with DC expressing the A27L variant.  There is strong 
recognition of DCs loaded with exogenous peptide at both 
time points, although spot counts were somewhat higher when 
the assay was performed at 24 hours.  These results are 










Finally, these same groups of DCs (3 and 24 hours post 
transfection) were analysed for a panel of cell surface 
markers of DC differentiation and maturation.  The results 
of surface antibody staining are presented in Table 5.1. 
Table 5.1. Phenotypic analysis of DC at 3 and 24 hours after transfection and 
maturation 









CD1a 97.1 97.0 98.6 
CCR7 9.8 9.2 9.8 
CD14 73.9 73.6 53.8 
CD25 4.3 4.3 9.0 
CD83 6.3 11.9 36.5 
CD86 25.8 95.3 84.5 
MHC Class I 97.0 98.2 97.2 
 
The result of staining for maturation markers CCR7, CD25, 
CD83 and CD86 and MHC Class I molecules is shown in Figure 
4.25.  There are increases in proportion of cells expressing 
CD83 and to a lesser extent CD25 at 24 hours compared to 3 
hours.  The staining intensity for MHC Class I may be lower 
at 3 hours.  Phenotypic analysis suggests that at both time-







As a whole, this set of results suggests that in RNA 
transfected DCs, presentation of the Melan A 26-35 epitope 
from endogenous source protein lags behind detection of 
whole antigen.  Exogenously supplied peptide can be 
presented at both time-points at comparable levels.   
  
 
In conclusion, experiments suggest that early after 
transfection when whole antigen is detected epitope 
presentation is not occurring, whereas once more time has 
elapsed, DCs are epitope positive but whole antigen 





5.9. In transfected DCs, the relationship between detection of whole 
antigen and presentation of MHC Class I restricted epitopes is antigen 
dependent. 
 
In the case of Melan-A transfected dendritic cells, there is 
a delay between detection of whole antigen that peaks at 2-4 
hours post transfection and presentation of the 26-35 
epitope to a specific T-cell clone that is only seen at 24 
hours.   
 
The aim of this set of experiments was to determine what the 
relationship between whole antigen detection and epitope 
presentation is for EBNA1 and Melan A in parallel, in the 
same experiment.   
 
The glycine-alanine repeat deleted isoform of EBNA1 
(EBNA1∆GA) was chosen for these experiments as it has the 
same (nuclear) localisation as unmanipulated protein but it 
is less stable and more likely to produce DRIPs (Tellam et 
al., 2007) than full length antigen.   
 
In this set of experiments, dendritic cells were prepared 
from a laboratory donor whose haplotype included both the 
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B35 and A2 alleles.  This allowed detection of both the B35-
HPV epitope of EBNA1, and the A2-EAA/ELA epitope of Melan-A.  
 
HLA A2 and B35 positive immature DCs were transfected with 
EBNA1∆GA RNA, Melan A (wild-type) or Melan A A27L variant 
RNA.  Transfected DCs were returned to medium supplemented 
with TNFα and IL1β. At 4 hours and 24 hours after 
transfection, DCs were harvested and used for assays.  At 
each time-point, cells were used for intracellular antigen 
staining and also as targets for T-cell recognition in IFNγ 
ELISPOT assays.  In both antigen staining and T-cell 
recognition assays, the two antigens acted as internal 
negative controls for each other.   
 
 
In terms of whole antigen detection, EBNA1 is detected is 
the majority (over 80%) of EBNA1∆GA transfected DCs.  This 
is seen at the 4 and 24 hour time point.  The staining 
intensity and frequency of positive cells is similar at each 
time point.  There is no non-specific EBNA1 fluorescence in 








Moving on to Melan-A, there are occasional Melan-A positive 
cells seen at 4 hours post transfection, but no positive 
cells after 24 hours.  There is no non-specific Melan-A 
staining of EBNA1∆GA transfected DCs.  There appears to be a 
higher frequency of positive cells with the wild-type as 
compared to A27L variant Melan-A.  This is shown in Figure 
5.26B.   
 
In terms of epitope presentation, for EBNA1, there is 
definite recognition of EBNA1∆GA expressing DCs above 
background levels with Melan-A transfected DCs.  This 
approaches 70% of peptide-stimulated responses.  The level 
of epitope presentation from endogenous EBNA1 is slightly 
higher at 4 compared to 24 hours (172 v 104 spot increase).  
These results are presented in Figure 5.27.   
 
As shown in Figure 5.28, presentation of the Melan A 26-35 
epitope to the Mel c5 clone is only clearly evident at 24 
hours after transfection.  After 4 hours, there is a slight 
suggestion of higher spot counts in Melan A and A27L 
transfected DCs versus EBNA1∆GA expressing DCs, but the 
triplicates overlap.  In contrast, at 24 hours, triplicates 









presentation is occurring at this time.  The peptide-
stimulated responses are comparable at either time point.   
 
A comparison of the kinetics of epitope presentation for the 
Melan A 26-35 epitope and EBNA1 407-417 epitope is made in 
Figure 5.29.  It is clear that the fold-increase in 
recognition with Melan-A expressing DCs above background is 
greater at 24 compared to 4 hours, for the wild-type and 
variant A27L.  In contrast, the fold-increase in recognition 
is twice as high at 4 hours compared to 24 hours for 
EBNA1∆GA.   
 
In summary, this set of experiments shows that the delay 
between detection of whole antigen and presentation of MHC 
Class I restricted epitopes is seen only with Melan-A and 
not with EBNA1.  In the case of EBNA1, a high proportion of 
cells are EBNA1 positive by antibody staining early and late 
after transfection, and epitope presentation is occurring at 







Chapter 6: Presentation of MHC Class I restricted epitopes by 
transfected dendritic cells: discussion 
 
6.1.   The Melan-A 26-35 epitope is presented by Melan-A transfected DCs 
 
The generation of MHC Class I restricted peptides is 
proteasome dependent and therefore understanding proteasomal 
physiology is vital in understanding Class I presentation.  
The concept of differential epitope generation by standard 
and immunoproteasomes has existed for over a decade.  It is 
thought that substitution of the IFNγ inducible subunits 
(LMP2, LMP7 and Mecl-1, for β1, 2 and 5) leads to 
preferential polypeptide cleavage after hydrophobic or basic 
amino acid residues rather than after acidic residues 
(Cerundolo et al., 1995).  Thus, the repertoire of final 
antigenic peptides produced may be different (Rock and 
Goldberg, 1999).    
 
In terms of tumour antigens, Morel et al (2000) demonstrated 
that immunoproteasomes were unable to process an extended 
Melan-A 16-40 peptide into the 26-35 epitope, whereas 
standard proteasomes were able to do so - suggesting that 
the epitope is generated extremely inefficiently by the 




However, experiments using purified proteasomes in vitro are 
not totally analogous to the situation in vivo, as i post-
proteasomal processes contribute to the generation of final 
antigenic peptides for MHC loading (Rock, York and Goldberg, 
2004). 
 
Chapatte et al (2006) showed that human moDCs nucleofected 
with Melan-A plasmid DNA failed to be recognised by a Melan-
A 26-35 specific T-cell clone despite 30% transfection 
efficiency and good recognition of peptide-loaded targets. 
However, no maturation stimulus was used.  DC from LMP2 
knockout mice (lacking immunoproteasomes) were able to 
present the epitope.  
 
Held et al (2007) showed using MHC-peptide specific 
antibodies, that LCLs expressing Melan-A A27L as an 
ubiquitin fusion protein after viral transduction are 
epitope negative in comparison to cells expressing a 26-35 
minigene construct.  LCLs constitutively express 




However, the work presented here suggests that monocyte 
derived DC are able to present this epitope in an 
immunogenic fashion.  Across several experiments with DC 
from different donors, there is recognition of Melan-A A27L 
and wild-type transfected DCs by a Melan-A 26-35 specific 
clone.  Levels of recognition range from 8-20% maximal.  
Unlike Chapatte et al (2006), these experiments used 
cytokine-matured DC as targets.  In addition, the 
transfection efficiency in these experiments approached 90% 
in contrast to 30-40% and nucleofection of DNA is associated 
with higher cellular mortality than RNA transfection. 
Chapatte et al. used immunomagnetic selection of CD14 
positive monocytes, whereas this work used plastic 
adherence.  The possibility that a greater proportion of 
contaminating cells could be contributing towards epitope 
presentation is not totally excluded.   Also, T-cell 
recognition was measured by ELISPOT here, which allows 
quantification of individual IFNγ secreting cells and which 
may be more sensitive than ELISA. 
 
In agreement with these results, several studies have shown 
that DC can present the epitope after Melan-A transfection.  
Using electroporation of in-vitro transcribed RNA, Melan-A 
transfected DC were able to induce Melan A 26-35 tetramer 
positive cells in autologous PBMCs (Abdel-Wahab et al., 2003 
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and Abdel-Wahab et al., 2005).  Human moDC transfected with 
plasmid DNA encoding Melan-A using particle bombardment were 
also recognised by a 27-35 specific T-cell clone and were 
immunogenic in vitro (Tuting et al., 1998). 
 
The 26-35 epitope has also been shown to be generated on DC 
expressing whole Melan-A after viral transduction – in terms 
of antigenicity (Butterfield et al., 1998) and 
immunogenicity (Kim et al., 1997). Viral transduction is, 
however, much more efficient than non-viral methods. 
 
Residual expression of standard proteasomes could be 
responsible for the ability of these DCs to present the 
epitope.  DCs generated from healthy donors in this 
institution, were found to express all 3 immunoproteasome 
subunits (Mecl-1, LMP2 and LMP7) prior to and after exposure 
to inflammatory cytokines. The presence of IFNγ in the 
culture medium did not influence the intensity of staining.  
The results are presented in Figure 6.1.  Future experiments 
could attempt to quantify the relative proportion of 








These results support the conclusion that DC expressing 
whole Melan-A antigen after RNA transfection do present the 
immunodominant A2 restricted epitope and this approach 
should remain under consideration for trials of DC 
vaccination in melanoma.   These experiments could be 
extended to determine whether or not transfected DCs are 
able to expand a Melan A 26-35 specific T-cell population 
within PBMCs, as even normal laboratory donors are known to 
have responses to this epitope. 
 
There is an obvious discrepancy between the ability of the 
26-35 specific T-cell clone to recognise peptide-loaded and 
endogenously expressing target cells.  As shown in Figure 
3.16, this clone barely recognises A2 positive target cells 
loaded with native (EAA) peptide above background levels. 
However, in three separate experiments, DC expressing wild-
type Melan-A were recognised above background.  This could 
reflect the fundamental difference between loading of 
exogenous peptide onto the cell surface by occupation of 
empty HLA molecules or displacement of lower-affinity 
peptides compared to peptide editing and loading in MHC 
loading compartments intracellularly.  The efficiency of 
binding of ELA peptide to A2 molecules is much higher than 
that of EAA (Rimoldi et al., 2001), thus, for EAA it may be 
the case that the 90 minutes for peptide-binding in vitro is 
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insufficient for formation of a significant number of 
peptide-MHC complexes whereas after endogenous production 
the longer time period for MHC loading (≈18-24 hours) 
compensates for this.   
 
 
A Melan A 26-35 recombinant T-cell receptor was also used to 
guage epitope presentation. This approach has been 
successfully used to detect tumour antigens and HIV epitopes 
in cells physiologically expressing antigen and those 
overexpressing it after transfection (Varela-Rohena et al., 
2008, Purbhoo et al., 2006, Purbhoo et al., 2007, Irvine et 
al., 2002).   
 
Melan-A A27L RNA transfected DC were epitope positive by TCR 
analysis.  There is a range of epitope positivity: the 
highest epitope density was 50 peptide-MHC complexes per 
cell and the average was 18 epitopes per cell (Figure 4.14).   
 
Neethling et al (2008) showed that after endocytosis of 
mannose-receptor-tagged βHCG protein by moDCs, an A2 
restricted epitope was presented between 24 and 72 hours 
300 
 
later.  Epitope density was 60-300 epitopes per cell using 
TCR mimetic antibodies.  
 
Using soluble T-cell receptors, it was demonstrated that an 
HLA-A2 positive bladder carcinoma cell line, transfected 
with a minigene construct encoding the epitope fused with 
ubiquitin, displayed approximately 13,000 epitopes per cell 
(Purbhoo et al., 2006).  This is unsurprising as antigen is  
pre-processed and delivered peptide directly into the Class 
I pathway.   
 
The level of epitope presentation on melanoma cell lines was 
far lower –25-45 epitopes per cell.  In common with the 
results presented here, there was a great degree of 
variability from cell to cell in terms of epitope counts.  
Similar epitope densities were demonstrated on CD138 
positive myeloma cells freshly isolated from bone marrow 
samples.   
 
Although technological advances such as recombinant soluble 
T-cell receptors allow increasingly precise quantification 
of epitope numbers, it remains difficult to be certain about 
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the physiological relevance or importance of these 
densities.   
 
T-cells are exquisitely sensitive to the presence of 
extremely low numbers of peptide-MHC complexes on the target 
cell surface (Irvine et al, 2002).  Earlier studies in this 
area had suggested thresholds for recognition by CD4 cells 
of 50-200 peptides and 10-50 peptides for CD8 cells.  These 
studies were, however, limited in that it is uncertain what 
proportion of the antigen-presenting-cell surface is 
available for interaction with T-cells and also loading of 
bulk populations of APCs probably leads to variability in 
the amount of peptide loaded onto each cell.  In TCR 
transgenic mice, the presence of even a single cognate 
peptide-MHC complex on the APC surface was sufficient to 
generate a transient calcium influx suggestive of T-cell 
activation.  More than 10 peptide MHC complexes per cell 
were able to produce sustained calcium influx, T-cell and 
APC stabilisation and formation of an ‘immunological 
synapse’ with mobilisation of ICAM-1. In fact, there was a 
plateau in calcium influx after the peptide-MHC density 
exceeded 10-20 per APC.  Using CD8 T cell responders, almost 
identical peptide density sensitivity was demonstrated 
(Purbhoo et al., 2004).  This work also showed that 
signalling via the CD8 co-receptor is vital for maximal 
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sensitivity of antigen recognition and that in terms of 
cytolytic activity, as few as 3 p-MHC complexes are 
sufficient  to sensitise the target cell to killing. 
 
In the work discussed above, effector memory T cells are 
being studied, and the relationship between epitope density 
and T-cell activation in naive cells interacting with 
antigen-presenting cells is not explored.  Additional, this 
work is in a transgenic murine system with ectopically 
expressed recombinant TCR molecules. 
 
Several other factors, aside from peptide-MHC density, need 
to be considered in terms of the ability of APCs to form 
stable and immune-stimulatory interactions with cognate T-
cells.  Although peptide-density is important, the affinity 
of the p-MHC:T-cell receptor interaction is highly relevant.  
In the presence of an optimal off-rate for the p-MHC-TCR 
interaction, low-peptide density is not disadvantageous 
(Vallitutti and Lanzavecchia, 1997).  Other important 
factors are the ability of the T-cell to move and survey the 
APC surface and the stability of the immunological synapse.  
The presence of costimulatory molecules and bystander cells 




The relationship between p-MHC density and T-cell responses 
is not linear.  In a murine model using the gp100 antigen 
and mice transgenic for AAD, a chimeric MHC Class I 
molecule, it was demonstrated that bone-marrow derived 
dendritic cells loaded with 0.1-1µg/ml tyrosinase 369-377 
peptide were significantly better inducers of try369 
specific CD8 T-cells than DCs pulsed with higher 
concentrations of peptide (Bullock et al., 2000). A similar 
effect was observed for the gp100 280-288 epitope.  
 
Again using transgenic mice, the magnitude of the primary 
immune response to tyrosinase 369 immunisation was related 
in a linear fashion to the quantity of peptide pulsed onto 
immunising DC.  However, the functional and structural 
avidity of Tyrosinase 369 specific T-cells in recall 
responses was lower when higher concentrations of immunising 
peptide had been used.  This inverse correlation between 
immunising peptide density and avidity of recall responses 
may relate to preferential selection of cells bearing higher 







6.2. Melan-A transfected DCs are whole antigen negative but epitope 
positive 24 hours after RNA transfection 
 
Melan-A transfected DCs are able to present the A2-EAA/ELA 
epitope.  However, at 24 hours after transfection when T-
cell assays were performed there is no Melan-A specific 
staining with the A103 antibody.  This is not due to failure 
of antibody staining, degradation of RNA or low 
transfectability. 
 
In the recently completed clinical trial of DC vaccination 
in metastatic melanoma (Steele et al., 2011), Melan-A was 
detectable, albeit at low levels, in CL22 peptide tansfected 
DC – in contrast to the findings presented in this thesis.   
 
In terms of DC preparation, clinical trial DC were 
transfected on day 4 of culture as were experimental DC, but 
patient DC were exposed to inflammatory cytokines for 48 
rather than 24 hours.  The transfection method was different 
– RNA electroporation versus CL22 peptide-based DNA 
transfection and, of course, experimental DC were derived 
from healthy lab donors rather than metastatic cancer 
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patients.  Also, in the trial, plasmid DNA encoded both 
Melan-A and gp100 rather than either antigen individually.   
 
There could be several reasons behind the difference in 
Melan-A detection.  In vitro transcribed RNA has a far 
shorter half-life than plasmid DNA and plasmid DNA is 
transcribed in-vivo and physiologically polyadenylated 
whereas in-vitro transcribed RNA was artificially 
polyadenylated using a yeast enzyme.  RNA stability is 
partially governed by the length of Poly (A) tails.  
Although the integrity of RNA was assessed by gel 
electrophoresis and staining with ethidium bromide, there 
was no discernable difference in electrophoretic mobility 
between RNA pre and post polyadenylation.  It would be 
informative in future to determine precisely the length of 
Poly-A tails and compare this to these achievable in vivo.  
The co-expression of gp100 with Melan-A could be relevant as 
it is thought that the two proteins interact and form a 
complex with each other, at least in melanocyte lineage 
cells (Hoashi et al., 2005).   
 
There have been several studies of DC expressing whole 
Melan-A after either nucleic acid transfection (Abdel-Wahab 
et al., 2003, Abdel-Wahab et al., 2005 and Tuting et al., 
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1998), or viral (Kim et al., 1997, Butterfield et al., 1998 
and Perez-Diez et al., 1998) transduction.    Only one 
investigated the presence of whole antigen after 
transfection (Butterfield et al., 1998).  48 hours after 
adenoviral transduction, Melan-A RNA was detectable by RT-
PCR and continued to be so for 196 hours.  At the protein 
level, immunocytochemistry showed that 90% of transduced 
cells expressed Melan-A protein at 24 hours.  No specific 
maturation stimulus was applied to these DC, in contrast to 
the work presented here. There is evidence that the nature 
of the maturation stimulus used can have a profound 
influence on the ability to detect expression of tumour-
associated-antigens in transfected DCs (Schuurhuis et al., 
2009).  Dendritic cell maturation is associated with a 
decrease in lysosomal pH which leads to activation of 
proteases and hydrolases.   
 
It was demonstrated that epithelial cells show positive 
Melan-A fluorescence after RNA transfection and EBV 
transformed B-cells also exhibited Melan-A positivity, 
albeit at low levels.  This could possibly be explained by 
higher levels of lysosomal activity in maturing DCs compared 
to B-cells (intermediate) and epithelial cells (low).  This 
hypothesis could be further investigated by determining 
whether or not the presence of TNFα and IL1β in DC culture 
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medium affected the presence of whole Melan-A antigen in 
transfected cells.  It is also possible that Melan-A RNA 
might have a different half-life in different cell types, 
although this appears less likely as the cell type had less 
of an effect on the detection of GFP.   
 
That whole Melan-A negative DCs presented the 26-35 epitope 
is entirely consistent with earlier results that 
demonstrated a likely modest inverse correlation with 
percentage of whole Melan-A positive DCs and recognition by 
the Melan-A 26-35 specific T-cell clone.   
 
The relationship between antigen detection and epitope 
presentation is, however, antigen-dependent and not merely a 
DC specific function.  EBNA1 transfected DC are both epitope 
and whole antigen positive at 24 hours after RNA 
transfection.  EBNA1 is easily detectable even though the 
RNA used encodes GA repeat deleted EBNA1 that is relatively 
unstable. 
 
These results raise two, not mutually exclusive 
possibilities.  The first is that, as suggested by the DRiP 
hypothesis, the predominant substrates for proteasomal 
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processing and MHC Class I loading are misfolded or 
prematurely truncated translation products rather than 
mature, full length proteins.  Thus, the ability to detect 
whole protein would be irrelevant to the ability to present 
immunogenic epitopes.  The second possibility is that 
further destructive processing of full-length antigen is 
required in order to generate peptide-epitopes.   
 
The relationship between whole antigen expression and 
presentation of MHC Class I restricted epitopes has been 
examined in melanoma cell lines (Michaeli et al., 2009).  
Cell lines with high levels of tyrosinase mRNA and protein 
had low surface A2 restricted epitope densities and vice 
versa.  In general, epitope presentation was inversely 
related to the antigen’s half-life in the cell.  
 
Although this study examined melanoma cell lines as opposed 
to professional APCs and the cells naturally expressed the 
antigens, it is in agreement with the results presented here 




6.3. Melan-A transfected DCs are whole antigen positive at early time 
points and lysosomal function is involved in Melan-A degradation and 
Class I epitope generation after RNA transfection. 
 
The diminuition of whole Melan-A positivity in RNA 
transfected DC with time could be explained by instability 
of the in vitro transcribed RNA or further intracellular 
processing of the antigen. The constant GFP levels with time 
and the effect of cell type suggest that further destructive 
processing of Melan-A may be responsible.  Although the 
kinetics of Melan-A expression were not formally studied by 
protein synthesis inhibition and pulse-chase experiments, 
the rapid drop in antigen positivity between 4 and 8 hours 
would be compatible with the previously determined half life 
of Melan-A of approximately 4-5 hours in epithelial cells 
(Michaeli et al., 2009).  It has been estimated as 3-4 hours 
in pigmented melanoma cell lines (SK23MEL) (De Maziere et 
al., 2002).   
 
To determine whether intracellular protein degradation plays 
a role, DC were transfected with Melan-A RNA and immediately 
exposed to inhibitors of lysosomal acidification and 
proteasomal function in addition to the proinflammatory 
maturation stimulus.  The effect of these inhibitors on 
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epitope presentation was also determined.  In order to 
assess whether or not any observed effects were antigen 
specific or a feature of dendritic cell physiology, 
experiments were performed in parallel with EBNA1∆GA where 
Class I processing and presentation are classically 
proteasome dependent.   
 
In the presence of balifomycin, occasional cells were Melan-
A positive and EBNA1 transfected DCs showed a slightly more 
intense staining, although only a single concentration of 
bafilomycin was used in this experiment and it had been 
chosen on the basis of experiments on lysosomal inhibition 
in LCLs (G.Taylor, personal communication).  The reason for 
a very modest increase in antigen expression could have been 
an inadequate concentration of bafilomycin.  In future, the 
optimal concentration for lysosome inhibition in DCs should 
be determined. This could be achieved by staining for LAMP1 
in the presence of a range of bafilomycin concentrations.  
These data suggest that Melan A, and perhaps to a lesser 
extent EBNA1 are subject to lysosomal degradation within 
maturing DCs.   
 
In contrast, the presence of epoxomycin had little effect on 
antigen detection.  That proteasomal inhibition did not lead 
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to an increase in whole antigen detection is unsurprising as 
the substrates for proteasomes are generally thought to be 
DRiPs rather than full length antigen, and the antibodies 
used to detect whole antigen only bind to a specific epitope 
which may not be present in prematurely truncated or 
misfolded proteins.  It was also noted that cells treated 
with epoxomycin exhibited abnormally shaped nuclei and the 
cell viability was lower in this group.  This has been found 
to be the case in other published work (Naujokat et al., 
2007) – where inhibition of β5 chymotrypsin-like proteasomal 
activity led to reductions in cell surface HLA and co-
stimulatory molecules, increased apoptosis and decreased 
secretion of IL12p70 and IL12p40 cytokines.   
 
In terms of epitope presentation, inhibition of proteasomal 
function led to abrogation of T-cell recognition by clones 
specific for the EBNA1409-419 and Melan A 26-35 epitopes, as 
expected.  However, the results obtained do not totally 
exclude the possibility of non-specific effects particularly 
in view of the lower cell viability and the known effects of 
proteasome inhibition on HLA molecule expression.  It 
remains possible that the lack of T-cell recognition of 
epoxomycin treated DCs could be due to poor viability and 
low MHC Class I surface expression rather than decreased 
peptide generation intracellularly.  In future, this could 
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be addressed by loading epoxomycin-treated DCs with 
exogenous peptide to confirm that the cells were viable and 
surface HLA molecules were present.   
 
However, treatment of transfected DCs with bafilomycin 
clearly attenuated the level of T-cell recognition of Melan-
A transfected DCs by the 26-35 specific clone.  In contrast, 
lysosomal inhibition of EBNA1∆GA expressing DCs in fact 
slightly enhanced the level of EBNA1 409-419 presentation.  
This result suggests that lysosomal processing may be 
involved in the generation of an MHC Class I restricted 
epitope in the case of Melan-A but not EBNA1.  The fact that 
lower levels of T-cell recognition are only seen with Melan-
A and not EBNA1 strongly suggests that there is a degree of 
specificity and the effects are not due to off-target 
actions of bafilomycin.  However, in future it would be 
prudent to attempt to load bafilomycin treated DCs with 
exogenous peptide as a positive control.   
 
Presentation of the Melan A 26-35 epitope seems to depend 
upon lysosomal acidification as well as proteasomal 
function.  This is a departure from the conventional 
doctrine that there is a segregation between lysosome 
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dependent Class II and proteasome dependent Class I 
presentation (Peters et al., 1991).   
 
Melan-A is a melanosome associated protein in common with 
other melanoma antigens including gp100/PMEL17, tyrosinase 
and TRP1 and 2 (Kawakami, 1998).  In pigmented melanoma 
cells, there was significant overlap between punctate 
structures that were positive for Melan-A and melanosomal 
markers although the majority of Melan-A staining was seen 
in a peri-nuclear location (De Maziere et al., 2002).  
Melan-A is enriched in early melanosomes but is also present 
in lysosomes.   
 
 
There are two potential mechanisms by which Melan-A could 
come to be present in endolysosomes – it could naturally 
localise there due to melanosomal targeting sequences or the 
protein could be secreted and then re-internalised.  Once in 
the MHC Class II loading compartments, cross presentation 
could occur.  
 
This would not be without precedent, as it is known that 
some melanosomal proteins naturally localise to 
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endolysosomes in non-melanocyte lineage cells.  In the case 
of gp100/PMEL17 (Lepage and Lapointe, 2006), there was 
evidence of LAMP-1 and gp100 co-localisation in transfected 
human epithelial cells and melanoma cells.  It was also 
demonstrated that deletion of the last 70 amino acids or the 
internal transmembrane domain of the protein led to loss of 
MHC Class II presentation in the face of maintained Class I 
presentation.  These mutants showed no vesicular 
localisation and no LAMP-1 co-localisation.  Finally, it was 
demonstrated that addition of these sequences to GFP led to 
an endolysosomal localisation of GFP.   
 
In terms of EBV viral antigens, there is accumulating 
evidence that redirection of the EBNA1 antigen into 
endolysosomal compartments by fusion with LAMP1 (Taylor et 
al., 2006) or the invariant chain has no deleterious effect 
on the presentation of MHC Class I restricted epitopes, 
indeed this is often seen to be enhanced.  This supports the 
concept that MHC Class I binding peptides can be sourced 
that the endolysosomal compartment.   
 
For gp100, however, Class I presentation in melanoma cells, 
epithelial cells or B-cells was not inhibited by chloroquine 
(Lepage and Lapointe, 2006).  Chloroquine inhibits lysosomal 
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acidification in similar way to bafilomycin but dendritic 
cells were not studied.   
 
It has also been demonstrated that the melanosomal protein 
gp100 localises to conventional endosomes in non-pigmented 






6.4. Presentation of the Melan A 26-35 epitope is delayed in transfected 
DC compared to the EBNA1 409-419 epitope. 
 
The rationale for this set of experiments was the fact that 
Melan-A is detectable from 2 to 8 hours post transfection 
and that experiments using patient DCs suggest an inverse 
correlation between antigenicity and whole antigen 
detection. The aim was to determine whether or not Melan-A 
positive cells did, in fact, present the 26-35 epitope. 
 
It was demonstrated that the level of recognition of Melan-A 
A27L transfected DCs by the Melan-A 26-35 specific clone was 
much lower at 3-4 hours as compared to 24 hours.  As 
expected, Melan-A positive DCs were only seen at the earlier 
time point.  This conclusion remained unchanged even after 
variations in maximal responsiveness of the T-cell clone 
were taken into account and T-cell recognition was 
calculated as percentages of maximal responses.  Thus there 
is a delay between whole antigen detection and generation of 
surface epitopes.  The minor differences in HLA expression 
at 4 and 24 hours are probably insufficient to explain the 




In understanding this result, one must consider dendritic 
cell aggresome related structures (DALIS) (Lelouard et al., 
2002). These structures form approximately 4 hours after a 
maturation stimulus (such as lipopolysaccharide (Watts et 
al., 2007)) is applied to DCs, and typically have 
disaggregated by 24-36 hours.  They contain newly 
synthesised proteins and polyubiquitination occurs in the 
DALIS; which likely function as a depot for antigenic 
substrates (Lelouard et al., 2004).  These structures delay 
Class I mediated antigen presentation in DCs, so that 
epitope density is maximal at the time with interactions 
with T-cells are likely to be occurring.  Delayed epitope 
presentation to cytotoxic T-cells, by approximately 10 hours 
has been observed in dendritic cells infected with influenza 
virus – in contrast no such delay was noted in lymphoma or 
epithelial cell lines (Herter et al., 2005).   
 
However, EBNA1 transfected DC were whole-antigen positive at 
both 3 and 24 hours after transfection and there was no 
difference in epitope presentation at the two time points.  
Thus, delayed epitope presentation and dissociation of 
antigen detection and epitope generation are only seen in 
the case of Melan-A and not EBNA1∆GA.  However, EBNA1∆GA is 
translated rapidly and is rapidly degraded by the proteasome 
(Tellam et al., 2007) and could be described as having a 
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natural affinity for the proteasome.  It is therefore 
possible that the production of high levels of defective 
ribosomal products exceeds the storage capacity of DALIS and 
leads to early epitope presentation being detectable.  
Future experiments should extend these observations by 
including a range of other tumour antigens that do not have 
a natural affinity for endolysosomes or proteasomes – full 
length EBNA1 for example.   
 
In view of the modest inverse correlation between Melan-A 
26-35 epitope presentation and whole antigen detection in 
clinical DC preparations, the slight increase in whole 
antigen detection on exposure of transfected DCs to 
bafilomycin, and the dependence of 26-35 epitope generation 
on lysosomal acifidication, it is reasonable to propose that 
initially Melan-A localises in endolysosomal compartments 
and antigen processing occurs here prior to transport to the 
cytosol and subsequent proteasomal processing and MHC Class 
I loading.  This ‘two compartment sequential’ processing 
takes longer than direct proteasomal processing (i.e. in the 
case of EBNA1∆GA).  There is an obvious precedent for this 
as DC are known to be able to cross present exogenously 




This model would predict that endogenous Melan-A should be 
presented via the Class II pathway, and in the next section 
evidence suggestive of this is presented.  
 
There is a close relationship between endolysosomes and 
melanosomes.  Melanosomes are considered to be specialised 
endolysosomes and both organelles have a common biogenetic 
origin (Orlow, 1995).  These melanin-rich organelles are, in 
the murine setting, found to be enriched in lysosomal 
hydrolases including cathepsin B and L (Diment et al., 
1995).  LAMP-1 is also expressed in melanosomes (Zhou et 
al., 1993) Acid phosphatise is expressed in lysosomes and 
also in melanosomes (Seiji and Kukuchi, 1969).   
 
There is also clinico-pathological evidence for a shared 
origin of the two organelles.  These are the ‘melano-
lysosomal’ syndromes.  In Chediak-Higashi syndrome (Barton 
et al., 2004), there are also a host of other associated 
features, many of which can be attributed to abnormal 
lysosomal function in cells such as platelets, neutrophils 
and lymphocytes – such as hepatosplenomegaly, 





This condition is inherited in an autosomal recessive 
fashion, and the fact that a single genetic mutation gives 
rise to functional deficits in melanosomal and lysosomal 
function provides further support for the concept that the 
two organelles are intimately related (Novak and Swank, 
1979).   
 
Furthermore, there is a shared acidic pH in the two 
organelle compartments.  Estimated melanosomal pH is 3-5 




6.5. gp100/PMEL17 is not seen 24 hours after transfection of DCs with 
gp100 RNA although such DCs are positive for the gp100 280-288 epitope. 
 
 
As for Melan-A, at 24 hours after RNA transfection, there is 
evidence of the gp100 280-288 epitope being displayed despite 
the cells being negative for whole gp100.  SK23 melanoma 
cells, known to be gp100 positive, were strongly stained by 
the HMB45 antibody in parallel experiments, GFP positivity 
of control DCs was over 90% and HEK293 cells transfected 
with the same batch of gp100 RNA were also strongly gp100 
positive.  It should be noted that the control group in the 
YLE epitope display assay was DC transfected in the absence 
of RNA; the ideal control would have been DC transfected 
with RNA encoding an irrelevant antigen such as GFP or 
Melan-A. 
 
In contrast to these results, other clinical and preclinical 
studies have demonstrated that gp100 is detectable after 
whole antigen transfection.  
 
Prabakaran et al (2007) showed 20% gp100 positivity using 
the HMB50 antibody in virally transduced DC, although the 
proportion of gp100 positive cells was far smaller than the 
stable marker protein B-galatosidase. This is in keeping 
322 
 
with the results presented here. However, the antibody used 
recognised a different epitope within gp100 (HMB50 versus 
HMB45), gp100 expression was achieved by viral transduction 
rather than RNA electroporation and the DCs used were 
generated with IL12 and IL2 rather than IL4 in conjunction 
with GM-CSF.   
 
Schuurhuis et al (2009) found gp100 positive DC by 
immunocytochemistry using HMB45 in dissected lymph nodes 
following intralymphatic injection in melanoma, 
approximately 24 hours after RNA transfection.  It is 
unclear what proportion of total DCs was gp100 positive 
however.  This group also demonstrated that human moDC 
electroporated with gp100 encoding RNA were gp100 positive 
as soon as 30 minutes after electroporation.  These cells 
were electroporated with gp100 RNA in the mature state and 
maximal gp100 expression occurred 2-4 hours after 
transfection, but gp100 positive cells remained detectable 
72 hours after transfection.  However, cells were fully 
matured before transfection and this could, conceivably, 
lead to differences in antigen handling.   
 
Even at earlier time points after transfection, only a very 
small proportion of DCs show detectable gp100 fluorescence 
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after antibody staining.  Positive cells are seen from 4 to 
8 hours after transfection.  There is minimal background 
(non-specific staining) with an isotype control antibody and 
very little staining of gp100 negative cells with the gp100 
antibody, alongside strong gp100 staining in the SK23 
melanoma cell line.  Approximately 1/50 to 1/100 cells are 
gp100 positive by immunocytochemistry. 
 
These results are quite different to previously published 
results and those seen in the clinical trial (Steele et al., 
2011). 
 
The intracellular processing and maturation of gp100/PMEL17 
is complex, and it has only been studied in the context of 
melanocyte-lineage.  There are 5 potential N-glycosylation 
sites and active intracellular processing of the protein by 
enzymes including endoglycosidases, proprotein convertases, 
metalloproteinases and γ-secretases produces a variety of 
smaller protein fragments.  This is summarised in Figure 
7.2. 
Additionally PMEL17 is extensively alternatively spliced and 
four different splice variants can be produced depending on 









The gp100 protein appears to play an essential structural 
role in more mature melanosomes and it forms a scaffold upon 
which melanin deposit can begin (Berson et al., 2001).  
Formation of fibrillar structures within early Stage 2 
melanosomes is dependent on normal gp100 function (Hoashi et 
al., 2005).     
 
There are several different monoclonal antibodies that 
recognise gp100 – illustrated in Figure 7.2.  However, each 
one has unique epitope specificity.  Thus, not all breakdown 
products of gp100 will react with all of the antibodies (de 
Vries et al., 2001).  HMB45, the antibody used for gp100 
detection in this work and in the DC vaccine clinical trial, 
reacts with a sialyated epitope in the RPT domain of the 
protein (Hoashi et al. 2006).  It reacts with the form of 
gp100 found in Stage 2 melanosomes.  In this vein, WM266-4 
melanoma cells were found, by immunoblotting, to be gp100 
non-reactive using the HMB45 antibody but positive using 
αPEP13h (Hoashi et al., 2005).  
 
There is also evidence that gp100 can be secreted from 
cells, and indeed a small proportion of total gp100 is found 
at the cell surface (Berson et al., 2001 and Maresh et al., 
1994).  It is possible that increased activity of the 
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secretory pathway could lead to active secretion of gp100 
from DCs, and this could explain why very few cells stain 
positive for the protein.  This could be further 
investigated in future experiments by collecting DC 
supernatants and performing immunoblotting.   
 
It is possible that in RNA transfected dendritic cells, 
active intracellular processing leads to the production of 
breakdown products of gp100 that are not recognised by HMB45 
– either because the epitope is cleaved or because 
sialyation does not occur normally (Kapur et al., 1992).  
The fact that DCs expressing gp100 from plasmid DNA after 
CL22 transfection does require explanation, however.   
 
There are two possible reasons.  First, there are 
fundamental differences between the two transfection 
processes – use of electrical impulses, exposure of cells to 
chloroquine, and crucially differences in the nucleic acid 
used.  It is not inconceivable that the 
activation/maturation programme in DCs exposed to plasmid 
DNA could be very different to that occurring in those 
electroporated with RNA.  There is some evidence of this in 
published work.  For example, NOD2 stimulation by bacterial 
muramyldipeptides induces autophagy in maturing DCs (Cooney 
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et al., 2009).    This could lead to alterations in gp100 
processing.  The second key difference is that in the work 
presented here, single-species gp100 encoding RNA was 
transfected into the DCs rather than the plasmid encoding 
both Melan-A and gp100 in the clinical trial.  An 
interaction between gp100 and Melan-A has been suggested 
(Hoashi et al., 2005).  In the absence of Melan-A, the 
stability of PMEL17 is reduced.  There was, in melanocytic 
cells, complex formation between the two proteins.  
Complexes also formed in non-melanocytic cells transiently 
transfected with gp100 and Melan-A DNA.  Critically, in 
normal melanocytes and a melanoma line (SK28MEL), Melan-A 
knockdown with small interfering RNA leads to a reduction in 
gp100 reactivity using HMB45.  In fact, attenuation of HMB45 
reactive gp100 is sensitive to even slight downregulation of 
Melan-A function.  In the clinical trial, co-expression of 
both antigens could have led to stabilisation, and 
subsequent detection, of gp100.  In pre-trial experiments, 
transfection of plasmid DNA encoding only gp100 into HEK293 
cells led to detectable gp100 levels at 48 hours, however 
this was not formally demonstrated in dendritic cells (Jane 
Steele, personal communication).  Future experiments should 
co-transfect Melan-A and gp100 RNA into DCs and determine 





In future, it would be important to utilise the full range 
of gp100 specific antibodies in view of the complexity of 
intracellular processing of the protein in order to 
ascertain whether or not the vast majority of transfected 
DCs are genuinely gp100 negative or merely express forms of 
the protein that are not recognised by the HMB45 antibody.  
 
Further experimental work is required in order to elucidate 
the significance of the vast majority (≈98-99%) of gp100 
whole antigen negative cells within RNA transfected DC 
populations.  In the re-directed T-cell ELISPOT assay, using 
the gp100 280-288 specific T-cell receptor fusion protein, 
there is a ten-fold excess of target DCs over effector T-
cells.  Thus, in each well of the ELISPOT assay, there 
should be approximately 100 whole antigen positive cells.  
Although there is evidence of epitope presentation, these 
data do not discriminate between direct presentation by the 
≈100 antigen positive cells or indirect presentation by the 
majority antigen negative DCs.  In future, this should be 
investigated by using a range of input DC numbers/well in 
the ELISPOT assay.  If epitope presentation remained 
detectable when fewer than 100 DCs were used per well, then 




Finally, the fact that gp100 can, under certain 
circumstances, be a cell-surface or secreted protein means 
that it would be important, in future, to determine whether 




7.  Presentation of MHC Class II restricted epitopes by RNA 
transfected clinical-grade dendritic cells. 
 
 
7.1.  Aims. 
 
The aim of this set of experiments were to determine whether 
presentation of MHC Class II restricted peptide epitopes 
from endogenous antigen, in RNA transfected DCs, depends 
upon the nature and cellular localisation of the antigens.  
The antigens studied were EBNA1 and Melan-A. 
 
7.2: Presentation of MHC Class II restricted epitopes from endogenous 
Melan-A in RNA transfected DCs. 
 
7.2.1. Generation of Melan A specific CD4 T-cell clones. 
 
Attempts to generate these T-cell clones focussed on a 
laboratory donor who had a detectable Melan-A IgG response 
in plasma, on the basis that this IgG response would have 
required a CD4 helper T-cell response.   
 
The initial aim was to determine whether or not there were 
Melan-A specific T-cells, in particular CD4 cells, within 
the PBMCs of this donor.  In order to maximise the 
likelihood of detection of CD4 helper T cell responses, the 
antigenic stimulus used was exogenously delivered whole 
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(recombinant) Melan-A protein.  As shown in Figure 7.1, 
there is evidence of cells secreting IFNγ in response to 
Melan-A protein at a frequency of approximately 0.025% in 
overnight ELISPOT assays.  There was no dose-response 
relationship.  In order to assess the relative contribution 
of CD4 and CD8 T-cells to the observed response, whole PBMCs 
were depleted of CD8 positive cells using magnetic beads 
before analysis.  The number of cells secreting IFNγ in 
response to Melan-A protein was greater in the CD8 depleted 
group (Figure 7.2).  This suggests that CD4 T cells may make 
a large contribution towards the observed responses.  
 
Similar assays were performed, using a range of Melan-A 
protein concentrations, assessing cellular proliferation 
rather than cytokine release.  In 7 day cellular 
proliferation assays, it was shown that there was an 
impressive increase in proliferation with exogenous Melan-A 
protein as compared to in its absence.  The proliferative 
response approached that of the non-specific mitogen PHA, 
although it is noted that the peak effect of PHA probably 
occurs before the time of the proliferation assay.  There 
was, again, no dose-response relationship within the protein 













On the basis of these results, an attempt to generate Melan-
A specific T-cells of a CD4 phenotype was made.  Initially, 
polyclonal cultures were generated from PBMC.  At first, the 
antigenic stimulus was exogenous Melan-A protein alone, and 
after one week, a further stimulation with autologous 
dendritic cells loaded with exogenous Melan-A protein was 
performed.  T-cell cloning was performed as described in 
Methods.  Five micro cultures were obtained that 
proliferated in the presence of Melan-A. Of these, 2 had 
been cloned at 0.3 cells/well and 3 at 3 cells per well.   
 
7.2.2. Characterisation of  Melan A specific T-cell clones. 
 
The ability of these ‘clones’ to proliferate in response to 
antigenic stimulation with whole Melan-A protein was 
determined in 4 day 3H thymidine proliferation assays.  T-
cells were cultured with autologous irradiated PBMCs in the 
presence or absence of Melan-A protein, and 3H thymidine 
incorporation was measured between 72 and 88 hours.  As 
shown in Figure 7.4, there were strong proliferative 
responses to Melan-A protein with proliferation indices 
ranging from 4-8.  The ability of one of these clones, the 
one exhibiting maximal growth, to secrete IFNγ in response to 
exogenously added Melan-A protein is shown in Figure 7.5.   









using blocking antibodies raised against MHC Class I, HLA DR 
and HLA DQ.  There was evidence of low-level IFNγ secretion 
in response to Melan-A, and the anti MHC-I antibody has less 
of an inhibitory effect than the HLA DQ and HLA DR 
antibodies.  This suggests MHC Class II restriction. 
 
The phenotype of these T-cell populations was also 
determined by surface antibody staining and as expected, all 
clones showed a CD8 negative and CD4 positive phenotype.  
Antibody staining on one T-cell clone (5B8) is shown in 
Figure 7.6.   
 




The aim of these experiments was to determine whether or not 
DC endogenously expressing Melan-A after RNA transfection 
are able to present MHC Class II restricted epitopes from 
the antigen.  In order to achieve this, the ability of 
Melan-A specific CD4 T-cell clones to recognise DCs 
transfected with Melan-A RNA in IFNγ ELISPOT and 
proliferation assays was determined.  The positive control 







As shown in Figure 7.7, both in terms of IFNγ secretion and 
cellular proliferation, there was recognition of DC loaded 
with exogenous Melan-A protein above background (DC not 
loaded with protein).  In terms of cytokine release, there 
was a relatively low level of cytokine production (≈100 
pg/ml/24 hours), whereas there was an eight-fold increase in 
thymidine incorporation when DCs loaded with Melan-A protein 
were used as targets compared to cells not loaded with 
protein.  This would be expected, as delivery of the antigen 
as exogenously protein requiring internalisation by DCs 
should lead to endolysosomal processing and Class II 
restricted epitope presentation. 
 
Experiments moved forward to determine whether a similar 
recognition by this CD4 T-cell clone occurred when the 
dendritic cells had been transfected with Melan-A RNA and 
expressed the antigen endogenously.  Unfortunately, at the 
time this experiment was performed recombinant Melan-A 
protein was no longer commercially available to act as a 
positive control.  However, dendritic cells were derived 
from the same donor as all experiments were performed within 
the autologous system.  In addition, the same T-cell clone 







In order to control for the efficiency of RNA transfection, 
the ability of transfected DCs to present the Melan A 26-35 
epitope to a specific CD8 T-cell clone (Mel c5) was also 
measured in IFNγ ELISPOT assays in parallel.   This takes 
advantage of the fact that this laboratory donor possessed 
the HLA-A2 allele. 
 
As shown in Figure 7.8, there was definite evidence of 
recognition of the transfected DCs by the Mel c5 clone in 
overnight IFNγ ELISPOT assays.  In line with previous 
experiments, the level of recognition of transfected DC was 
approximately 7 times lower than that of peptide-loaded 
cells.  This result showed that these DCs expressed Melan-A 
and processed it normally via the Class I pathway.  
 
Finally, the ability of these DCs to present epitopes to the 
Melan-A specific CD4 clone 5B8 was determined in parallel 
cellular proliferation and IFNγ ELISPOT assays.  In terms of 
cytokine release, there was no evidence of recognition by 
the 5B8 clone – spot counts were very similar whether gp100 








However, in the 3H thymidine proliferation assays, there was 
evidence of recognition of Melan-A expressing DCs above 
gp100 expressing ones.  Proliferation was 1.5 times greater 
when Melan-A expressing DCs were used as targets.  This was 
not accounted for by increased proliferation in the 
dendritic cells alone (Figure 7.9).   
 
The lack of recognition in IFNγ release assays of these 
transfected DCs may relate to the kinetics of antigen 
presentation and the timing of the assays.  The 
proliferation assay is carried out 48 hours after 
transfection, whereas the IFNγ ELISPOT assay takes place 
after 24 hours.  It is possible that presentation of antigen 
via the MHC Class II pathway takes longer when the antigen 
is produced intracellularly rather than being delivered 
directly to the endolysosomal compartment after endocytosis.  
This could explain the IFNγ response seen when Melan-A 
protein loaded DCs are used as targets and its absence in 
transfected cells. 
 
In conclusion, this set of experiments suggested that Melan-
A specific CD4 T-cells recognise DCs endogenously expressing 
Melan-A after RNA transfection.  However, this was only seen 






Proliferative responses to DCs loaded with exogenous protein 
are larger in magnitude than responses to Melan-A 
transfected DCs – approximately 10 fold versus 1.5 fold.   
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7.3.  Cellular localisation of Melan-A after RNA transfection of dendritic 
cells. 
 
Experiments presented in Sections 5.6 and 5.7 show that 
presentation of a Class I restricted epitope from Melan-A 
may be dependent upon lysosomal acidification, that 
inhibition of lysosomal function increases detection of 
whole Melan-A antigen, and that Melan-A transfected DCs are 
recognised by Melan-A specific T-cells of a CD4 positive 
phenotype.   
 
One explanation for these results may be that Melan-A 
localises to endolysomal compartments after synthesis in 
ribosomes after RNA transfection.  The aim of this set of 
experiments was to determine whether there was any degree of 
co-localisation of Melan-A with the lysosomal marker protein 
LAMP1 in dendritic cells after RNA transfection.   
 
Immature DCs were transfected with Melan-A (wild-type) RNA 
and after 3 hours they were fixed, permeabilised and co-
stained with anti LAMP1 and anti Melan-A antibody. 
Appropriate secondary antibodies were added and after 
extensive washing and nuclear staining with DAPI, cells were 




A representative high-power field (x 90) is shown in Figure 
7.10.  In the upper right quadrant of the images is a cell 
that showed intense green fluorescence indicating the 
presence of Melan-A protein, and also intense red 
fluorescence indicative of LAMP1.  When the images were 
merged, there was a clear circular area appearing white as a 
result of combined blue (nuclear), red and green 
fluorescence.  This could suggest that Melan-A can co-
localise with the lysosomal marker LAMP-1.  However, it was 
noted that whilst suggestive these results do not absolutely 
confirm co-localisation of the two proteins as they are two-
dimensional images.  It would be necessary to perform 
confocal microscopy to verify the result.   
 
The aim of the next experiment was to determine whether or 
not similar co-localisation of the two antigens was present 
in another Melan-A positive cell.  For this, the SK23 
melanoma cell line was studied, as it is not a professional 
antigen-presenting-cell and it contains melanosomes.  Once 
again, intracellular staining for Melan-A and LAMP1 was 
performed and cells were analysed by fluorescence 
microscopy.  In Figure 7.11, two typical cells are shown at 
a magnification of x90.  There was definite punctate 
staining throughout the cells of both Melan-A and LAMP1.  









lower than that seen in transfected DC.  In terms of co-
localisation, there was a low degree of partial co-
localisation.  This is shown by very occasional yellow 
punctate staining – highlighted by red arrows. 
 
In conclusion, these experiments suggested that there was a 
greater degree of co-localisation of Melan-A and LAMP1 in 




7.4: Cellular localisation of EBNA1 influences presentation of MHC Class II 
restricted epitopes in transfected DCs. 
 
The experiments described above suggest that after RNA 
transfection and endogenous production of Melan-A protein in 
clinical-grade dendritic cells, presentation of MHC Class II 
restricted epitopes to CD4 T-cells occurs.  Additionally, in 
transfected DCs, there is some evidence of co-localisation 
of Melan-A and a lysosomal marker – LAMP1 – at early time 
points after transfection.   
 
Experiments using CL22 peptide-based transfection indicate 
that when full-length, native EBNA1 was produced in 
dendritic cells, the HLA-DR restricted TSL epitope was 
presented, as assessed by T-cell clone recognition and in-
vitro stimulation assays.  However, the transfection 
efficiency in these experiments, whilst detectable by 
immunocytochemistry, was very low and this makes drawing 
definitive conclusions from this experiment more difficult. 
 
The aim of this set of experiments was, therefore, to 
determine whether or not cellular localisation of EBNA1 had 
any effect on the ability of transfected DCs expressing 
whole antigen to present MHC Class II restricted epitopes in 
an immunogenic fashion.  In order to achieve this, the 
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transfection methodology chosen was electroporation of in-
vitro transcribed RNA, as this has been shown to lead to 
high levels of transgene expression and excellent cellular 
viability.   
 
Plasmid DNA encoding full length EBNA1 (EBNA1), glycine-
alanine repeat deleted EBNA1 (EBNA1∆GA), glycine-alanine 
repeat deleted EBNA1 with nuclear localisation signal 
mutation (EBNA1∆GA-NLS) and glycine-alanine repeat deleted 
EBNA1-invariant chain fusion protein (EBNA1∆GA-Ii) have been 
described in Chapter 3. The functionality of these plasmids 
was confirmed using HEK293 cells transfected using 
Lipofectamine 2000.  It was demonstrated that proteins had 
the expected molecular weights by western blotting, and that 
the mutation of the nuclear localisation sequence did indeed 
lead to a cytoplasmic distribution of protein by 
immunocytochemistry.  These plasmids were used as templates 
for in vitro transcription to produce RNA encoding these 
proteins.   
 
Presentation of the TSL epitope was assessed using specific 
CD4 T-cell clones.  These have been described in Chapter 3 – 
they are DR1 restricted, specific and able to recognise 




Immature DCs were prepared from an HLA B35 and DR1 positive 
laboratory donor.  The coexistence of these two HLA alleles 
on the same DCs allowed simultaneous measurement of Class I 
(HPV) and II (TSL) restricted epitope presentation.  It was 
important to assess Class I presentation as a marker of 
normal DC function and maturation as Class I presentation 
would be predicted to occur from an endogenous antigen.  
These cells were electroporated with in-vitro transcribed 
RNA encoding all four EBNA1 species in parallel and were 
cultured in the presence of TNFα and IL1β for a further 24 
hours.   DCs were also transfected with GFP encoding RNA – 
as an internal positive control for transfection efficiency 
and as an antigen-negative control in immunogenicity and 
antigenicity assays.   
 
At this point, cells were harvested and presentation of the 
HPV and TSL epitopes was measured; as was whole antigen 
expression.  Epitope presentation was assessed in two ways: 
recognition of DCs in overnight IFNγ ELISPOT assays with 
specific T-cell clones (TSL and HPV) as responders, and use 
of DCs as stimulator cells in polyclonal cultures with 
autogous lymphocytes as responder cells.  DCs were fixed, 
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permeabilised and stained with an EBNA1 specific antibody; 
EBNA1 expression was visualised by fluorescence microscopy.   
 
Whole antigen expression is shown in Figure 7.12.  There was 
strong EBNA1 expression in DCs transfected with EBNA1∆GA and 
EBNA1∆GA-NLS RNA, intermediate level expression in cells 
expressing native full-length EBNA1 and weak expression in 
those cells expressing the invariant-chain fusion protein 
(Figure 7.12A).  However, the proportion of DCs displaying 
detectable EBNA1 expression was 70-80% regardless of the 
EBNA1 isoform used.  The stronger EBNA1 expression in cells 
expressing glycine-alanine repeat deleted antigen (as 
opposed to full length protein) may relate to the known 
inhibitory effect of the GAr on the rate of mRNA translation 
and protein production (Tellam et al., 2007), particularly 
as antigen expression is measured only 24 hours after 
transfection.  The weak expression in cells expressing the 
invariant chain fusion protein reflects ectopic expression 
in endolysosomes (Chaux et al., 1999) and rapid degradation.  
There is no EBNA1 staining in GFP expressing cells, 
confirming the specificity of the staining.  In Figure 
7.12B, a higher magnification view of the cells demonstrates 
that the NLS mutation does indeed redistribute the protein 
from exclusively nuclear to nuclear and cytoplasmic 






cells expressing the invariant chain fusion protein, and 
diffuse punctate staining in seen throughout the cytoplasm.  
Finally, as shown in Figure 7.12D, almost all GFP 
transfected cells show obvious green fluorescence as 
expected.   
 
The next experiments assessed the antigenicity of these 
EBNA1 positive DCs.  The cells’ antigenicity was measured in 
overnight IFNγ ELISPOT assays using DCs as target cells for 
recognition by HPV (Class I) and TSL (Class II) specific T-
cell effectors.  The positive control in these assays was 
GFP transfected (i.e EBNA1 negative) DCs loaded with 
exogenous peptide. As shown in Figure 7.13A, there was 
clear-cut recognition of DCs expressing all glycine-alanine 
repeat deleted forms of EBNA1 above background levels by the 
HPV specific clone.  Epitope presentation by EBNA1∆GA was 
slightly more efficient than both cytoplasmic and invariant 
chain tagged EBNA1∆GA.  There was no recognition of full-
length EBNA1; this was not unexpected given the inhibitory 
effect of the GAr on proteasomal degradation (Tellam et al., 
2001) and DriP generation (Tellam et al., 2007). Recognition 
of transfected DCs by the HPV specific clone was 







In terms of presentation of a Class II restricted epitope 
(TSL), there was evidence of recognition by the TSL-specific 
clone of DCs expressing only invariant chain tagged or 
cytoplasmic EBNA1∆GA.  These results are presented in Figure 
7.13B.  There was no evidence of recognition of nuclear 
EBNA1 (whether full length or GA repeat deleted).  Compared 
with MHC Class I restricted epitope presentation, 
presentation of the TSL epitope from endogenous EBNA1 
appeared to be less efficient – levels of recognition were 
approximately 20% of maximal.  This is of the same order of 
magnitude as recognition of LCL overexpressing EBNA1∆GA-
invariant chain from MVA virus vectors. 
 
Taken together, these results suggest that cellular 
localisation of antigen in DCs after RNA transfection may 
influence the presentation of  Class II restricted epitopes, 
with cytoplasmic and endolysosomal protein able to access 
the MHC Class II loading machinery in contrast to nuclear 
protein.  For Class I presentation, the presence or absence 
of the glycine-alanine repeat is the critical factor.  
However, these conclusions are based on the detection of 
epitope presentation at a single, predetermined time point 
24-40 hours after transfection.  In terms of dendritic cell 
physiology in vivo, this may not be the most relevant time-
point.  After intradermal administration of DCs, migration 
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to T-cell zones of lymph nodes takes about 48 hours (Adema 
et al., 2005) and so persistence of antigen presentation is 
an important consideration.   
 
For this reason, and in view of the delayed presentation of 
MHC Class II (as compared to I) restricted EBNA1 epitopes in 
transfected B-cells (Mackay et al., 2009) and the reliance 
of Class II presentation on stable, long-lived proteins 
rather than DRiPs, experiments were extended to assess 
immunogenicity rather than antigenicity.   
 
The influence of time after transfection on epitope display 
is also suggested by a comparison of presentation of the TSL 
epitope by DCs following CL22 peptide-based transfection and 
RNA electroporation.  In the former experiment, there was 
recognition of full-length EBNA1 expressing DCs by the TSL 
clone, whereas when RNA transfected DCs were used as targets 
24 hours earlier, no recognition was evident.   
 
The aim of the immunogenicity experiments was to measure 
epitope display by transfected DCs over a longer time period 
than T-cell recognition assays.  To achieve this, DCs were 
coincubated with autologous lymphocytes (i.e. non-adherent 
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PBMCs) in polyclonal cultures.  After 7 days culture in the 
absence of exogenous cytokines, a further stimulation with 
transfected DCs was performed and low-dose IL2 was added.  
At 14 days, polyclonal lines were analysed for the presence 
of HPV and TSL peptide specific T-cells. Positive control 
was again GFP transfected DCs loaded with exogenous peptide.   
 
For HPV-specific T-cell responses, quantification was by 
bulk cytotoxicity assay.  As shown in Figure 7.14, 
polyclonal lines stimulated with HPV peptide loaded DCs show 
strong specific lysis of HPV peptide-loaded targets.  
However, DCs transfected with all isoforms of EBNA1, 
including the full-length protein, generate polyclonal lines 
with HPV specific cytolytic activity.  The cytotoxic 
activity of cultures driven by EBNA1 full length transfected 
DCs is lower, but still detectable.  However, there is an 
obvious reduction in cytotoxicity at the E:T ratio of 5:1 in 
these cultures.  It is also noted that at the lower 
effector: target ratio, cells transfected with EBNA1 are 
more immunogenic than those loaded with exogenous peptide.  
This could reflect greater persistence of antigen 
presentation with endogenous whole protein expression. This 
result suggests that full-length EBNA1 can be presented via 










For presentation of the TSL epitope, TSL specific T-cell 
responses were quantified in polyclonal cultures using 
autologous B-cell blasts loaded with TSL peptide or DMSO 
alone as stimulator cells in overnight IFNγ ELISPOT assays.  
There is evidence of an increase in frequency of TSL 
specific T-cells in polyclonal cultures stimulated with 
EBNA1 compared to GFP transfected DCs, as shown in Figure 
7.15. The size of the TSL-specific population is similar 
regardless of which isoform of EBNA1 stimulating DCs were 
transfected with.  The frequency of TSL specific cells is 
approximately 50-60% of peptide-driven levels.  This result 
is quite different to that obtained using the TSL specific 
clone in recognition assays.  Firstly, the dependence on 
cytoplasmic or lysosomal localisation of EBNA1 is not seen – 
nuclear protein is equally well presented via the Class II 
pathway.  This could suggest that even nuclear EBNA1 can 
gain access to the MHC Class II pathway but by a slower 
mechanism than cytoplasmic protein.  Secondly, there is a 
much less dramatic difference between peptide driven 
responses and those seen with transfected DCs.  Once again, 
this could reflect persistence of epitope display. 
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7.5: Presentation of TSL epitope by DCs nucleofected with EBNA1 
encoding DNA.   
 
The aim of this experiment was to determine whether 
nucleofection of DNA into mature DCs led to presentation of 
Class II restricted epitopes (i.e. the TSL epitope).  The 
ability of nucleofected DC to present immunogenic epitopes 
has not been reported by other investigators.  Mature DCs, 
rather than immature ones, were selected for use in this 
experiment as previous experiments had suggested that 
nucleofection impairs the ability of DCs to respond to the 
maturation stimulus (IL1β and TNFα). 
 
In the previously described three way comparison of 
transfection methods, nucleofection of invariant-chain 
tagged EBNA1∆GA into immature DC followed by maturation led 
to a very low level of recognition by the TSL clone.  
Presentation of the HPV epitope was, however, easily 
detected. 
 
Mature DCs were prepared from an HLA DR1 and B35 positive 
laboratory donor.  On day 4 cells were exposed to TNFα and 
IL1β for a further 48 hours.  Cells were stained with a 
panel of antibodies against phenotypic markers.  As shown in 
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Figure 7.16, these cells displayed a typical phenotype of 
mature DCs with high CD83, CD86 and CD25 expression.  CD14 
expression was retained however, and CCR7 expression was 
unimpressive; as would be expected in the absence of PGE2 in 
the maturation cocktail.   
 
DCs were nucleofected with EBNA1 encoding plasmid DNA or 
antigen negative controls - empty vector (pcDNA3.1) and GFP 
DNA.  After 8 hours further culture to allow time for 
transcription and translation to occur, antigen expression 
and antigenicity were determined. This time point was chosen 
as previous experiments had shown that after 12 hours 
viability of nucleofected cells rapidly decreased.  The 
presence of large numbers of non-viable cells would be 
suspected to lead to high levels of background (non-
specific) recognition by T-cell clones. 
 
Whole antigen expression was determined by antibody staining 
and fluorescence microscopy.  As shown in Figure 7.17, the 
majority of GFP transfected cells were GFP positive (≈80%) 
as were the majority of EBNA1 transfected DCs (≈60%).  There 
was no EBNA1 staining on cells transfected with empty 










Presentation of the HPV and TSL epitopes by these 
nucleofected DCs is shown in Figure 7.18.  As shown in 
Figure 7.18A, there was evidence of recognition of 
nucleofected DC by the HPV specific T-cell clone.  DCs 
expressing all isoforms of EBNA1 were recognised, although 
recognition of EBNA1 full-length expressing DCs was slightly 
lower.  Recognition levels are approximately 75% of maximal 
(peptide-driven) responses.   
 
Moving on to presentation of the TSL epitope, there was 
recognition of DCs loaded with exogenous TSL peptide, 
although this appeared to be suboptimal(Figure 7.18B).  In 
previous experiments with this clone, maximal responses were 
typically 150-200 IFNγ secreting cells/1000 T-cells, whereas 
in this case only approximately 75 spots/well were seen. 
 
Despite this, there was evidence that the TSL epitope is 
presented by DCs expressing EBNA1.  Again, full-length EBNA1 
expressing DCs were only recognised slightly above 
background levels.  However, a critical difference in 
epitope presentation was seen compared to the experiment 
where DCs were transfected by RNA electroporation.  In this 
experiment, there was no difference in epitope presentation 







These two experiments, whilst similar are not identical: the 
nucleic acid used is different, as is the maturation state 
of the DCs and the time after transfection when T-cells 
assays were performed.   
 
A further examination of antigen expression in these DCs is 
presented in Figure 7.19, where higher-power views of EBNA1 
staining are presented.  At a magnification of x60, it is 
clear that there was no difference in cellular localisation 
between cells expressing the various forms of EBNA1.  
Essentially, in all cases the protein was cytoplasmic in 
distribution.  This would be expected for the invariant 
chain fusion protein and also EBNA1∆GA with a NLS mutation.  
However, it was unexpected for nuclear EBNA1.  This antibody 
staining was performed as early as 8 hours after 
nucleofection, and it is possible that this was insufficient 
time for the effect of the nuclear localisation sequence to 
be felt.   
 
Taken as a whole, these experiments lend further support to 
the conclusion that cellular localisation of EBNA1 in 
transfected DCs influences presentation of Class II 
restricted epitopes.  In nucleofected DCs, early after 






whether EBNA1∆GA or EBNA1∆GA-NLS DNA and there is a similar 
level of recognition by the TSL specific T-cell clone.    
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7.6.  Investigation of the mechanism of presentation of the TSL epitope by 
DCs expressing cytoplasmic EBNA1∆GA. 
 
As suggested in sections 7.4 and 7.5 above, cytoplasmic (and 
invariant chain tagged) EBNA1 can be presented via the MHC 
Class II pathway to T-cells specific for the DR1 restricted 
TSL epitope.  With time, however, the influence of cellular 
location wanes.   
 
The aim of this set of experiments was to ascertain the 
relative importance of two putative mechanisms of MHC Class 
II restricted epitope (i.e. TSL) presentation from 
endogenous antigen.   
 
One mechanism is antigen transfer between DCs (Mendoza-
Naranjo et al., 2007). This could take the form of release 
of whole antigen by DCs followed by re-uptake by endocytosis 
and endolysosomal processing, or transfer of pre-processed 
peptides between DCs.  To explore the possible involvement 
of this process, experiments using HLA-matched (DR1 
positive) and mismatched (DR1 negative) DCs were conducted.  
There were three experimental groups of DCs – positive 
control (DR1 positive - EBNA1∆GA-NLS RNA, DR1 negative – no 
RNA), negative control (DR1 positive – no RNA, DR1 negative 
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– no RNA) and experimental group – (DR1 positive – no RNA, 
DR1 negative – EBNA1∆GA-NLS RNA).  Negative control cells 
were loaded with exogenous peptide as a control for T-cell 
function.  Mixed DC populations were used as targets for T-
cell recognition in overnight IFNγ ELISPOT assays with TSL 
specific T-cells as effectors.  Antigen expression was also 
assessed by antibody staining.   
 
As shown in Figure 7.20, the level of antigen expression was 
relatively low compared to what was typically seen with 
electroporation of RNA.  For DR1 positive DCs electroporated 
with RNA (and mixed with mock transfected DR1 negative DCs) 
approximately 25% of cells showed EBNA1 fluorescence, this 
was about 50% for DR1 negative EBNA1 transfected cells. 
 
As shown in Figure 7.21, there was evidence of recognition 
of EBNA1 negative target DCs when loaded with exogenous TSL 
peptide, but no recognition of DR1 positive EBNA1 
transfected DCs mixed with DR1 negative mock transfected 
DCs.  This was unexpected and may relate to the low level of 
whole antigen or to the effects of contaminating lymphocytes 










Finally, experiments moved forward to assess the possible 
role of macroautophagy (Blum et al., 2008) in presentation 
of an MHC Class II restricted epitope from endogenous EBNA1 
in transfected DC.  In the B-cell system, autophagy has been 
demonstrated to have a role in this process (Paludan et al., 
2005).     
 
The aim of this set of experiments was to determine whether 
or not inhibition of autophagy with 5-methyladenine led to 
attenuation of presentation of the TSL epitope by DCs 
endogenously expressing EBNA1.  
 
In order to assess presentation of Class I and II restricted 
epitopes simultaneously, immature DCs were prepared from an 
HLA B35 and DR1 positive laboratory donor.  Cells were 
electroporated with RNA encoding cytoplasmic EBNA1∆GA or in 
the absence of RNA (mock).  DCs were returned to culture 
medium either supplemented with 3-MA or not.  After 48 hours 
culture in the presence of TNFα and IL1β, cells were 
harvested.  EBNA1 expression was measured by intracellular 
antibody staining and fluorescence microscopy.  As shown in 
Figure 7.22, there was again sub-optimal expression EBNA1 in 
transfected DCs.  Approximately 20% of DCs show detectable 






around 40% in 3-MA treated cells.  There was no EBNA1 
staining on mock transfected cells.   
 
The ability of these DCs to present the HPV and TSL epitopes 
was assessed in overnight IFNγ ELISPOT assays using specific 
T-cell clones as effectors.  As shown in Figure 7.23A, there 
was evidence of recognition of EBNA1 expressing DCs by the 
HPV specific clone above background levels.  However, levels 
of recognition were only 25% of maximal (peptide-driven) 
levels.  This is in contrast to previous experiments with 
this clone, where typically 60-70% maximal recognition was 
seen. This could reflect suboptimal transfection efficiency. 
It was also noted that exposure of target DCs to 3-MA 
actually abrogates this recognition by the HPV specific 
clone.  This was unexpected as 3-MA, at the concentrations 
used, is thought to be a highly specific inhibitor of 
autophagy.   
 
Unfortunately, as shown in Figure 7.23B, although there was 
recognition of peptide-loaded DCs, there was no recognition 
of EBNA1 expressing DC above background.  Once again, this 
could reflect weak EBNA1 expression.  In the presence of 3-
methyladenine, however, spot counts were slightly higher 






DCs.  This could suggest that involvement of an autophagy 
independent process that is unmasked when autophagy is 
inhibited by 3-MA. 
 
In conclusion, these experiments do not provide further 
insight into the mechanism by which cytoplasmic EBNA1∆GA is 
presented via the MHC Class II pathway.  However, an 
incidental finding that autophagy may be involved in 
presentation of a Class I restricted epitope in transfected 
DCs, is noted.  These experiments also lend support to the 
theory that, for endogenously produced antigens, MHC Class I 
processing and presentation in more efficient than MHC Class 
II; which may be more dependent on high levels of whole 




Chapter 8: MHC Class II processing and presentation in clinical 
grade dendritic cells. 
 
As discussed in the introduction in more detail, the CD4 T-
cell response to tumour associated antigens is of central 
importance in a coordinated and effective immune response 
against malignancy.  One of the putative advantages of whole 
antigen transfection methods for vaccine dendritic cells is 
the presentation of a range of both Class I and II 
restricted epitopes.  Of course, this goes against the 
conventional immunological dogma that MHC Class II 
substrates are exogenously acquired by endocytosis into 
endo-lysosomal compartments.  The aim of this set of 
experiments was to determine the extent to which the nature 
and localisation of antigen influences access to the Class 





8.1. Presentation of a MHC Class II restricted Melan-A epitope by RNA 




Results presented so far suggest that Melan-A may have a 
natural affinity for the lysosomal compartment in 
transfected DC: the rapid loss of protein expression from 4 
to 24 hours, the slight increase in proportion of Melan-A 
positive cells at 24 hours on exposure to bafilomycin-A, the 
dependence of Class I presentation (26-35 epitope) on 
lysosomal acidification, delayed epitope presentation 
compared to EBNA1 and preliminary experiments showing a 
degree of co-localisation of LAMP1 and Melan-A.  
 
If the hypothesis that Melan-A enters endolysosomal 
compartments in DCs is correct, it would be predicted that 
MHC Class II restricted epitopes should be presented to CD4 
T-cells without additional modifications to the antigen.   
 
The generation of a Melan-A specific CD4 positive T-cell 
clone allowed this hypothesis to be tested within an 
autologous system.  RNA electroporated DC were used as 
targets for this experiment in order to maximise transgene 
expression.  It was shown that the proliferative response of 
the CD4 clone to DCs transfected with Melan-A RNA was 
somewhat higher than that seen with gp100 (control) 
transfected DCs.  However, the response was relatively 
modest compared to that obtained with DCs loaded with 
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exogenous recombinant Melan-A protein. It was shown that 
these same target DCs were also recognised by the Melan-A 
26-35 specific CD8 T-cell clone in parallel IFNγ ELISPOT 
assays. 
 
This result is in keeping with published work that Melan-A 
(Bioley et al., 2006 and Godefroy et al., 2006) and other 
melanoma antigens (Lepage and Lepointe, 2006) are presented 
via the Class II pathway when endogenously expressed in DCs 
or other cell types.   
 
However, there are several limitations with this set of 
experiments (presentation of endogenous Melan-A to CD4 
clones).  
 
First, due to the sudden and unexpected unavailability of 
commercially sourced recombinant Melan-A protein it was not 
possible to perform a positive control assay (using 
recombinant protein) simultaneously with the transfected DC 
assay.  This makes it difficult to make an accurate 
assessment of the efficiency of Class II presentation from 
an endogenous compared to an exogenous Melan-A source, 




Second, there is the issue of the true specificity of these 
T-cell clones.  Unfortunately, at no point along the 
development pathway for these cells were they tested against 
a control (irrelevant) recombinant protein.  The ideal 
negative control would have been a protein produced in an 
identical fashion to Melan-A.  In future, this would be a 
crucial experiment as the possibility remains that 
contaminants in the protein preparation (particularly 
residual E.Coli proteins) could have driven the 
proliferation of these cells in cultures.  
 
Despite this limitation, it is possible that the clones are 
truly Melan-A specific, as the manufacturer states that 
protein preparations are 99.8% pure and protein 
electrophoresis shows a single discrete band.  However, the 
second limitation is that the specific epitope recognised by 
these T-cells is, at present, undetermined.  There are 
several described MHC Class II epitopes from Melan-A in the 
literature and in future it would be important to try to 
determine the precise epitope recognised.  This could 
achieved by the use of a pool of overlapping peptides 
spanning the entire coding sequences of Melan-A – this 
approach would be relatively straightforward in view of the 
small size of Melan-A.  Alternatively, computer algorithms 
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on peptide-MHC binding could be used to predict likely 
epitopes based on the donor’s haplotype and these could be 
tested individually.   
 
Third, although the cells have a CD8 negative and CD4 
positive phenotype, it was not possible to convincingly 
demonstrate that the observed recognition of Melan-A protein 
loaded target cells was MHC Class II restricted.  Although 
the greatest reduction in IFNγ secretion was seen with anti 
HLA-DR and DQ antibodies there was also a degree of 
inhibition with a pan MHC Class I specific antibody.   
 
Perhaps most interesting is the observation that the 
proliferative responses of these T-cells to antigen (whether 
exogenous or endogenous Melan-a) are far more impressive 
than the IFNγ responses.  As mentioned previously, one 
explanation might relate to the kinetics of antigen 
presentation - IFNγ assays were performed early after 
transfection, whereas proliferation was assessed over a 72 
hour period.  However, even when exogenous Melan-A protein 




It is important to consider the origin of these T-cells.  
They were isolated from the PBMCs of a healthy laboratory 
donor with no evidence of dermatological malignancy or 
vitiligo.  In this context, it might perhaps not be unusual 
for the cells to release little IFNγ as persistent CD4 T-cell 
help would lead to the development of powerful cytolytic 
responses against skin antigens.  In addition, the CD4 
helper subset of T-cells are known to produce a wide range 
of effector cytokines not merely IFNγ.  The fact that 
detectable levels of anti Melan-A IgG antibodies were seen 
in the plasma of this donor, and that directly ex-vivo there 
were IFNγ responses detected by ELISPOT argues that they are 
probably Th1 cells.  It is possible that cells became 
functionally exhausted after repeated rounds of in-vitro 
stimulation with Melan-A protein loaded dendritic cells and 
levels of IFN gamma production declined.   
 
In terms of Melan-A specific CD8 responses that have been 
found in healthy individuals, there are some functional 
differences between responses seen in lab donors and 
melanoma patients.  For example, in healthy donors Melan A 
27-35 tetramer positive cells, whilst detectable, do not seem 
to be able to respond to antigen with cytokine secretion in 
contrast to cells from a subset of melanoma patients (Dunbar 
et al., 2000).  In fact, in a lab donor with a particularly 
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large 27-35 tetramer positive CD8 population, the cells were 
ultimately found to be cross-reactive with a mycobacterium 
tuberculosis antigen (Voelter et al., 2008).  A survey of 
CD8 responses to this epitope in lab donors also raised the 
possibility that they may partly be due to cross-reactive 
subsets of naive CD8 T cells (DuToit et al., 2002).   
 
It should be borne in mind that, in comparison to other 
published work on generation of Melan-A specific CD4 T-cells 
that used IFNγ capture based assays for selection of T-cell 
clones (Bioley et al., 2006, Godefroy et al., 2006 and 
Zarour et al., 2000), this work relied upon selection based 
on cell proliferation.  The microcultures that showed good 
viability and dense cellular proliferation by light 
microscopy were selected for amplification.  It is entirely 
possible that T-cells with a lower turnover rate could have 
been producing more IFNγ and would have been discarded.   
 
Future work should include a more comprehensive analysis of 
these T-cell clones.  This would encompass phenotypic 
analysis using antibodies specific for markers of Th17 
cells, regulatory T-cells (FOXP3, CD25) and naive, effector 
and memory CD4 subsets.  In addition the ability of the 
cells to secrete additional cytokines in response to Melan-A 
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stimulation needs to be determined – these would include 
other Th1 cytokines such as GM-CSF and TNFα, IL2 and Th2 
cytokines such as IL10 and IL4. The formal demonstration 
that the cells are MHC Class II restricted remains 
problematic in the absence of a defined epitope particularly 
if cell proliferative is the only cellular readout.  The 
proliferation assay is a longer term assay and so the short 
duration of action of MHC blocking antibodies make this a 





8.2. Presentation of a MHC Class II restricted epitope from EBNA1 RNA 
transfected dendritic cells. 
 
Several human malignancies are associated with EBV 
infection.  These include epithelial (nasopharngeal 
carcinoma) and lymphoid cancers (Hodgkin’s lymphoma, Burkitt 
lymphoma and post-transplant lymphoproliferative disease).  
Predisposing factors include possession of certain HLA 
haplotypes particularly in NPC and the presence of T-cell 
immunosuppression.   
 
Immunotherapeutic approaches, particularly in classical 
PTLD, have had some success in the clinical setting.  
Adoptive transfer of donor derived EBV specific cytotoxic T-
cell clones driven by LCLs after allogeneic stem cell 
transplantation has been highly effective in the therapeutic 
and prophylactic setting for PTLD (Heslop et al., 2010).  
After solid organ transplantation and refractory PTLD, 50% 
duration remission rates were achieved using third-party HLA 
matched T-cell clones stimulated with LCLs (Haque et al., 
2010).  In contrast to PTLD, other EBV associated 
malignancies express a more limited set of EBV antigens, 
making the use of LCL driven T-cells more difficult.  
Attempts to overcome these difficulties have included the 
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use of LCLs loaded with specific epitope peptides or 
overexpressing the particular antigen (Bollard et al., 2007) 
expressed in the tumour type of interest.   
 
Vaccination approaches have also been studied.  In 
particular, for NPC, intradermal vaccination with a MVA 
virus vector expressing a LMP2-EBNA1 fusion protein has been 
shown to reactivate memory CD4 and CD8 T-cell responses with 
minimal toxicity (Taylor GS, personal communication).   
 
It is interesting that all EBV driven malignancies express 
EBNA1 and that whilst MVA vaccination is being attempted, no 
clinical trials have used EBNA1 expressing dendritic cells 
as a therapeutic vaccine for EBV positive cancers.  
 
On this basis, the rationale for this set of experiments was 
to determine whether or not EBNA1 expressing dendritic cells 
could present Class I and II epitopes from EBNA1 and whether 
or not cellular localisation had an effect on epitope 
presentation.  It is pertinent to note that this work has 
potential therapeutic relevance as both in Hodgkin’s disease 
(Heller et al., 2008) and Burkitt lymphoma suboptimal CD4 T-
cell responses to EBNA1 have been observed.  The extent to 
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which this reflects a cause or consequence of the disease is 
as yet undetermined.  On a more fundamental note, the fact 
that in-vivo CD4 T cell responses to EBNA1 do exist and yet 
in-vitro derived B-LCLs are barely recognised by most of 
these CD4 clones requires explanation.  One possibility is 
that dendritic cells are involved in-vivo (Subklewe, 2002).   
 
Electroporation of in-vitro transcribed RNA was used to 
transfect dendritic cells, as prior experiments had shown 
this to be the most immunogenic transfection method with 
good cellular viability.  The TSL specific T-cell clone has 
a functional avidity of 10-7M (approximately 100nM) which is 
similar to previously published work (Long et al., 2005) and 
is able to recognise target cells endogenously expressing 
invariant chain tagged EBNA1.   
 
The results showed that DCs were efficiently transfected and 
expressed high levels of EBNA1 and that alterations in the 
nuclear localisation sequences and invariant chain tag did 
demonstrably affect the pattern of EBNA1 staining seen on 
indirect immunofluorescence.  As a whole, presentation of 
the EBNA1 HPV (B35) epitope was easily detectable at levels 
that approached maximal (peptide-driven) levels in T-cell 
recognition and in-vitro stimulation assays.  As predicted 
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from the known inhibitory effect of the GA repeat on 
proteasomal processing (Levitskaya et al., 1995), the full 
length construct is less immunogenic for the HPV epitope.   
 
For the HLA-DR1 restricted TSL epitope, a quite different 
pattern emerges.  In terms of T-cell recognition assay, in 
which surface epitope display is measured between 24 and 40 
hours post transfection, there is no increase in IFNγ 
secreting responder T-cell counts with nuclear EBNA1.  This 
is in line with the work of Mautner et al (2004) who found 
that EBNA1 specific CD4 T-cell clones only recognised LCLs 
when nuclear (full length or ∆GA) when the protein was 
overexpressed 60 times above physiologic levels.  There is 
low-level recognition of invariant chain tagged and 
cytoplasmic EBNA1.  However, the recognition of invariant 
chain EBNA expressing DCs remains low in comparison to TSL 
peptide loaded targets.  It is difficult to explain this, as 
several studies in the B-cell system suggest that expression 
of EBNA1 as a fusion protein with the cytoplasmic domain of 
the invariant chain (aa 1-80) leads to near maximal 
recognition by CD4 clones.  There is, however, some evidence 
that in murine DCs the invariant chain may play less of a 
role in control of MHC Class II presentation than in other 
cell types (Rovere et al., 1998).  It is also interesting to 
note that in clinical trials of DC vaccination, the LAMP1 
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sequence has been used to redirect antigen to endolysosomes 
rather than the invariant chain.  It would be interesting in 
future to generate a LAMP1-EBNA1 fusion RNA to determine 
whether this was more effective in generating EBNA1 CD4 
epitopes.   
 
In in-vitro stimulation assays, the derived T-cell 
populations show much less variation in the proportion of 
TSL specific T-cells regardless of which isoform of EBNA1 
the stimulating DCs were transfected with.   
 
 
Having demonstrated that certainly in short term T-cell 
recognition assays, the cellular localisation of EBNA1 does 
influence presentation of the EBNA1 515-529 epitope, 
attempts were made to determine the route by which 
cytoplasmic EBNA1 comes to interact with the MHC Class II 
loading pathway.  Unfortunately, experiments using 3 
methyladenine to determine the role of macro-autophagy and 
antigen transfer experiments with HLA matched and mismatched 
DCs were not successful due to low levels of EBNA1 
expression and lack of immunogenicity, as indicated by whole 
antigen staining and a suboptimal recognition by the HPV 
specific clone.   However, a close evaluation of the results 
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shows that in fact, in the presence of 3-methyladenine, 
there is a slight increase in TSL clone response with cells 
expressing cytoplasmic EBNA1 compared to GFP control.  This 
raises the possibility that under conditions of limited 
antigen availability autophagy inhibition unmasks an 




However, there was an incidental finding of note.  In 
experiments with 3-MA, the presentation of the B35 
restricted HPV epitope from EBNA1 was markedly attenuated by 
exposure of cells to 3-methyladenine after transfection.  
Since the positive control in this experiment was 
untransfected DCs loaded with cognate peptide rather than 
peptide-loaded 3-MA exposed DCs, the possibility remains 
that the observed effect is due to an off target effect of 
3-MA.  However, the dose of 3-MA used typically does not 
have off-target actions and the cell viability by light 
microscopy remained excellent.   
 
Macroautophagy has been found in many recent studies to 
inhibit the presentation of MHC Class II restricted epitopes 
from viral and tumour antigen in various cell types 
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(Croetzer and Blum, 2008).  However, there is a precedent 
for its involvement in MHC Class I epitope generation in 
macrophages – antigen-presenting-cells that share some 
characteristics of DCs such as an ability to cross-present 
antigens.  English et al (2009) examined in detail the 
presentation of an MHC Class I restricted epitope from HSV-1 
in infected murine macrophages.  Presentation of the epitope 
was determined by the response of a specific T-cell 
hybridoma of the CD8 positive phenotype.  Epitope display 
was determined in the first 12 hours after infection as 
cytopathic effects of HSV-1 began after this time.  T-cell 
recognition occurred from 6 hours after infection and was 
markedly reduced by pre-exposure of cells to brefeldin A and 
a proteasome inhibitor (MG-132).  However, between 8 and 12 
hours post infection bafilomycin-A strongly inhibited 
recognition.  Interestingly, although resting macrophages 
were negative for LC3, a marker of macroautophagy, this 
protein was induced on HSV infection and 3-MA also reduced 
the size of T-cell responses.  This finding is also relevant 
to the result presented earlier that the presentation of 
Melan A 26-35 from endogenous Melan-A protein is dependent 
on lysosomal acidification.  It is also important to note 
that in a previous experiment comparing antigen processing 
of Melan-A and EBNA1, there was no inhibitory effect of 
Balifomycin-A treatment on presentation of the HPV epitope 
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from nuclear EBNA1∆GA, in contrast to the finding with 
cytoplasmic antigen.   
 
The finding that surface display of the TSL epitope depends 
upon cellular localisation in the short, but not the longer 
term extends some very recently published observations on 
CD4 T-cell responses to EBNA1 (Leung et al., 2010 and Mackay 
et al., 2010). The key differences between these studies and 
this work are the cell type – DC versus B-cells, different 
nucleic acid for transfection (RNA versus DNA) and a 
different CD4 epitope was studied (TSL).  Of note, TSL is in 
fact an overlapping epitope with VYG.   
 
In the work of Leung, levels of recognition of HLA matched 
LCLs by three different EBNA1 specific CD4 T-cell clones 
varies – there is a very low level of recognition (less than 
2% maximal) by VYG (509-528, DR11) and SNP (474-493, DR52) 
specific clones and no recognition by PQC (529-548, DR11) 
specific ones.  This does raise the question of how the 
responses are generated in vitro.  When target LCLs were 
loaded with cognate peptide, powerful T-cell recognition was 
restored.  An exogenous-reinternalisation route to the MHC 
Class II pathway was excluded by experiments with 
concentrated cell supernatants.  Overexpression of EBNA1, 
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EBNA1∆GA and EBNA1∆GA-invariant chain from a doxycycline-
inducible episomal vector achieved 100 fold increases in 
antigen expression over 72 hours, yet recognition by VGY and 
SNP clones was minimal (2-3 times background).  There was no 
recognition of the PQC epitope.  However, invariant chain 
EBNA1 transfected LCL were recognised by all three clones 
and nuclear EBNA1 overexpression upregulated recognition by 
the CD8 HPV clone.  On unmanipulated LCLs, autophagy 
inhibition with 3-MA abrogated presentation of the SNP 
epitope but actually enhances presentation of VYG.  
Transfection with cytoplasmic EBNA1∆GA however led to easily 
detectable presentation of all 3 Class II epitopes early 
after transfection at levels of 25-50% of invariant chain 
tagged EBNA1.  The production of all epitopes from 
cytoplasmic EBNA1 was autophagy dependent as assessed by 3-
MA and ATG7 knockdown.   
 
The kinetics of Class I and II epitope presentation from 
endogenous EBNA1 was examined in some detail by Mackay et al 
(2009).  In this work, B-cells were transformed with a 
Chinese strain of the virus – CKL.  This viral isolate has 
sequence variations compared to the B95.8 isolate and these 
markedly attenuate certain CD8 and CD4 T-cell responses.  
Into these CKL-LCLs, a doxycyline inducible DNA construct 
encoding EBNA1 was introduced by electroporation.  Stable 
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transfectants were immuno-magnetically selected and used as 
targets in T-cell recognition assays.  Expression of EBNA1 
and EBNA1∆GA increased after doxycycline induction and 
reached steady state (equivalent to long-term induced cells) 
by 72 hours, although the peak expression was earlier and 
stronger with EBNA1∆GA.  As expected, presentation of two 
Class I restricted epitopes (HPV, B35 and IPQ, B7) was 
detected as early as 12 hour post induction and was maximal 
within 48 hours. However, for the CD4 epitopes there was no 
recognition within the first 72 hours and after this there 
was a slow increase in recognition with levels not reaching 
those of long-term induced cells by 168 hours.  This 
profound delay in Class II epitope presentation was not due 
to a requirement for inter-cellular antigen transfer and was 
not due to general characteristics of LCLs as re-routing 
antigen into the Class II pathway with an invariant chain 
tag allowed early Class II presentation to occur.  It was 
finally demonstrated that presentation of Class II epitopes 
was much less affected by termination of protein synthesis 
than Class I presentation, suggested that CD4 T-cell 
recognition of EBNA depended more on mature, stable protein 
than DRiPs.  These data, that nuclear EBNA1 can be presented 
via the Class II pathway albeit very slowly, are entirely 
consistent with the findings presented here that cytoplasmic 
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or endolysosomal localisation of EBNA1 only affects 
presentation of the TSL epitope in the short term.   
 
Future work should seek to extend the range of epitopes 
studied in DCs, although clearly there would be limitations 
on the number of different epitopes that could be examined 
simultaneously in the same target cells due to HLA haplotype 
limitations.  In terms of in-vitro stimulation assays, it 
would be important to dissect further functional 
characteristics of the induced TSL specific T-cell 
populations in terms of functional avidity by varying the 
concentrations of stimulating peptide used and effector – 
target ratios.  The route by which cytoplasmic or nuclear 
EBNA1 gains access to the Class II pathway in DCs remains 
undetermined.  Further attempts to elucidate this should 
include a formal determination of the optimal concentration 
of 3-MA to inhibit macroautophagy in DCs using an indicator 
protein such as the neomycin resistance gene, and then T-
cell recognition assays in the presence or absence of 3-MA.  
Although EBNA1 has never been shown to reach the Class II 
pathway by an extracellular route in B-cells, DCs have a 
higher phagocytic and endocytic capacity and the levels of 
cell death in DC cultures may be higher than LCLs, and so 
experiments to determine whether or not transfected 
(mismatched) DC culture supernatants can sensitise HLA 
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matched DCs to T-cell recognition would be important.  It 
would be especially useful to elucidate how nuclear EBNA1 is 
presented via the Class II pathway over a longer time 
period.  This could be achieved by culturing transfected DCs 
for a prolonged period (7 days) and performing T-cell 
recognition assays daily in the presence of autophagy 
inhibitors.  
 
In conclusion, these results show that the localisation and 
stability of antigen, as well as the time-frame over which 
epitope display is assessed, can influence MHC Class II 
presentation of an endogenous viral antigen in clinical 
grade DCs.  This would have clinical implications for 
vaccine design.  It would be important to study the 
localisation of antigen within the cell after transfection 
and to assess whether there was any overlap with 
endolysosomes or autophagosomes and to judge whether or not 
manipulation of cell localisation might be necessary to 
optimise Class II presentation. They also emphasise the 
fluidity and non-exclusivity of the MHC Class I and II 




CHAPTER 9: CONCLUSIONS AND CLINICAL IMPLICATIONS 
 
 
Despite the undeniable promise of ex-vivo derived DC 
vaccines for cancer (Gilboa, 2007) and isolated reports of 
durable clinical responses, the labour-intensive and 
individualised nature of these therapies means that constant 
re-evaluation and re-appraisal are necessary, especially in 
light of emerging evidence that in-vivo targeting of DC in 
situ may be feasible and efficacious (Tacken et al., 2007).   
    
The recently completed clinical trial of DC vaccination in 
metastatic melanoma (Steele et al., 2011) is only the second 
clinical application of plasmid DNA transfected DC 
expressing whole antigen after non-viral transfection. It is 
distinguished from the previous study (Pecher et al., 2002) 
by a more homogenous and precisely defined patient group, 
more objective assessment of clinical response and a more 
thorough characterisation of the vaccine and immune 
responses.  There was an increase in frequency of gp100 and 
Melan-A specific T-cell responses with vaccination that was 
not seen for control viral epitopes.  However, it remained 
crucial – as a proof-of-principle - to formally demonstrate 
that patient DC presented epitopes as there was no control 
(unvaccinated or vaccinated with irrelevant antigen) group 
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and experiments with CL22 transfection had studied viral 
rather than self-antigens and had used healthy donor DC.  In 
this work low-level presentation of Class I restricted 
epitopes from gp100 and Melan-A is seen.  In the case of 
Melan-A, this is seen despite low whole antigen expression. 
The result is in contrast to many studies that suggest that 
human DC are extremely poorly immunogenic after transfection 
of DNA, rather than RNA.   
 
The lack of correlation between epitope presentation and 
whole antigen detection in transfected vaccine DC has 
important clinical implications.  Quality control of the DC 
vaccine cellular product remains in its infancy and there is 
uncertainty over desirable and necessary vaccine 
characteristics.  This work suggests that quantification of 
the proportion of cells expressing whole antigen by antibody 
staining at a fixed time point after RNA transfection does 
not define a group of more immunogenic DC.  However, it was 
possible to use a soluble, recombinant T-cell receptor to 
detect immunogenic Class I epitopes on the DC surface and 
further consideration should be given to this technique in 
DC quality control.  This would be more reproducible, 
standardised and less labour-intensive than using T-cell 
clones for such purposes.  However, it would not be 
straightforward to determine the significance of very low-
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level epitope presentation and in this work epitope 
detection using recombinant TCR required either single cell 
fluorescence microscopy or use of a re-directed T-cell 
assay.  In either case, this is less than ideal and in 
future efforts will be needed to adapt the technique to flow 
cytometric methods if possible.   
 
In DNA based DC transfection, quantification of tumour-
associated-antigen transcripts by RT-PCR would allow 
detection of an intermediate that would be expected to lead 
to translation and subsequently Class I epitope generation.  
The relation between mRNA and epitope presentation would 
then need to be determined. Of course, if RNA transfection 
is used, then measurement of RNA levels would not be very 
informative as it would not discriminate between presence of 
RNA and translation of RNA. 
 
If direct detection of defective ribosomal products were 
possible, this would appear to be the ideal surrogate marker 
for immunogenicity, certainly via the MHC Class I pathway, 
as the consensus view is that the majority of proteasomal 




In general terms, DRiP generation can be monitored by 
protein synthesis inhibition followed by delivery of 
radiolabelled precursor amino acids and pulse-chase 
experiments.  However, measurement of a specific DRiP is 
more problematic.  
 
Long lasting and highly-avid CTL responses, the ultimate 
goal of DC vaccination, require support from CD4 T-cells.  
It was established that a viral tumour antigen (EBNA1) was 
able to gain access to the MHC Class II processing and 
presentation pathway after endogenous expression following 
CL22 peptide-based transfection.  This occurred even in the 
absence of an endolysosomal targeting sequence and after 
transient DC exposure to chloroquine that inhibits 
endolysosomal acidification.  This had not been determined 
previously (Irvine, 2000).  This is a significant result 
particularly because in the clinical trial, there were few 
known Class II epitopes to determine frequency of induced 
CD4 responses and because T-cell responses to nucleofected 
B-cell blasts were not analysed as separate CD4 and CD8 
subsets.   
 
It was also possible to put CL22 peptide based transfection 
into context, in terms of other transfection methodologies.  
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It was distinguished by the highest cellular viability, of 
paramount importance, particularly as vaccine DC must 
survive a further 48 hours after administration to reach 
lymph nodes and initiate T-cell responses.  Despite very low 
transfection efficiencies, there was epitope presentation 
particularly for Class II restricted epitopes.  Importantly, 
in terms of ability to amplify specific T-cell responses 
within a bulk T-cell population, CL22 transfection was not 
especially inferior to nucleofection of DNA or RNA 
electroporation.  Insertion of plasmid DNA into DC using 
CL22 peptide also appeared to have immune-stimulatory 
effects on the vaccine cells, although this was not 
investigated in nucleofected or RNA transfected DC.  This 
would be another potential benefit of CL22 transfection.   
 
Building on the observation of lack of correlation between 
whole antigen expression and immunogenicity in trial patient 
DC, it was demonstrated using a highly efficient 
transfection method (RNA electroporation) that at 24 hours 
after transfection, DC were whole antigen negative but Class 
I restricted epitope positive.  At early time points after 
transfection, Melan-A and to a lesser extent gp100 whole 
antigen was detectable.  In contrast, the viral antigen 
EBNA1 was easily detected at all time points.  This result 
illustrates the vital importance of understanding the 
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kinetics of antigen expression in the cell type of interest 
for the particular antigen being vaccinated against, if 
whole antigen detection is to be used.  The finding that, 
for the Melan-A antigen, presentation of Class I restricted 
epitopes is time-dependent suggests that it will be 
important to determine when optimal epitope presentation is 
occurring and try to align this with when the DCs arrive in 
lymphoid tissues.   
 
In terms of MHC Class II restricted presentation, this was 
detected for two classes of tumour antigen – differentiation 
(Melan-A) and viral (EBNA1), even though the antigen was 
produced endogenously within the cell.  Unmanipulated Melan-
A antigen was presented in a specific fashion by RNA 
electroporated DC to CD4 T-cell clones, and this may well 
have been due to localisation of Melan-A to lysosomes by 
virtue of their similarity to melanosomes.  There was some 
preliminary evidence of co-localisation of a lysosomal 
marker and Melan-A in transfected DC.  In contrast, for 
EBNA1, Class II presentation was dependent on cellular 
localisation and was only observed when the protein was 
routed into cytoplasmic or endolysosomal compartments.  
However, the influence of cellular localisation was reduced 
when experiments measured epitope presentation over a longer 
time-frame rather than as a short-term ‘snap-shot’ using T-
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cell clones.  When epitope presentation was measured in this 
way, even DC preparations with few whole antigen positive 
cells were able to reactivate specific T-cell responses 
within PBMC. In terms of vaccine design, these results raise 
the possibility of optimising immunogenicity by manipulation 
of cellular localisation and this has already been attempted 
in some clinical trials (Su et al., 2005).  It is possible 
that ectopically expressing antigens in the cytoplasm rather 
than lysosomes might be advantageous by allowing more 
prolonged epitope presentation rather than a short-lived 
pulse.   
 
 
Ex-vivo dendritic cell vaccination remains a promising 
option for treatment of immunologically visible malignancies 
such as malignant melanoma and renal cell carcinoma.  In 
future, an improved understanding of transfection 
methodologies, determinants of immunogenicity and 
intracellular handling of antigen will all lead to more 
effective vaccines.  As DC vaccination is used in patients 
with less advanced disease and lesser degrees of immune-
paresis such as those with minimal residual disease, and in 
combination with more established therapies such as 
chemotherapy and immune modulation, its true potential is 
likely to be realised.   
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